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Summary 
Viral pathogenesis involves the intricate interactions between multitudes of viral and 
host factors. Emerging evidences showed that dengue virus non-structural proteins 
can contribute to the pathogenesis of dengue virus infection by regulating key 
signalling pathways in the host. To date, the underlying molecular mechanisms by 
which dengue virus non-structural proteins modulate host signalling pathways are 
still not clearly defined. Hence, this study aims to dissect the molecular basis of 
signalling pathway regulation by dengue virus non-structural proteins. Profiling of 
signal transduction pathways modulated during dengue virus infection was first 
performed using a customized phospho-protein detection assay. Dengue virus non-
structural proteins were next screened for their ability to regulate these pathways. In 
depth analyses using yeast-two-hybrid interaction domain screening, co-
immunoprecipitation, immunofluorescence, Western Blot and interferon-β (IFNβ) 
promoter reporter assays were then performed to identify the mechanisms of action 
of dengue virus non-structural proteins on these pathways. Dengue virus infection 
resulted in the modulation of nuclear factor kappa of activated B cells (NF-κB), janus 
kinase/signal transducers and activators of transcription (Jak/STAT), 
phosphoinositide 3-kinase/Akt (PI3K/Akt) and mitogen-activated protein kinase 
(MAPK) signalling pathways. Dengue virus non-structural 1 protein exhibited 
significant inhibitory effect on Jak/STAT signalling. The coiled-coil domain of 
STAT3β was identified as the interaction domain between dengue virus non-
structural 1 and STAT3β proteins in yeast-two-hybrid system. Interaction studies in 
mammalian cells, however, revealed that dengue virus non-structural 1 protein did 
not block Jak/STAT signalling through direct interaction with STAT3α/β protein. 
Summary 
xvii | P a g e  
 
Dengue virus non-structural 1 protein also did not inhibit IFNα- and IL6-mediated 
STAT3 activation. Analysis of upstream IFNβ promoter activity showed that dengue 
virus as well as its non-structural 1 protein down-regulated polyinosine-polycytidylic 
acid (pIC)-induced IFNβ gene induction. This attenuation of IFNβ promoter 
activation was found not to be attributed to the modulation of NF-κB signalling. 
Instead, dengue non-structural 1 protein hampered pIC-stimulated IFNβ promoter 
induction by antagonising upstream interferon regulatory factor 3 (IRF3) activation. 
Reduced IRF3 nuclear localization was observed in dengue virus non-structural 1 
protein-expressing cells. Impairment of IRF3 activation by dengue virus non-
structural 1 protein also led to transcriptional inhibition of downstream interferon-
stimulated genes (ISGs) such as chemokine (C-C motif) ligand 5 (CCL5), (IRF1), 
(IRF7), interferon-stimulated gene 56 (ISG56), myxovirus resistance protein 1 (Mx1), 
2'-5'-oligoadenylate synthetase 1 (OAS1) and viperin. Lastly, viperin protein 
expression was also blocked by dengue virus non-structural 1 protein. The findings 
of this study offered novel insights into the suppression of innate immune responses 
by dengue virus through its non-structural 1 protein which could lead to increased 
virus replication. This could impact clinical outcomes as elevated virus production 
was shown to be associated with greater disease severity. This implicates targeting 
dengue virus non-structural 1 protein as an innovative strategy for anti-viral 
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Dengue virus (DENV) belongs to the family Flaviviridae which comprises of over 
70 members of closely related RNA viruses (Billoir et al., 2000; Kuno et al., 1998). 
Other members of the Flaviviridae family include yellow fever (YF) virus, West Nile 
virus (WNV), Kunjin virus (KUNV), Japanese encephalitis virus (JEV) and tick-
borne encephalitis virus (TBE) (Gaunt et al., 2001; Heinz and Allison, 2000; Kuno et 
al., 1998). All these members share a common gene order and homology. Most 
flaviviruses are arthropod-borne and are maintained in zoonotic pools involving 
animal-arthropod-animal transmission cycles with humans essentially as dead-end 
hosts (Mackenzie et al., 2004).  
 
1.2. Dengue 
In the past 25 years, there was a global re-emergence of dengue epidemic, making 
dengue the most significant arthropod-borne human disease (Mackenzie et al., 2004). 
Dengue virus is transmitted mainly by Aedes aegypti and to a lesser extent Aedes 
albopictus and Aedes polynesiensis mosquitoes. Anthropological factors such as 
rapid urbanization and globalization with little mosquito control measures 
contributed to this global resurgence of dengue (Mackenzie et al., 2004). To date, 
four different dengue serotypes (DENV1 to DENV4) have been identified (Zanotto 
et al., 1996). The clinical manifestations of DENV infections in humans can vary 
widely, ranging from a mild febrile illness to an acute self-limiting dengue fever and 
to a severe hemorrhagic disease which can progress into shock. The severe forms of 
DENV infection, which are termed as dengue haemorrhagic fever (DHF) and dengue 
shock syndrome (DSS), are characterized by vascular leakage, thrombocytopenia and 
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hemoconcentration, which are routinely treated using fluid replacement therapy 
(Pang et al., 2007). Annually, there are about 50 to 100 million new cases of mild 
dengue fever, and a mortality rate of approximately 20 % out of more than 500,000 
cases of DHF/DSS each year (Pang et al., 2007). 
 
1.2.1. Dengue virus genome and translational strategy 
DENV is a positive-sense single-stranded RNA virus with a genome size of about 11 
kb. The positive-sense RNA is directly infectious (Ada and Anderson, 1959). The 
genome contains a long open reading frame with untranslated regions (UTRs) at the 
5’ and 3’ ends (Chambers et al., 1990a). The 5' end of the genome contains a type I 
cap preceding the conserved di-nucleotide sequence AG while the 3’ end lacks a 
poly(A) tract and terminates with the conserved di-nucleotide CU (Chambers et al., 
1990a). The DENV genome encodes three structural proteins, namely the capsid (C) 
protein, the precursor membrane (prM) protein and the envelope (E) protein, and 
seven non-structural (NS) proteins, namely NS1, NS2A, NS2B, NS3, NS4A, NS4B, 





Figure 1-1: Schematic representation of polypeptide encoded by dengue virus 
genomic RNA.  
The DENV genome is flanked by 5’ and 3’ un-translated regions (UTRs). The 5’ end 
of the genome begins with structural proteins (green), namely the capsid (C) protein, 
precursor membrane (prM) protein and the envelope (E) protein, respectively. This is 
followed by the non-structural (NS) proteins (yellow), namely NS1, NS2A, NS2B, 
NS3, NS4A, NS4B, and NS5.   
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The currently accepted model of translation is that the full length open reading frame 
of the DENV genome is translated into a single polyprotein. This polyprotein is then 
is cleaved by viral serine protease, host signalase, and other cellular proteases to 
yield the individual viral proteins (Perera and Kuhn, 2008).  
 
1.2.2. Structural proteins 
The C protein is a 12 kDa protein and is made up about 25 % lysine and arginine 
residues (Henchal and Putnak, 1990). It is believed that these basic residues serve to 
neutralize the negatively-charged DENV genomic RNA. The C protein binds to viral 
genomic RNA to form the nucleo-capsid (Kiermayr et al., 2004; Kunkel et al., 2001; 
Patkar et al., 2007). The highly conserved hydrophobic domain of the C protein 
helps in the formation of C protein oligos and aids in anchoring of C protein to the 
membrane of the endoplasmic reticulum (ER) (Bhuvanakantham and Ng, 2005; 
Markoff et al., 1997; Wang et al., 2004a). Other than its structural roles in binding 
viral RNA, the C protein has also been implicated in triggering apoptosis 
(Limjindaporn et al., 2007; Netsawang et al., 2010).  
 
The prM protein is a glycoprotein of about 18.1 to 19 kDa and it serves critical 
functions in virus maturation mediated by the cleavage of prM to membrane (M) 
(Chambers et al., 1990a; Stadler et al., 1997). The prM protein is also important for 
the functional folding of the E protein (Holbrook et al., 2001; Konishi and Mason, 
1993; Lorenz et al., 2002). During virus assembly, prM protein prevents premature 
fusion of E protein in the secretory vesicles ensuring proper virus packaging (Allison 
et al., 1995; Guirakhoo et al., 1992; Heinz and Allison, 2000, 2003; Heinz et al., 
1994; Li et al., 2008; Yu et al., 2008). Interaction with host proteins such as V-
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ATPase and claudin-1 is also mediated by the prM protein during virus entry and 
release (Duan et al., 2008; Gao et al., 2010).  
  
The E protein is a 53 – 54 kDa glycoprotein that is found on the surface of mature 
virions. It is important for virus packaging (Chambers et al., 1990a), binding to host 
receptors (Chambers et al., 1990a; Modis et al., 2004; Rey et al., 1995) and 
facilitating membrane fusion (Allison et al., 2001; Allison et al., 1995; Bressanelli et 
al., 2004; Heinz and Allison, 2000, 2003; Rey et al., 1995). It is also highly antigenic 
(Chambers et al., 1990a; Modis et al., 2004; Rey et al., 1995) and is the main 
candidate target for vaccine development (Block et al., 2010; De Paula et al., 2008). 
 
1.2.3. Non-structural proteins 
1.2.3.1. Non-structural 1 (NS1) protein 
The NS1 protein is a 42 kDa glycoprotein that is present naturally in three forms, 
namely a cytosolic (Noisakran et al., 2007; Westaway, 1987), a membrane associated 
(Jacobs et al., 2000; Noisakran et al., 2007) and a secreted form (Alcon-LePoder et 
al., 2005; Flamand et al., 1999). Roles of NS1 protein in DENV replication has been 
suggested as it was found to be closely associated with replicating viral double-
stranded ribonucleic acids (dsRNA) in the replication complex (Lindenbach and Rice, 
1999; Mackenzie et al., 1996). The NS1 protein can be found in the circulation of 
infected patients as early as the first day after fever onset all the way to day nine 
(Alcon et al., 2002). Elevated NS1 protein in the circulation also correlated with 
disease severity (Avirutnan et al., 2006; Libraty et al., 2002b). Hence, efforts have 
been made now to develop and validate DENV NS1 antigen-capture ELISA for use 
as rapid diagnostic kits (Kumarasamy et al., 2007; Wang and Sekaran, 2010).  
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Like the E protein, the NS1 protein is also immunogenic and can elicit circulating 
anti-NS1 protein antibodies (Lazaro-Olan et al., 2008; Lemes et al., 2005). These 
anti-NS1 antibodies were found to target endothelial cells and platelets causing 
cellular damage and platelet dysfunction, respectively (Chen et al., 2009; Cheng et 
al., 2009; Lin et al., 2003). The NS1 protein has also been implicated in the 
complement pathway. High levels of circulating NS1 protein, anaphylatoxin C5a and 
terminal complement complex SC5b-9 were found to be linked to the severity of 
disease (Avirutnan et al., 2006). In addition, NS1 protein was also reported to bind 
complement C4 directly and target it for cleavage by C1 complement specific 
proteases, thereby impairing functional complement activation (Avirutnan et al., 
2010). Complement antagonism was also found to be associated with the more 
severe disease such as DSS and DHF (Nascimento et al., 2009). WNV NS1 protein 
was also found to attenuate TLR3-mediated innate immune responses (Wilson et al., 
2008). 
 
1.2.3.2. Non-structural 2A (NS2A) protein 
The NS2A is a hydrophobic protein of about 23 kDa in size that is needed for the 
proper cleavage and processing of NS1 protein from DENV polyprotein (Falgout and 
Markoff, 1995; Pethel et al., 1992). In KUNV, a close relative of DENV, NS2A 
protein was found to be co-localized with viral dsRNA, implicating it in the virus 
replication complex (Mackenzie et al., 1998). KUNV NS2A protein was also 
reported to be implicated in virus packaging (Liu et al., 2003). DENV, WNV and 
KUNV NS2A protein all possess the ability to antagonize interferon (IFN)-α/β innate 
immune signalling (Jones et al., 2005; Liu et al., 2004; Liu et al., 2006; Munoz-
Jordan et al., 2003).  
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1.2.3.3. Non-structural 2B (NS2B) protein 
The NS2B is a small 14 kDa hydrophobic protein (Liu et al., 2010) that serves as an 
essential co-factor for the NS3 serine protease (Falgout et al., 1991; Zuo et al., 2009). 
The functional NS2B-3 protein complex is needed for the proper cleavage and 
processing of the DENV polyprotein into the individual viral proteins (Chambers et 
al., 1990a). NS2B-3 protease complex was recently reported to be involved in 
antagonism of type I IFNα/β signalling in dendritic cells (Rodriguez-Madoz et al., 
2010). In JEV, NS2B protein triggered increased permeability of host cells during 
JEV infection (Chang et al., 1999).  
 
1.2.3.4. Non-structural 3 (NS3) protein 
The NS3 protein is a serine protease of about 70 kDa in size (Chambers et al., 1990a). 
The catalytically active NS2B-3 serine protease complex cleaved the DENV 
polyprotein at the C/anchor C, NS2A/NS2B, NS2B/3, NS3/NS4A, and NS4B/5 
juntions, and within the NS2A and NS3 protein regions (Amberg and Rice, 1999; 
Falgout et al., 1991; Perera and Kuhn, 2008; Preugschat et al., 1990). Additionally, 
NS3 protein also possesses RNA helicase activity and acts to uncoil the 3’ UTR of 
the viral genomic RNA and also the viral dsRNA replicative intermediate (Benarroch 
et al., 2004; Chen et al., 1997; Matusan et al., 2001). RNA-stimulated nucleoside 
triphosphatase (NTPase) activity within NS3 protein was also found to be vital for its 
helicase activity (Li et al., 1999). The NS3 protein also has RNA triphosphatase 
(RTPase) activity which helped in the generation and processing of the 5'-cap of 
newly synthesized viral RNA (Wengler, 1993). Enzymatically active NS2B-3 protein 
was also observed to attenuate IFNα/β innate immunity signalling in dendritic cells 
(Rodriguez-Madoz et al., 2010). 
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1.2.3.5. Non-structural 4A (NS4A) protein 
The NS4A is a 16 kDa hydrophobic protein (Perera and Kuhn, 2008). It was 
implicated in membrane modifications that appeared to be similar to those observed 
during DENV infection (Miller et al., 2007). The NS4A protein of WNV was also 
found to be involved in similar membrane alterations during WNV infection 
(Roosendaal et al., 2006). Inhibition of IFNα/β induction by NS4A protein was 
observed in several flaviviruses such as DENV (Jones et al., 2005; Munoz-Jordan et 
al., 2003) and JEV (Lin et al., 2008). In addition, NS4A protein was found to 
localize together with dsRNA, NS3 and NS5 replication complex in KUNV, 
implicating it in virus replication (Mackenzie et al., 1998). Experiments done in YF 
virus also suggested the recruitment of NS1 protein to the replication complex by 
NS4A protein (Lindenbach and Rice, 1999).  
 
1.2.3.6. Non-structural 4B (NS4B) protein 
The NS4B protein is about 27 kDa in size (Perera and Kuhn, 2008). It was reported 
to interact with and mediate the dissociation of NS3 protease from single-stranded 
viral sRNA and stimulate the RNA helicase activity of NS3 protein (Umareddy et al., 
2006). The NS4B protein was found to block IFNα/β innate immune responses 
(Jones et al., 2005; Munoz-Jordan et al., 2005)    
 
1.2.3.7. Non-structural 5 (NS5) protein 
The NS5 protein (104kDa) is a RNA-dependent RNA polymerase indispensable for 
the viral RNA replication (Khromykh et al., 1998; Khromykh et al., 1999). Its 
sequence is the most highly conserved among all the flavivirus viral proteins (Mandl 
et al., 1989). In addition to the RNA polymerase activity, NS5 protein also possesses 
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methyl-transferase activity which mediates the methylation of type I cap at the 5’ end 
of viral RNA (Ray et al., 2006; Zhou et al., 2007). The NS5 protein was also recently 
reported to attenuate the IFNα/β-induced phosphorylation of signal transducers and 
activators of transcription 2 (STAT2) (Mazzon et al., 2009). Replicon-bearing cells 
expressing NS5 protein together with the other NS proteins also antagonize IFNα/β 
signalling by inhibition of STAT2 expression levels (Jones et al., 2005).  
 
1.3. Immuno-pathogenesis 
To date, the underlying mechanisms of DHF/DSS still remain unclear. Stemming 
from the studies and observations made during the 1970s dengue epidemics, an 
immune-pathogenesis hypothesis of DHF/DSS was put forth (Fink et al., 2006). 
Various components of the human immunological system such as sub-neutralizing 
antibodies, over-stimulated T-cells, cytokine cascades, complement system and 
cross-reactive auto-antibodies, are believed to contribute to the clinical 
manifestations of DHF/DSS. Epidemiological observations, augmented by in vitro 
studies, suggested a role of sub-neutralizing antibody-dependent enhancement (ADE) 
of virus entry and replication in monocytes and macrophages during a secondary 
infection with DENV of a different serotype (Lei et al., 2001). T-cell activation was 
found to be greater in that of DHF/DSS patients than those with only dengue fever 
(Pang et al., 2007). It is proposed that an intricate network of numerous cytokine 
pathways is responsible for altering the endothelial permeability observed clinically 
in DHF/DSS patients (Fink et al., 2006). Next, high amounts of activated 
complement components have been found to be associated with DHF/DSS patients 
indicating a potential role of complement activation in the pathogenicity of 
DHF/DSS (Avirutnan et al., 2006). Finally, recent studies have shown that NS1 
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antibodies generated in human patients targeted endothelial cells and platelets 
leading to increased cell death and impairment of platelet function, respectively 
(Chen et al., 2009; Cheng et al., 2009; Lin et al., 2003). 
 
1.4. Understanding pathogenesis 
Viral pathogenesis is defined as the series of events occurring after a viral infection 
that leads to the development of disease (Baron and Albrecht, 1996). In general, the 
pathogenic processes include initial virus entry into a host, local multiplication at the 
site of infection, spread to effector organs where diseases are often caused and 
eventually the transmission of the virus into new hosts (Baron and Albrecht, 1996). 
These pathogenic progressions entail the multifaceted cross-talk between multitudes 
of viral and host determinants, which usually involve the perturbation of key host 
signalling pathways. Hence, an approach to studying pathogenesis is to examine the 
host signal transduction pathways implicated during virus infection.  
 
1.4.1. The importance of the innate immune system 
One of the main signal transduction pathways that would be modulated during a 
virus infection is the immune signalling pathways, both innate and adaptive. The 
innate immune system represents the host initial defense response against infectious 
pathogens. It is responsible for sensing foreign pathogens, triggering a signal 
transduction cascade and mounting cellular defense mechanisms against the 
pathogens. For viruses, in particular, the Type I IFN pathway of the innate immune 
signalling plays a critical role in establishing an anti-viral state. Other than activating 
mechanisms directly targeting the pathogens, the innate immune response is also 
crucial for the initiation, mobilization and modulation of specific downstream 
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adaptive immune responses to combat and clear the infection (Biron, 1999). For 
instance, the type I IFN induced by the innate immunity signalling at the site of 
infection is vital for the proper activation and maturation of antigen presenting cells 
such as dendritic cells (Pace et al., 2010; Zietara et al., 2009). Propagation and 
survival of antigen-specific activated T-cells have also been shown to be regulated 
by Type I IFN (Le Bon et al., 2006a; Le Bon et al., 2003; Marrack et al., 1999; 
Tough et al., 1997).  This is extremely essential as activated T-cells die rapidly in the 
absence of IFNα/β, impairing their ability to clear virus-infected cells (Marrack et al., 
1999). Type I IFN was also shown to be crucial for the stimulation of antigen-
specific humoral response (Bachmann and Zinkernagel, 1997; Le Bon et al., 2001; 
Le Bon et al., 2006b). Hence, the type I IFN innate immune signalling is vital for 
linking the innate to the adaptive immune responses. 
 
Epidemiological studies conducted on dengue patients suggested that the clinical 
observed outcome of vascular leakage, haemorrhage and thrombocytopenia in 
DHF/DSS was correlated with elevated levels of circulating cytokines produced 
mainly by adaptive immune cells and also DENV-infected endothelial cells (Kurane, 
2007). As the nature and extent of adaptive immune responses is regulated by the 
innate immune system, investigation of the initial interactions between DENV and 
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1.4.2. Innate immune response against virus infection  
1.4.2.1. RNA-helicases and nuclear factor kappa of activated B 
(NF-κB) signalling 
Retinoic-acid-inducible gene-I (RIG-I) and melanoma-differentiation-associated 
gene 5 (MDA5) are cytoplasmic receptors for detecting the presence of foreign viral 
dsRNA within the cell (Yoneyama et al., 2005). Both RIG-I and MDA5 are made up 
of two N-terminal caspase-recruitment and activation domains (CARDs) and one C-
terminal DExD/H box RNA helicase domain (Honda et al., 2006). The DExD/H box 
RNA helicase domain is responsible for binding to and uncoiling cytosolic dsRNA 
while the CARDs are for interaction with downstream signalling complex.  
 
As depicted in Figure 1-2, binding of RIG-I and MDA5 to dsRNA triggers 
conformation changes, leading to binding of these helicases to CARD-containing 
IFNβ promoter stimulator 1 (IPS-1) (Kawai et al., 2005). Activated IPS-1 in turn 
stimulate the activation of TRAF-family member-associated NF-κB activator 
(TANK)-binding kinase 1 (TBK1) through tumour-necrosis factor (TNF)-receptor-
associated factor 3 (TRAF3) (Honda et al., 2006) (Figure 1-2). Activated IPS-1 also 
mediates the activation of inhibitor of kappa B (IκB) Kinase (IKK) protein complex 
through TNF-receptor-associated factor 6 (TRAF6), Fas-associated protein with the 
death domain (FADD) or receptor interacting protein-1 (RIP1) (Honda et al., 2006) 
(Figure 1-2).  
 
Activated TBK1 phosphorylates and activates interferon regulatory factor 3 (IRF3) 
and interferon regulatory factor 7 (IRF7) (Fitzgerald et al., 2003) (Figure 1-2). As 
shown in Figure 1-2, stimulated IKK phosphorylates IκB, targeting it for degradation  
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Figure 1-2: Schematic representation of RNA-helicases and NF-κB signalling 
pathway. 
Infection with positive-sense single-stranded RNA viruses results in the production 
of dsRNA intermediates within the cytosol. Binding of dsRNA to RIG-I and MDA5 
trigger conformational changes, leading to interactions with IPS-1. Activated IPS-1 
in turn stimulates the activation of IKK complex through TRAF6, FADD (not shown) 
or RIP1 (not shown). Stimulated IKK complex phosphorylates IκB, targeting it for 
degradation and freeing up NF-κB. Activated NF-κB translocates to the nucleus to 
activate downstream inflammatory genes including IFNβ. Activated IPS-1 also 
activates TBK1 through TRAF3. In turn, stimulated TBK1 activates IRF3 and IRF7 
through phosphorylation. Activated IRF3 and IRF7 then form homodimers or 
heterodimers to induce downstream type I IFNs. The figure is adapted from Honda et 
al. (2006). 
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and freeing up nuclear factor kappa of activated B cells (NF-κB) (Kawai et al., 2005). 
Activated NF-κB translocates to the nucleus to activate downstream inflammatory 
genes (Figure 1-2). IRF3 and IRF7 either associate to form homodimers by 
themselves or associate with each other to form heterdimers to activate downstream 
genes (Figure 1-2). IRF3 activates mainly IFNβ gene transcription whereas IRF7 can 
stimulate both IFNα and IFNβ gene transcription (Marie et al., 1998; Sato et al., 
2000).  
 
1.4.2.2. Toll-like receptor 3 (TLR3) signalling 
Toll-like receptor 3 (TLR3), found in endosomes (Matsumoto et al., 2003), 
recognizes dsRNA replicative intermediates from ssRNA virus such as WNV (Wang 
et al., 2004b) or viral dsRNA from dsRNA virus such as reovirus (Honda et al., 
2006). Dimerization of TLR3 upon binding dsRNA triggers activation of 
downstream Toll/interleukin-1 receptor (TIR)-domain-containing adaptor protein 
inducing IFNβ (Trif). Recruitment of TRAF6 and NAK (TBK1)-associated protein 1 
(NAP1) to activated Trif stimulates the activation of TBK1 (Sasai et al., 2005; Sato 
et al., 2003) (Figure 1-3). Activated TBK1 in turn phosphorylates IRF3 and IRF7. 
This causes IRF3 and IRF7 to homodimerize or heterodimerization to trigger the 
activation of downstream IFNβ and IFNα. IRF3 predominantly activates IFNβ while 
IRF7 can activate both IFNα and IFNβ (Marie et al., 1998; Sato et al., 2000) (Figure 
1-3). IRF3 can also induce the activation of interferon stimulated response element 
(ISRE)-regulated genes such as IFNγ-induced protein 10 kDa (IP-10), interferon-
stimulated gene 15 (ISG15) and interferon-stimulated gene 54 (ISG54) (Taniguchi 
and Takaoka, 2002) (Figure 1-3).  
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Figure 1-3: Diagram of TLR3 signalling pathway. 
Viral dsRNA intermediates are produced by positive-sense single-stranded RNA 
viruses. Endosomal TLR3 binds dsRNA and activates cytosolic Trif. Activated Trif 
recruits TRAF6 and NAP1, leading to the activation of TBK1. Stimulated TBK1 in 
turn phosphorylates IRF3 and IRF7. Activated IRF3 triggers the induction of IFNβ 
and ISRE-controlled genes such as IP-10, ISG15 and ISG54. IRF7 triggers both 
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1.4.2.3. Interferons (IFN) 
Interferons form a family of cytokines with diverse functions. They were initially 
discovered as proteins implicated in the activation of cellular immunity to virus 
infection. Further elucidation of their characteristics revealed more functions in the 
regulation of cell proliferation, differentiation and immune responses (Degre, 1996; 
Friedman et al., 1996).  Interferons can be classified into two main sub-categories 
based on their molecular characteristics. Type I IFN, namely IFNα and IFNβ, are 
mainly synthesized across various cell types in response to virus infection. Type II 
IFN, IFNγ, are made mainly by natural killer (NK) and stimulated T-cells (Degre, 
1996; Friedman et al., 1996). 
 
1.4.2.4. Janus kinase/signal transducers and activators of 
transcription (JAK/STAT) signalling 
Both type I and II IFNs activate downstream interferon-stimulated gene (ISGs) 
through the janus kinase/signal transducers and activators of transcription (Jak/STAT) 
signalling. IFNα/β activate through Janus kinase 1 (Jak1) and tyrosine kinase 2 
(Tyk2) whereas IFNγ signals through Jak1 and Janus kinase 2 (Jak2) (Darnell et al., 
1994; Ihle and Kerr, 1995) (Figure 1-4a and b). All these protein kinases are found 
associated on either IFNα/β receptors 1/2 (IFNAR-1/2) or IFNγ receptor 1 (IFNGR-
1). Activated Jaks and Tyk2 phosphorylate STAT1 and STAT2, which bind IRF9 to 
form the interferon-stimulated gene factor 3 (ISGF3) (Figure 1-4a and b).  ISGF3 
activates the transcription of ISRE-controlled genes such as chemokine (C-C motif) 
ligand 5 (CCL5), interferon regulatory factor (IRF1), IRF7, interferon-stimulated 
gene 56 (ISG56), myxovirus resistance protein 1 (Mx1), 2'-5'-oligoadenylate  
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Figure 1-4: Illustration of Jak/STAT signalling pathway. 
(a) Binding of IFNα/β to IFNAR-1/2 triggers the activation of Jak1 and Tyk2, which 
in turn phosphorylates STAT1 and STAT2. Phosphorylated STAT1 and STAT2 bind 
with IRF9 to form ISGF3. Phosphorylated STAT1 homodimerize to form AAF. 
ISGF3 and AAF in turn activate ISRE- and GAS-regulated genes, respectively. The 
ISRE-regulated genes include CCL5, IRF7, ISG56, Mx1, OAS1, viperin while GAS-
controlled genes include IRF1. (b) IFNγ-bound IFNAR-1/2 and IFNGR-1 activate 
Jak1 and Jak2 to phosphorylate STAT1. Activated STAT1 homodimers (AAF) then 
induce GAS-controlled genes. (c) Binding of IL6 to IL6 receptor recruits gp130 and 
causes their dimerization. This receptor complex then activates Jak1, Jak2 and Tyk2, 
which in turn activate STAT3. Phosphorylated STAT3 forms homodimers to activate 
acute phase response factors. The figure is adapted from Sato et al. (2001). 
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synthetase 1 (OAS1) and viperin (Darnell et al., 1994; Ihle and Kerr, 1995) (Figure 1 
4a and b). Phosphorylation of STAT1 can also lead to STAT1 homodimerization to 
form IFNα-activated factor (AAF), which directs the downstream induction of IFNγ 
activated site (GAS)-regulated genes such as IRF1 (Figure 1-4a and b). 
 
Jak/STAT3 signalling occurs through the IL6 receptor and glycoprotein 130 (gp130) 
receptors. Binding of IL6 to IL6 receptor triggers recruitment and dimerization of 
gp130 (Streetz et al., 2001) (Figure 1-4c). This triggers the phosphorylation of 
receptor-associated Jak1, Jak2 and Tyk2, which in turn phosphorylate STAT3 
(Heinrich et al., 1998) (Figure 1-4c). Phosphorylated STAT3 form homodimers and 
translocate to the nucleus to activate gene transcription of acute phase response 
factors (Figure 1-4c).  
 
1.4.3. Phosphoinositide 3-kinase (PI3K)/Akt (PI3K/Akt) Signalling 
The Phosphoinositide 3-kinase (PI3K)/Akt (also known as protein kinase B (PKB)) 
signalling pathway is one of the pathways regulating proliferation and apoptosis 
within the cell (Burgering and Coffer, 1995; Franke et al., 1997; Franke et al., 1995). 
Receptor tyrosine kinase found on the plasma membrane is activated through binding 
of extracellular ligands (Figure 1-5). Activated receptor tyrosine kinase recruits and 
stimulates the activation of PI3K, which in turn phosphorylates inositol 
phospholipids (Alberts, 2002) (Figure 1-5). Phosphorylated inositol phospholipids on 
the plasma membrane function as binding sites for Akt and phosphoinositol-
dependent kinase 1 (PDK1) (Alberts, 2002) (Figure 1-5). Phosphoinositol-bound 
PDK1 phosphorylates Akt. Activated Akt then decouples from membrane bound 
inositol phospholipids and stimulates the phosphorylation of downstream pro-
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apoptotic proteins such as B-cell lymphoma 2 (BCL2)-associated agonist of cell 
death (BAD) (Cardone et al., 1998), forkhead transcription factors (Brunet et al., 
1999), c-Raf (Zimmermann and Moelling, 1999) and cysteine-dependent aspartate-
directed protease-9 (caspase-9). Phosphorylation of these pro-apoptotic proteins lead 
to their inhibition, resulting in the attenuation of apoptosis (Figure 1-5). 
 
Akt also inactivates Glycogen synthase kinase 3 (GSK-3) through phosphorylation, 
implicating Akt in glucose uptake by cells (Cross et al., 1995). In addition, 
inactivation of GSK-3 by Akt also blocks GSK-3-induced degradation of cyclin D1, 
involving Akt in cell cycle control (Diehl et al., 1998). Akt also inhibits apoptosis 
signal-regulating kinase 1 (ASK1), causing the down-regulation of ASK1-induced 
activation of c-Jun N-terminal kinase (JNK) (Kim et al., 2001). This causes the 
cross-talk between PI3K/Akt and stress-activated protein kinase (SAPK)/JNK 
signalling pathways, resulting in the up-regulation of JNK downstream effectors such 
as activating transcription factor 2 (ATF2).  
 
Akt also indirectly activates p70 S6 Kinase through tuberin and mammalian target of 
rapamycin (mTOR) (Inoki et al., 2002). The p70 S6 Kinase is important for 
controlling protein synthesis in cells through regulating 40S ribosomal S6 protein-






























Figure 1-5: Schematic representation of PI3K/Akt signalling pathway. 
Extracellular ligand binding to receptor tryrosine kinase leads to the recruitment and 
activation of PI3K. Stimulated PI3K phosphorylates inositol phospholipids found on 
the plasma membrane. Phosphorylated inositol phospholipids serve as docking sites 
for PDK1 and Akt. Phosphoinositol-bound PDK1 phosphorylates Akt, leading to 
dissociation of Akt from inositol phospholipids. Activated Akt then phosphorylates 
pro-apoptotic BAD, resulting in its binding to 14-3-3 protein. The inactive death-
inhibitory protein is then released from BAD and causes the inhibition of apoptosis. 
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1.4.4. Mitogen-activated protein kinase (MAPK) signalling 
The mitogen-activated protein kinase (MAPK) signalling pathway controls cell 
proliferation, differentiation and also plays vital roles in responding to cellular stress 
and extracellular cytokines (Freshney et al., 1994; Han et al., 1994; Lee et al., 1994; 
Rouse et al., 1994). The MAPK signal transduction can be sub-divided into three 
pathways, namely extracellular signal-regulated kinase (Erk), p38 MAPK and 
SAPK/JNK (Davis, 2000; Lewis et al., 1998). The Erk sub-pathway is mainly 
important for controlling cell survival and cell death (Murray et al., 1998; Stanciu 
and DeFranco, 2002) while the p38 MAPK and JNK sub-pathways are essential for 
cellular responses to stress (Harper and LoGrasso, 2001; Mielke and Herdegen, 
2000).  
 
All three MAPK signalling pathways share the same mechanism of activation but 
with different proteins involved (Alberts, 2002). In response to extracellular stimuli, 
MAPK kinase kinase (MAPKKK) is phosphorylated (Figure 1-6) by upstream signal 
transduction proteins such as rat sarcoma (Ras). MAPKKK in turn phosphorylates 
and activates MAPKK (Figure 1-6). Stimulated MAPKK activates Erk, p38 MAPK 
and JNK through phosphorylation (Figure 1-6). Activated Erk, p38 MAPK and JNK 
then translocate into the nucleus where they induce the direct or indirect activation of 
transcription factors such as ATF2 and cyclic adenosine monophosphate (cAMP) 





























Figure 1-6: Diagram of MAPK signalling pathway.  
In response to external stimuli, MAPKKK is phosphorylated through multi-steps 
reaction involving several upstream signal transduction proteins (not shown). 
Activated MAPKKK phosphorylates MAPKK, which in turn activates MAPK 
through phosphorylation. Stimulated MAPK then translocates into the nucleus to 
directly or indirectly activate other transcription factors such as ATF2 and CREB, 
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1.5. Objectives 
Virus-host interactions, implicated in virus pathogenesis, determine virus infectivity, 
host cell susceptibility and eventually the disease outcome (Baron and Albrecht, 
1996). To date, there are still no effective anti-viral or vaccine available for the 
treatment of DENV infection. Emerging evidences pointed towards the role of 
DENV NS proteins in the pathogenesis of DENV infection via the modulation of 
various signalling pathways within the host cells. Despite advances in the 
understanding of cellular signalling pathways involved during DENV infection, there 
are still gaps in our knowledge in terms of the mechanisms and viral factors involved 
in the regulation of these signal transduction pathways during DENV infection. Due 
to multifaceted nature of virus-host interactions, there remain also the possibilities of 
discovering new signal transduction pathways that are perturbed during DENV 
infection. Unravelling the underlying mechanisms by which DENV disrupts key host 
signalling pathways could yield insights into the pathogenesis of DENV infection. In 
comprehending these mechanisms, new targets and strategies for therapeutic 
intervention and vaccine development, respectively can be identified. 
 
Hence, the specific objectives of this study are as follows: 
1) Identify signal transduction pathway(s) modulated by DENV infection. 
2) Determine the DENV NS protein(s) responsible for the modulation of the 
identified signalling pathway(s) 
3) Decipher the underlying molecular mechanisms of actions responsible for the 
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2. Materials and methods 
2.1. Cell lines and cell culture 
BHK 21 (clone 13) baby hamster kidney fibroblast cell line was a kind gift from 
Associate Professor John Aaskov (Queensland University of Technology, Brisbane, 
Queensland, Australia). C6/36 mosquito cells derived from Aedes albopictus were 
kindly provided by the late Emeritus Professor Edwin Westaway (Sir Albert 
Sakzewski Virus Research Centre, Herston, Brisbane, Australia).  
 
HeLa (adenocarcinoma) and MRC-5 (lung fibroblast) cell lines were kindly provided 
by Professor Yong Eu Leong (Department of Obstetrics & Gynaecology, National 
University of Singapore, Singapore) and Associate Professor Theresa May Chin Tan 
(Department of Biochemistry, Yong Loo Lin School of Medicine, National 
University of Singapore, Singapore), respectively. Both cell lines were originally 
purchased from American Type Culture Collection (Manassas, U.S.A.).  
 
HepG2 (hepatocellular carcinoma) was purchased from American Type Culture 
Collection (Manassas, U.S.A.). Huh7 (hepatocellular carcinoma) was a kind gift 
from Professor Ding Xiang Liu (School of Biological Sciences, Nanyang 
Technnological University, Singapore).  
 
Various variants of the HEK293 cells (primary human embryonic kidney cells 
transformed by sheared human adenovirus type 5 deoxyribonucleic acids (DNA)) 
were used in this study. HEK293FT cells, which stably-express the SV40 large T 
antigen, were obtained from Invitrogen (Carlsbad, CA, U.S.A.) and HEK293-hTLR3 
cells, which stably-express human TLR3, were obtained from Invivogen (San Diego, 
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CA, U.S.A.). HEK293T-sNS1-HA cells, which stably-express an endoplasmic 
reticulum targeted NS1 (sNS1) protein fused with the HA epitope, were kindly 
provided by Dr. Prida Malasit (Medical Molecular Biology Unit, Faculty of 
Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand).  
 
Table 2-1: Cell lines and growth media used 
Cell Line Growth Media Additional Supplementation 
BHK 21 RPMI-1640 10 % (v/v) foetal bovine serum 
C6/36 L15 10 % (v/v) foetal bovine serum 
HeLa & MRC-5 EMEM 10 % (v/v) foetal bovine serum 
6 mM L-glutamine (GLUTAMAXTM I) 
HepG2 & Huh7 DMEM 10 % (v/v) foetal bovine serum 
HEK293FT DMEM 10 % (v/v) foetal bovine serum 
0.1 mM MEM NEAA 
6 mM L-glutamine (GLUTAMAXTM I) 
1 mM MEM Sodium Pyruvate 
500 μg/ml Geneticin® (G418) 
HEK293-
hTLR3 
DMEM 10 % (v/v) foetal bovine serum 
0.1 mM MEM NEAA 
6 mM L-glutamine (GLUTAMAXTM I) 
1 mM MEM Sodium Pyruvate 
10 μg/ml Blasticidin 
HEK293T-sNS1 RPMI-1640 10 % (v/v) foetal bovine serum 
100 μg/ml Hygromycin 
 
The cell lines were routinely cultured in their respective growth media supplemented 
with 10 % (v/v) foetal bovine serum (PAA Laboratories, GmbH, Austria) as listed in 
Table 2-1. Dulbecco’s Modified Eagle’s Medium (DMEM), L15 and RPMI-1640 
media were purchased from Sigma (St. Louis, MO, U.S.A.). Eagle's Minimum 
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Essential Medium with Earle’s Salts (EMEM) was obtained from PAA Laboratories 
(GmbH, Austria). Trypsin, GLUTAMAXTM I, MEM non-essential amino acids 
(NEAA), MEM Sodium Pyruvate, Geneticin® (G418) and Blasticidin were from 
Gibco, Invitrogen (NY, U.S.A.). Hygromycin were obtained from Clontech 
(Heidelberg, Germany). The preparations of the various culture media and reagents 
are described in Appendix 1a-g. C6/36 cells were grown at 28 °C in an incubator 
(Memmert, GmbH, Germany) without carbon dioxide. All other cell lines were 
cultured at 37 °C in an incubator (Thermo Fisher Scientific, Massachusetts, USA) 
with humidified atmosphere of 95 % air and 5 % carbon dioxide.  
 
2.1.1. Sub-culturing 
All cell lines were routinely cultured in T-75 cm2 flask (Iwaki Glass, Japan) to about 
80 - 100 % confluency before sub-culturing. The medium was first aspirated and the 
cell monolayer was washed with 10 ml phosphate buffered saline (PBS) (Appendix 
1h). Next, the cells were incubated with 2 ml of trypsin (Appendix 1i) at 37 °C for 
about 1 - 2 min until most of the cells are rounded up. The cells were then detached 
by gently tapping the culture flask. Cell clumps were dispersed by repeatedly 
pipetting up and down. The cell suspension was then re-seeded according to the 
splitting ratio of 1:4 (C6/36) and 1:10 (all other cell lines).  
 
2.1.2. Cryo-preservation of cells 
Cells were grown to 70 - 90 % confluency and the cells were detached from the flask 
as described in Section 2.1.1. A small sample of the cells were stained with trypan 
blue (Gibco, Invitrogen, NY, U.S.A.) and the cell density and viability were 
determined using a hemocytometer. The remaining cells were centrifuged (Sigma 
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Laborzentrifugen GmbH., Germany) at 250 x g for 5 min at room temperature. 
Following which, the supernatant was discarded and the cells were resuspended in 
freezing medium consisting of 10 % (v/v) DMSO (Sigma Aldrich, Missouri, USA), 
20 % (v/v) foetal bovine serum and 70 % of the appropriate complete culture 
medium (Table 2-1) such that the final cell density is at least 3 x 106 cells/ml. One ml 
of the cell suspensions in freezing medium was then dispensed into each cryovial 
(Nalge Nunc International, Roskilde, Denmark) and frozen at a controlled freezing 
rate of 1 °C decrease per min in a 5100 Cryo 1 °C Freezing container (Nalgene, 
Thermo Fisher Scientific, Rochester, U.S.A.) placed in a -80 °C freezer. Lastly, the 
frozen cryovials were transferred to liquid nitrogen storage. A vial of frozen cells per 
batch was typically thawed 2 - 8 weeks after transferring to liquid nitrogen storage to 
test the viability of the frozen cells according to the procedure described in Section 
2.1.3.  
 
2.1.3. Thawing of cryo-preserved cells 
The required number of vials of frozen cells were removed from liquid nitrogen 
storage and thawed quickly in a 37 °C water bath (Gesellschaft fü̈r Labortechnik 
GmbH, Burgwedel, Germany).  
 
For HEK293FT, HEK293-hTLR3 and HEK293T-sNS1, the thawed cells were 
transferred to a sterile 15 ml tube (BD Falcon, BD Biosciences, New Jersey, USA) 
containing 14 ml of complete medium without antibiotics (Table 2-1). The cell 
suspension was centrifuged at 200 x g for 5 min. After discarding the supernatant, 
the cells were resuspended in 1 ml of pre-warmed complete medium without 
antibiotics and transferred to T-75 flasks (Iwaki Glass, Japan) containing 14 ml of 
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pre-warmed complete medium without antibiotics. The thawed cells were then 
incubated overnight at 37 oC under normal culture conditions to allow for attachment 
to the flask. The next day, the medium was discarded and replaced with complete 
medium containing the appropriate antibiotics (Table 2-1).  
 
For the other cell lines, the thawed cells were transferred to T-75 flasks containing 14 
ml of pre-warmed complete medium without antibiotics (Table 2-1). The thawed 
cells were then incubated for about 3 - 4 hr under normal culture conditions to allow 
the cells to attach to the flask. Following which, the medium was aspirated and 
replaced with the appropriate fresh complete medium (Table 2-1). 
 
2.2. Dengue virus infection 
2.2.1. Virus strain 
The dengue virus type 2 (DENV2), New Guinea C (NGC) strain (GenBank 
Accession: M29095) were obtained from American Type Culture Collection 
(Manassas, U.S.A.). West Nile Virus, Wengler (WENV) strain (GenBank Accession: 
NC_001563) and Kunjin virus (KUNV) (GenBank Accession: D00246) were kindly 
provided by the late Emeritus Professor Edwin Westaway (Sir Albert Sakzewski 
Virus Research Centre, Herston, Brisbane, Australia). All viruses used in this study 
are under the biological safety level class II. Hence, all work involving these viruses 
were conducted in class II biological safety cabinets in an isolated room dedicated 
for handling organisms of biological safety level class II. All equipments and 
biological materials were decontaminated in chlorox solution at a final concentration 
of 500 parts per million for at least 30 min before disposal.  
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2.2.2. Preparation of virus stock 
C6/36 cells, grown to about 90 % confluency in T-75 flasks (Iwaki Glass, Japan), 
were used for virus propagation. The medium was first aspirated and the cells were 
washed with virus diluent (Appendix 2a). Two vials (500 µl each) of frozen DENV2 
stock were quickly thawed in a 37 °C water bath (Gesellschaft für Labortechnik 
GmbH, Burgwedel, Germany). The mosquito cells were then inoculated with 1 ml of 
DENV2 and incubated at 37 °C for 1 hr with rocking at 15-min intervals. After an 
hour, 14 ml of L15 maintenance medium containing 2 % (v/v) foetal bovine serum 
(Appendix 2b) was added. The cells were then grown in a 28 °C incubator (Memmert, 
GmbH, Germany) for about 3 - 4 days until massive syncytia were observed. On the 
day of harvest, the pH of the medium was adjusted to 7.2 by adding 0.1 M sodium 
hydroxide (Appendix 2c) dropwise to the medium. Next, the culture supernatant 
containing the virus was transferred to sterile 15-ml tubes (BD Falcon, BD 
Biosciences, New Jersey, USA) and centrifuged (Sigma Laborzentrifugen GmbH., 
Germany) at 1000 x g for 10 min at 4 °C to remove any cell debris. Following which, 
500 µl of supernatant containing virus was aliquoted into each 1-ml cryovials (Nalge 
Nunc International, Roskilde, Denmark), and snap-frozen in -80 °C cold ethanol. The 
DENV2 virus stocks were stored at -80 °C (Thermo Fisher Scientific, Massachusetts, 
USA) until use. 
 
2.2.3. Viral quantification using plaque assay  
BHK cells were seeded into 24-well plates (Greiner Bio – One, St. Louis, USA) 24 hr 
before the infection of the cell monolayers for plaque assay. Each of the wells was 
seeded with 2 x 105 cells such that the cell monolayers would reach about 90 % 
confluency on the day of infection. Ten fold serial dilutions of the virus were 
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prepared in virus diluent (Appendix 2a) up to 10-5 dilution. The cell monolayers were 
then infected with 100 µl of each of the serially diluted virus in triplicates for 1 hr at 
37 °C in an incubator (Thermo Fisher Scientific, Massachusetts, USA) with 
humidified atmosphere of 95 % air and 5 % carbon dioxide with rocking every 15 
min to ensure even adsorption of the inoculum. After 1 hr, the virus was removed 
and the cells were washed with PBS (Appendix 1h). Next, 1 ml of overlay medium 
(Appendix 2d i & ii) was added to each well. The plates were incubated for four days 
at 37 °C in an incubator with humidified atmosphere of 95 % air and 5 % carbon 
dioxide prior to staining with 1 % crystal violet in a 20 % formaldehyde solution 
(Appendix 2e) for 4 hr at room temperature with shaking on an orbital shaker 
(Labnet Intl. Inc., Edison, USA). The crystal violet staining solution was removed 
after 4 hr and the cells were washed under running water until the water runs clear. 
The plates were then dried in a 60 °C oven. Plaques, which were visualised as 
clearings in the crystal violet stained monolayer, were counted and the virus titre was 
expressed as plaque forming unit/ml (PFU/ml). 
 
2.2.4. Infection of cell monolayers 
One day prior to infection, Huh7, HEK293-hTLR3 & HeLa cells were seeded at a 
density of 7 x 104 cells/cm2 of culture vessel surface area. The number of cells 
seeded for the various culture vessels are listed in Table 2-2. On the day of infection, 
the medium was aspirated and the cells were washed with virus diluent (Appendix 
2a). The cells were then infected with DENV2 at a multiplicity of infection (MOI) of 
1 for 1 hr at 37 °C with rocking at intervals of 15 min. After 1 hr, the virus was 
removed and the cells were washed with acid glycine (pH 3.0) solution (Appendix 2f) 
for 1 min at room temperature to inactivate any extracellular virus. Following which, 
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the cells were washed twice with PBS (Appendix 1h) and the appropriate volume of 
maintenance media (Appendix 2b) was added according to the type of culture vessel 
used (Table 2-2). For virus growth kinetics studies, duplicate wells were set up in the 
6-well format and the virus was collected at the various indicated timings post-
infection. 
 
Table 2-2: Parameters for infection using different culture vessel 
Culture 
vessel 
Surface Area per 
well or flask (cm2) 
Number of cells 
seeded per well or 
flask 
Volume of maintenance 
media added after 
infection (ml) 
24-well 2 1.4 x 105 1 
6-well 10 7 x 105 2.5 
 
 
2.3. Phospho-protein assay 
HeLa cells were infected (Section 2.2.4) or transiently transfected (Section 2.10) in 
6- well formats. Two biological replicates were done. At the indicated timings post-
infection or post-transfection, the cell lysates were harvested using the lysing 
solution from the Bio-Plex Cell Lysis Kit (Bio-Rad Laboratories, Hercules, U.S.A.). 
The lysing solution was pre-added with 40 µl of factor 1 (Bio-Rad Laboratories, 
Hercules, U.S.A.), 20 µl of factor 2 (Bio-Rad Laboratories, Hercules, U.S.A.) and 1 
tablet of cocktail of complete, mini protease inhibitors (Roche, Mannheim, Germany) 
before use. 
 
Following lysis, the lysates were freeze-thawed once at -80 ºC to improve lysis prior 
to conducting the phopho-protein assay using the customized Bio-Plex phospho-
protein detection assay (Bio-Rad Laboratories, Hercules, U.S.A.). The assay was 
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designed to detect for the phosphorylated forms of 19 signal transduction proteins. 
These proteins were namely Akt, ATF2, CREB, Erk, GSK-3, heat shock protein 27 
(HSP27), IκB, insulin receptor substrate 1 (IRS-1), JNK, p38 MAPK, MAPK/Erk 
Kinase 1 (MEK1), protein 53 (p53), p70 S6 Kinase, p90 ribosomal protein S6 kinase 
(p90RSK), Src non-receptor tyrosine kinase (Src), STAT2, STAT3, tropomyosin-
receptor-kinase A (TrkA) and Tyk2. 
The thawed cell lysates were diluted in assay buffer (Bio-Rad Laboratories, Hercules, 
U.S.A.) at a 1:1 ratio. Coupled beads were prepared by diluting the 50x coupled 
beads to 1x using wash buffer (Bio-Rad Laboratories, Hercules, U.S.A.). Next, the 
wells of the 96-well filter plate were pre-wetted with 100 µl of wash buffer and 
vacuum filtered using a vacuum apparatus (Millipore, Billerica, U.S.A). Fifty µl of 
cell lysate (1 µg/µl) were loaded onto each well followed by incubation overnight at 
4 ºC with shaking on an orbital shaker (N-Biotek, Gyeonggi, Korea) at 200 rpm. 
Plates were sealed with sealing tapes prior to any incubation steps.  
 
After overnight incubation, the plate was vaccum filtered and washed three times. 
Next, 25 µl of detection antibodies (1x) were added to each well and incubated for 1 
hr with shaking at 200 rpm. Following which, three washes were performed and 50 
µl of streptavidin-PE (1x) was added to each well and incubated at 10 min. After that, 
three rinsing steps with resuspension buffer (Bio-Rad Laboratories, Hercules, U.S.A.) 
were performed. Finally, 125 µl of resuspension buffer were added to each well and 
the plate was kept in the dark until assayed. The measurements of the assay were 
acquired using the Bio-Plex suspension array system (Bio-Rad Laboratories, 
Hercules, U.S.A.).  
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2.4. Total and viral ribonucleic acids (RNA) isolation 
Total ribonucleic acids (RNA) were extracted from MRC-5, HeLa and HEK293-
hTLR3 using the RNeasy mini kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol. Briefly, the cells were detached by trypsinization as 
described in Section 2.1.1. The cell suspensions were then transferred to new RNase 
free microfuge tubes (Axygen Scientific, Union City, USA) and centrifuged at 1000 
x g for 5 min (Sigma Laborzentrifugen GmbH., Germany). Next, the cells were 
washed once with 1 ml of PBS (Appendix 1h) and centrifuged at 1000 x g for 5 min. 
The cells were then lysed with either 350 ml (6-wells or T-25 flask) or 600 ml (T-75 
flask) of buffer RLT. All buffers used were provided in the kit. Following cell lysis, 
the lysates were loaded onto QIAshredder spin columns and centrifuged (Sigma 
Laborzentrifugen GmbH., Germany) at 14000 x g for 2 min to homogenize the 
lysates. Next, either 350 ml (6-wells or T-25 flask) or 600 ml (T-75 flask) of 70 % 
molecular grade ethanol (Merck KGaA, Darmstadt, Germany) were added to the 
homogenized lysates in the flowthrough.  
 
To bind the total RNA, up to 700 µl of the samples were then added to the RNeasy 
spin columns, followed by centrifugation at 8000 x g for 15 sec and discarding the 
flowthrough. All subsequent centrifugations were performed under the same 
conditions unless otherwise stated. The flowthroughs from the centrifugation steps 
were also all discarded except for the final elution step. Next, 700 µl of buffer RW1 
were added to the column followed by centrifugation. The columns were then 
washed with 500 µl of buffer RPE and centrifuged. The columns were washed again 
with another 500 µl of buffer RPE and centrifuged at 8000 x g for 2 min. The 
columns were then transferred to new 2 ml collection tubes from kit and centrifuged 
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at 14000 x g for 1 min to remove any excess buffer RPE. Next, the columns were 
placed in new 1.5 ml collection tubes. Total RNA was eluted by adding 50 µl of 
RNase-free water to the column, followed by a 1-min incubation and then 
centrifugation. The total RNA samples were then stored at -80 ºC until used.  
 
Viral RNAs from West Nile Virus (Wengler) (WENV) and Kunjin virus (KUNV) 
were extracted using the QIAamp® viral RNA mini kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s protocol. Briefly, 560 µl of buffer AVL containing 
carrier RNA were mixed with 140 µl of cell culture supernatant containing virus by 
pulse-vortexing for 15 sec. Viral particle lysis were then allowed to carry on for 10 
min at room temperature. After lysis, 560 µl of absolute molecular grade ethanol 
were added and mixed by pulse-vortexing. The contents on the tubes were collected 
at the bottom of the tubes by brief centrifugation before applying 630 µl of the 
solution to QIAamp Mini columns to bind the viral RNA to the columns. The 
columns were centrifuged at 6000 x g for 1 min and the flowthrough was discarded. 
The flowthroughs from the centrifugation steps were also all discarded except for the 
final elution step. Next, the columns were washed with 500 µl of buffer AW1, 
followed by centrifugation at 6000 x g for 1 min. The columns were then washed 
with 500 µl of AW2 and centrifuged at 20000 x g for 3 min. Excess AW2 was 
removed by placing the columns in new 2 ml collection tubes and centrifuging at 
20000 x g for 1 min. Viral RNA was eluted from the columns by adding 50 µl of 
RNase-free water, followed by incubating for 1 min before centrifuging at 6000 x g 
for 1 min. The isolated viral RNA samples were stored at -80 ºC until used. 
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Both the isolated total RNA and viral RNA were quantitated with NanoDrop ND-
1000 spectrophotometer (Wilmington, DE, U.S.A.) and diluted to 1 µg/µl using 
RNase-free water for downstream experiments. 
 
2.5. First strand complementary DNA synthesis 
The first strand complementary deoxyribonucleic acids (cDNA) synthesized from 
total RNA extracted from MRC-5 (Section 2.4) was used as template for 
amplification of STAT3 gene (Section 2.7.1). The first strand cDNA synthesis was 
performed using SuperScriptTM III reverse transcriptase (Invitrogen, Carlsbad, 
U.S.A.), which was engineered to have reduced RNase H activity and higher thermal 
stability. The nucleic acid mix consisting of 1 µg of total RNA, random hexamers 
and deoxyribonucleotide triphosphate (dNTP) dissolved in diethyl pyrocarbonate 
(DEPC)-treated water (Appendix 3a) were first heated at 65 ºC for 5 min followed by 
incubation on ice for at least 1 min to denature the secondary RNA structures. Next, 
the cDNA synthesis mixture containing RT buffer, magnesium chloride, DTT, 
RNase inhibitor (RNaseTM Out) and SuperScriptTM III reverse transcriptase were 
added to the nucleic acid mixture. The reaction volumes for the nucleic acid and 
cDNA synthesis mixtures are described in Appendix 3b and 3c. Annealing of the 
random hexamers to the RNA was carried out at 25 ºC for 10 min followed by cDNA 
synthesis at 55 ºC for 60 min. The reaction was next terminated by heating at 85 ºC 
for 5 min. Lastly the RNA was degraded by incubating with RNase H (Promega, 
Madison, U.S.A.) at 37 ºC for 20 min. The synthesized cDNA was then used as 
template for amplification of STAT3 gene (Section 2.7.1). 
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For the amplification of viral genes (Section 2.7.2), the first strand cDNA template 
was synthesized from WENV and KUNV viral RNA (Section 2.4) using 
SuperScript® VILOTM cDNA synthesis kit (Invitrogen, Carlsbad, U.S.A.). First, the 
reaction mixture containing VILOTM reaction buffer, random primers, SuperScript® 
III reverse transcriptase enzyme mix and 1 µg of viral RNA template (Section 2.4) 
were set up as described in Appendix 3d. Next, the mixture was incubated at 25 ºC 
for 10 min for primer annealing. RNA dependent cDNA synthesis was carried out at 
42 ºC for 120 min. Finally, the reaction was terminated by heating at 85 ºC for 5 min. 
After cDNA synthesis, the RNA is degraded by incubating with RNase H (Promega, 
Madison, U.S.A.) at 37 ºC for 20 min. 
 
2.6. DNA extraction 
2.6.1. Genomic DNA isolation 
Genomic DNA from Huh7 and HEK293FT was extracted using the PureLink™ 
genomic DNA mini kit (Invitrogen, Carlsbad, U.S.A.) and used as template for the 
amplification of IFNβ promoter (Section 2.7.4). All reagents otherwise stated are 
provided in the kit.  
 
Huh7 and HEK293FT cells were grown to confluency in T-75 flasks (Iwaki Glass, 
Japan). The cells were detached by trypsinization as described in Section 2.1.1. Next, 
the cell suspensions were centrifuged (Sigma Laborzentrifugen GmbH., Germany) at 
250 x g for 5 min and the supernatant were discarded. The pelleted cells were 
resuspended in 200 µl of PBS (Appendix 1h). Next, 20 µl of Proteinase K 
(Invitrogen, Carlsbad, U.S.A.) and RNase A (Invitrogen, Carlsbad, U.S.A.) were 
added to the samples, mixed by brief vortexing and incubated at room temperature 
Materials and Methods 
38 | P a g e  
 
for 2 min. This was followed by the addition of 200 µl of PurelinkTM Genomic Lysis 
/ Binding Buffer to obtain homogenous solutions. The solutions were then incubated 
at 55 ºC for 10 min to promote protein digestion. After 10 min incubation, 200 µl of 
100 % molecular grade ethanol was added to the lysates and mixed by vortexing.  
 
Next, the lysates were added to the PureLink™ spin columns to bind the genomic 
DNA. This was followed by centrifugation (Sigma Laborzentrifugen GmbH., 
Germany) at 10000 x g for 1 min and discarding the flowthrough. All centrifugation 
steps were performed under this condition and all flowthroughs from the 
centrifugation steps were discarded unless otherwise stated. The columns were then 
washed with 500 µl of wash buffer 1 and centrifuged. Next, the columns were 
washed with 500 µl of wash buffer 2 and centrifuged at 14000 x g for 3 min. Finally, 
to elute the genomic DNA, 50 µl of PureLink™ Genomic Elution Buffer was added 
and incubated for 1 min before centrifuging at 14000 x g for 1 min. The genomic 
DNA were quantitated using NanoDrop ND-1000 spectrophotometer (Wilmington, 
DE, U.S.A.) and stored at -20 ºC until they were used as templates for the 
amplification of IFNβ promoter (Section 2.7.4). 
 
2.6.2. Endotoxin free plasmid DNA preparation  
Endotoxin free plasmid DNA, used for all mammalian cell transfection studies, was 
isolated from bacteria clones using EndoFree® plasmid purification maxi kit (Qiagen, 
Hilden, Germany). All buffers used were provided in the kit unless otherwise stated.  
 
First, a starter culture of TOP10 or DH5α Escherichia coli (E. coli) cells, which were 
transformed with the appropriate plasmids (Section 2.7.6), were prepared. This was 
Materials and Methods 
39 | P a g e  
 
done by inoculating a single colony in 2 ml of LBA (Appendix 4a) and incubating 
overnight at 37 ºC with vigorous shaking (Labnet Intl. Inc., Edison, USA) at 220 rpm. 
Next day, 400 µl of starter culture were added into 200 ml of fresh LBA and grown 
overnight at 37 ºC with vigorous shaking at 220 rpm.  
 
On the following day, the bacterial cells were pelleted by centrifugation (Labnet Intl. 
Inc., Edison, USA) at 6000 x g for 15 min at 4 ºC. The supernatants were discarded 
and the pellets were resuspended in 10 ml of buffer P1. Alkaline lysis was then 
performed by adding 10 ml of buffer P2 and mixed by inverting the tubes 4 – 6 times, 
followed by 5 min incubation at room temperature. Next, the lysates were neutralised 
with 10 ml of buffer P3 and mixed by inverting the tubes 4 – 6 times to precipitate 
the proteins, genomic DNA and cell debris. The lysates were then loaded into 
QIAfilter cartridges and incubated at room temperature for 10 min. After 10 min 
incubation, the lysates were filtered into fresh 50 ml tubes. 
 
Next, 2.5 ml of buffer ER were added to the lysates and incubated on ice for 30 min 
to remove any endotoxin present in the lysates. During 30 min incubation, QIAGEN-
tips were equilibrated with 10 ml of buffer QBT. Following the 30 min incubation, 
the endotoxin free lysates were loaded into the equilibrated QIAGEN-tips to bind the 
plasmid DNA. The lysates were allowed to flow through the resin by gravity flow. 
Next, the QIAGEN-tips were washed twice with 30 ml of buffer QC. Following the 
washes, the plasmid DNA samples were eluted with 15 ml buffer QN.  
 
Next, 10.5 ml of room-temperature isopropanol was added to the eluted DNA and 
centrifuged at 20000 x g for 30 min to precipitate the DNA. The precipitated DNA 
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was then washed with 5 ml of endotoxin-free 70 % ethanol and centrifuged at 20000 
x g for 10 min. The supernatants were carefully decanted without disturbing the 
pellet. The DNA pellets were air-dried for 10 min and re-dissolved in 100 µl of 
endotoxin-free water. The plasmid DNA samples were quantitated using NanoDrop 
ND-1000 spectrophotometer (Wilmington, DE, U.S.A.) and stored at -20 ºC until 
they were used. 
 
2.6.3. Plasmid DNA mini-preparation 
Plasmids used for sequencing were extracted using QIAprep® Miniprep (Qiagen, 
Hilden, Germany). All buffers used were provided in the kit unless otherwise stated.  
 
First, a starter culture of TOP10 or DH5α Escherichia coli (E. coli) cells, which were 
transformed with the appropriate plasmids (Section 2.7.6), were prepared. This was 
done by inoculating a single colony in 2 ml of LBA broth (Appendix 4a) and 
incubating overnight at 37 ºC with shaking (Labnet Intl. Inc., Edison, USA) at 220 
rpm. 
 
On the next day, the bacteria cells were collected by centrifugation (Sigma 
Laborzentrifugen GmbH, Germany) at 14000 x g for 1 min in a microfuge tube. The 
supernatant was discarded and the pelleted bacteria cells were resuspended in 250 µl 
of buffer P1. Alkaline lysis was then performed by adding 250 µl of buffer P2 and 
mixed by inverting the tubes 4 – 6 times. Next, 350 µl of buffer N3 were added to 
neutralise the samples and precipitate the proteins, genomic DNA and cell debris. 
The precipitates were then separated from the clear supernatants containing the 
plasmid DNA by centrifuging at 18000 x g for 10 min. The clear supernatants were 
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then applied to the QIAprep spin columns and centrifuged at 10000 x g for 1 min to 
bind the plasmid DNA. The flowthroughs were discarded and the columns were 
washed with 750 µl of buffer PE, followed by centrifugation at 10000 x g for 1 min. 
An additional centrifugation at 10000 x g for 1 min was carried out to remove any 
excess buffer PE. Finally, the plasmid DNA samples were eluted by adding 50 µl of 
nuclease free water, incubating at room temperature for 1 min and centrifuging at 
10000 x g for 1 min. The plasmid DNA samples were quantitated using NanoDrop 
ND-1000 spectrophotometer (Wilmington, DE, U.S.A.) and stored at -20 ºC until 
they were used for sequencing (Section 2.7.8). 
 
2.7. Cloning 
2.7.1. STAT3α-GFP and STAT3β-GFP fusion constructs 
STAT3α and STAT3β were cloned as a fusion protein to the green fluorescent 
protein (GFP) for use in downstream co-localization and co-immunoprecipitation 
studies. For the cloning of STAT3α-GFP fusion construct, polymerase chain reaction 
(PCR) was first performed using the cDNA obtained from the total RNA of MRC-5 
as template (Section 2.5) and Taq DNA Polymerase (New England Biolabs, Ipswich, 
MA, U.S.A.). The primers used are listed in Table 2-3.  
 
The reaction set-up and thermal cycling conditions are described in Appendix 4b and 
4c. The STAT3α PCR product was purified using the PureLink™ PCR Purification 
Kit (Invitrogen, Carlsbad, U.S.A.) and cloned into pcDNA3.1/CT-GFP-TOPO vector 
(Invitrogen, Carlsbad, U.S.A.) using TA-TOPOisomerase cloning (Appendix 4h). 
The ligated product was transformed into One Shot® TOP10 Chemically Competent 
E. coli (Invitrogen, Carlsbad, U.S.A.) as described in Section 2.7.6. The transformed 
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cells were spread on Luria-Bertani Ampicillin (LBA) selective plates (Appendix 4l) 
and incubated overnight at 37 ºC. The colonies were then screened using colony PCR 
as described in Section 2.7.7. Lastly, the plasmid DNA of the positive clones was 
extracted using QIAprep® Miniprep (Invitrogen, Carlsbad, U.S.A.). The sequence 
integrity of the positive clones was verified by sequencing (1st BASE Pte Ltd, 
Singapore) and BLAST analysis was performed against the National Center for 
Biotechnology Information (NCBI) database (Section 2.7.8). 
 
Table 2-3: Primers used for cloning STAT3α and STAT3β GFP fusion constructs 























5'- gTTTCCAAACTGCATCAA -3' 
Underlined nucleotides
 
 denote gene specific sequences. Italicized nucleotides denote 
the Kozak sequences for translation initiation and lowercase nucleotides were 
included to make STAT3 gene in frame with GFP. 
For the cloning of STAT3β-GFP, the full length STAT3β PCR fragment was 
synthesized from two separately synthesized shorter PCR fragments using 
overlapping PCR. The left fragment was generated using STAT3α-GFP as template. 
The right fragment was generated using ∆N40-STAT3β-GFP (Chua et al., 2005) as 
template. The primers used are listed in Table 2-3. Proof reading Pfu DNA 
polymerase (Promega, Madison, U.S.A.) was used to create blunt-ended left and 
right PCR fragments as well as the full length STAT3β PCR fragment (Appendix 4d 
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and 4e). Taq DNA Polymerase (New England Biolabs, Ipswich, MA, U.S.A.) was 
used to add deoxyadenosine (A) to the 3´ end of the full length STAT3β PCR 
product before it was purified for use in TA-TOPOisomerase cloning (Appendix 4h) 
into pcDNA3.1/CT-GFP-TOPO vector (Invitrogen, Carlsbad, U.S.A.). The 
transformation of ligated product, selection of clones and checking of sequence 
integrity were carried out in the same way as that for STAT3α-GFP cloning (Section 
2.7.6 - 2.7.8). 
 
2.7.2. DENV NS proteins V5-His fusion constructs 
The DENV NS genes were amplified by PCR using the DENV2 infectious clone as 
template. The DENV2 NGC infectious clone was a kind gift from Dr Andrew 
Davidson (Department of Cellular and Molecular Medicine, University of Bristol, 
United Kingdom). Other than the seven NS proteins, NS1 to NS5, two additional 
clones were constructed. The first was sNS1 protein which includes the 28-amino-
acid long endoplasmic reticulum targeting sequence from the envelope protein of 
DENV. The second was NS2B-3 which encodes both NS2B and NS3 in the same 
construct where NS2B serves as the co-factor for NS3 protease. The primers used for 
the individual NS genes are listed in Table 2-4. Polymerase chain reaction was 
carried out using proof-reading AccuPrimeTM Pfx DNA polymerase (Invitrogen, 
Carlsbad, U.S.A.) to produce blunt-ended PCR products. The PCR products were 
purified using PureLink™ PCR Purification Kit and cloned into pcDNA™3.1D/V5-
His-TOPO® vector (Invitrogen, Carlsbad, U.S.A.) using directional-TOPOisomerase 
cloning (Appendix 4i). The transformation of ligated product, selection of clones and 
checking of sequence integrity were performed as described in Section 2.7.7 to 2.7.8.  
Materials and Methods 
44 | P a g e  
 
Table 2-4: Primers used for cloning DENV NS proteins V5-His fusion constructs 
Clone/ 
Fragment 







































































5’- CCACAG(a)ACTCCTGCCTC -3’ 
Underlined nucleotides
 
 denote gene specific sequences and italicized nucleotides 
denote the Kozak sequences for translation initiation. Lowercase nucleotides 
represent mutations introduced to incorporate the Kozak sequence into the clones and 
lowercase nucleotides in brackets ( ) are conserved mutations with no change in the 
final amino acid sequence introduced to prevent stem loop structures in the primers. 
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2.7.3. WNV NS1 proteins V5-His fusion constructs 
The WNV NS1 genes were amplified by PCR using the cDNA synthesized from 
WENV and KUNV viral RNA as template (Section 2.5), the primers listed in Table 
2-5 and AccuPrimeTM Pfx DNA polymerase (Invitrogen, Carlsbad, U.S.A.). Two 
forms of NS1 protein were cloned for each virus, one with the 24-amino-acid long 
endoplasmic reticulum targeting sequence from the envelope protein of WNV (sNS1) 
and the other without (NS1). The reaction set-up and thermal cycling conditions are 
described in Appendix 4. The blunt-end WNV NS1 PCR products were purified 
using PureLink™ PCR Purification Kit and cloned into pcDNA™3.1D/V5-His-
TOPO® vector (Invitrogen, Carlsbad, U.S.A.) using directional-TOPOisomerase 
cloning (Appendix 4i). The transformation of ligated product, selection of clones and 
checking of sequence integrity were performed as described in Section 2.7.6 to 2.7.8. 
 
Table 2-5: Primers used for cloning WNV NS1 proteins V5-His fusion constructs 
Clone/ 
Fragment 


























 - 3’ 
5’- (g)GCATTCACTCTCGATTGCAC -3’ 
Underlined nucleotides
 
 denote gene specific sequences and italicized nucleotides 
denote the Kozak sequences for translation initiation. Lowercase nucleotides 
represent mutations introduced to incorporate the Kozak sequence into the clones and 
lowercase nucleotides in brackets ( ) are conserved mutations with no change in the 
final amino acid sequence introduced to prevent stem loop structures in the primers. 
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2.7.4. IFNβ promoter luciferase reporter constructs 
The 110 base-pairs (bp) (position -110 to -1) and 300 bp (position -281 to +19) 5’ 
flanking promoter region of the IFNβ gene, which is found on chromosome 9 
complementary strand (GenBank Accession: NC_000009), was cloned into 
pGL4.10[luc2] vector (Promega, Madison, U.S.A.) upstream of a synthetic firefly 
luciferase gene (luc2) from Photinus pyralis which was codon optimized for better 
mammalian expression. The sequences of the promoters and the regulatory response 
elements are included in Appendix 5. The 300 bp promoter region was first 
synthesized using the genomic DNA from HEK293FT as template (Section 2.6.1). 
Next, this was used as the template for the synthesis of the 110 bp and 300 bp PCR 
product with NheI and BglII restriction endonuclease (RE) sites. The primers used 
are listed in Table 2-6 and AccuprimeTM Taq DNA polymerase high fidelity was 
used for all PCR (Appendix 4f and 4g). The PCR products were purified using 
PureLink™ PCR Purification Kit and subjected to restriction endonuclease cut by 
NheI and BglII (Promega, Madison, U.S.A.) as described in Appendix 4j. The 
digested products were then ligated with pGL4.10[luc2] vector which had been 
previously been cut with NheI and BglII using T4 DNA ligase (Promega, Madison, 
U.S.A.) and transformed into DH5α chemically competent E. coli (Section 2.7.6). 
Clones were selected and the sequence integrity of the clones was checked as 
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5’- cgtAGATCTAAGGTTGCAGTTAGAATGT -3’ 
Underlined nucleotides
 
 denote gene specific sequences and italicized nucleotides 
denote the restriction endoclease site. Lowercase nucleotides represent overhanging 
nucleotides added for the proper functioning of the restriction endonucleases. 
 
2.7.5. Yeast-two-hybrid constructs 
The DENV NS1 and STAT3 genes were cloned into the pGBKT7 (BD) and 
pGADT7 (AD) vectors (Clontech, Heidelberg, Germany), respectively. The NS1 
gene was amplified from DENV-sNS1-V5 (Section 2.7.2).  Full length STAT3α and 
truncated STAT3β were amplified from total RNA isolated from MRC-5 (Section 
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5'-gat CTCGAG TTA CTGTAGAAGGCGTGATT-3' 
Underlined nucleotides
 
 denote gene specific sequences and italicized nucleotides 
denote the restriction endoclease site. Lowercase nucleotides represent overhanging 
nucleotides added for the proper functioning of the restriction endonucleases. 
2.7.6. Transformation 
For TOPOisomerase-cloning (Section 2.7.1 to 2.7.3), One Shot® TOP10 Chemically 
Competent E. coli (Invitrogen, Carlsbad, U.S.A.) were used. The entire 6 µl of 
ligated products were mixed with one vial of One Shot® TOP10 Chemically 
Competent E. coli, mixed gently and incubated on ice for 30 min. The cells were 
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then heat-shocked at 42 ºC for 30 sec, following which, the tubes were transferred to 
ice for at least 2 min. Next, 250 µl of SOC medium (Appendix 4k) were added and 
the tubes were incubated with shaking (200 rpm) (Labnet Intl. Inc., Edison, USA) at 
37 ºC for 1 hr. The transformation mix was then spread on LBA selective agar plates 
(Appendix 4l) and incubated overnight at 37 ºC incubator (Thermo Fisher Scientific, 
Massachusetts, USA) with humidity atmosphere of 95% and 5% carbon dioxide. 
 
For DH5α Chemically Competent E. coli, the transformation procedure is similar to 
that of TOP10 Chemically Competent E. coli, with the exception that the heat-shock 
was performed at 42 ºC for 2 min. 
 
2.7.7. Colony PCR 
For each construct, at least 6 singly-spaced colonies that grew on selective plates 
were picked using a sterile 10 µl pipette tip and lightly streaked onto new replicate 
LBA plates (Appendix 4l). The remaining E. coli on the pipette tips was then mixed 
in the colony PCR mix, which contained the corresponding screening primers used 
for cloning and the other components needed for PCR using Taq DNA polymerase 
(Appendix 4). The PCR products were resolved using 1 % agarose gel for products 
above 1 kb and 1.5 % agarose gel for products below 1 kb (Appendix 4m). Positive 
clones would show PCR bands of the correct size under gel electrophoresis. The 100 
bp (Invitrogen, Carlsbad, U.S.A.) and 1 kb DNA ladder (Promega, Madison, U.S.A.) 
were used as standards for the determination the size of the PCR products. The 
corresponding positive clones from the replicate plates were then inoculated in LBA 
medium (Appendix 4a) and the plasmids were extracted using the QIAprep® 
Miniprep (Section 2.6.2). The plasmids of all positive clones showing the correct 
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PCR band sizes were then sequenced and analysed using BLAST to confirm their 
sequence integrity (Section 2.7.8). 
 
2.7.8. Sequencing and BLAST analysis 
The sequencing reaction mixture consisting of BigDye Terminator v.3.1 (Applied 
Biosystems, California, U.S.A.) reaction mix, sequencing primer (Table 2-8) and 
plasmid template was first prepared (Appendix 6a). The cycle sequencing reaction 
was then performed under the conditions stated in Appendix 6b.  
 
The extension products from the cycle sequencing reaction were precipitated by 
ethanol / potassium acetate precipitation. Briefly, the 10 µl sequencing reaction was 
transferred to a sterile 1.5 ml microfuge tube and made up to 100 µl with sterile 
autoclaved (Hirayama, Saitama, Japan) RO water (Millipore, Massachusetts, USA). 
Next, 250 µl of ethanol / potassium acetate solution (Appendix 6c) were added and 
incubated on ice for 10 min. Following which, the solution was centrifuged (Sigma 
Laborzentrifugen GmbH., Germany) at 14000 x g for 10 min at 4 ºC. The 
supernatant was discarded and the pellet was washed with 400 µl of 70 % ethanol, 
followed by centrifuging at 14000 x g for 10 min. The supernatant was discarded and 
the pellet was dried on a 50 °C heat block (USA Scientific Inc. Ocala, USA) before 
sending for sample electrophoresis and analysis using ABI Prism 3100 Genetic 
Analyser (Applied Biosystems, California, U.S.A.).  
 
Basic Local Alignment Search Tool (BLAST) analysis was conducted using the 
online bl2seq module to align the sequencing results against the corresponding genes 
and genomes sequence database on NCBI (Table 2-8).  
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T7 5'- TAATACGACTCACTATAGGG -3' 
S3seq-1 5’- GAGAATCTCCAGGATGACTT -3’ 
S3seq-2 5’- ATCAAGACCGGCGTCCAGTT -3’ 







T7 5'- TAATACGACTCACTATAGGG -3' 
S3seq-1 5’- GAGAATCTCCAGGATGACTT -3’ 
S3seq-2 5’- ATCAAGACCGGCGTCCAGTT -3’ 





T7 5'- TAATACGACTCACTATAGGG -3' 
BGH-R 5’- TAGAAGGCACAGTCGAGG -3’ 
KUNV-sNS1-
V5 & KUNV 
NS1-V5 
D00246 
T7 5'- TAATACGACTCACTATAGGG -3' 





T7 5'- TAATACGACTCACTATAGGG -3' 





NC_000009 RVp3 5'-  CTAGCAAAATAGGCTGTCCCC -3' 
BD-NS1 M29095 
T7 5'- TAATACGACTCACTATAGGG -3' 
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2.8. Yeast-two-hybrid 
2.8.1. Transformation of yeast cells 
The AH109 strain (Clontech, Heidelberg, Germany) Saccharomyces cerevisiae was 
transformed as described in the Clontech Yeast Protocols Handbook (Clontech, 
Heidelberg, Germany) and the Clontech Manual for the MATCHMAKER GAL4 
Two-Hybrid System (Clontech, Heidelberg, Germany). Briefly, 100 ng of each 
yeast-two-hybrid plasmid (Section 2.7.5), 100 µg of herring testes carrier DNA 
(Clontech, Heidelberg, Germany) and 100 µl of AH109 competent cells were re-
suspended in Tris-EDTA Buffer with 100 mM of lithium acetate (LiAc) (Clontech, 
Heidelberg, Germany).  Forty % polyethylene glycol (PEG) in 100 mM LiAc was 
added to the AH109 competent cell mixture and heat-shock was performed at 42 oC 
in a water bath (Gesellschaft für Labortechnik GmbH, Burgwedel, Germany) for 15 
min. Following heat-shock, the cells were pelleted and suspended in YPDA broth 
(Appendix 7a). Next, various dilutions of the transformed AH109 yeast cells were 
plated on the appropriate nutrient dropout media.  
 
2.8.2. Auto-activation assay 
AH109 yeast cells were co-transformed with BD-p53 and AD-T or BD and AD 
empty vectors as described in Section 2.8.1. Transformation was similarly carried out 
for single transformants of the various yeast-two-hybrid constructs (Section 2.7.5). 
Transformants were plated on histidine (-His) nutrient dropout plates (Appendix 7b).  
 
2.8.3. Yeast-two-hybrid 
Transformations were performed as described in Section 2.8.1 for BD-NS1 and the 
various AD-STAT3 constructs. Single transformants were grown on –Trp (Appendix 
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7b) or –Leu (Appendix 7b) nutrient dropout medium. Co-transformants were plated 
on double dropout (DDOb) plates (Appendix 7b), triple dropout (TDO) (Appendix 
7b). Colonies were then re-streaked onto quadruple dropout (QDO) plates with X-α-
gal (Appendix 7c) to determine the activation of ADE2 and MEL1 reporter genes. 
All plates were incubated for 5 – 7 days and observed for growth. 
 
2.9. Poly-D-Lysine coating 
HEK293FT and HEK293-hTLR3 cells were grown on culture plates, flasks and 
cover-slips (Marlenfeld, Lauda-Königshofen, Germany) coated with poly-D-lysine 
(Sigma-Aldrich, St. Louis, U.S.A.) for end-point experiments such as transfection 
studies  (Section 2.10), immunofluorescence assays (Section 2.13), co-
immunoprecipitation assays (Section 2.15), Western Blot analyses (Section 2.18) and 
dual luciferase assays (Section 2.21) . 
 
Briefly, the culture vessels were coated with poly-D-lysine (200 µl per well for 24-
well plate and 1 ml for T-25 flask) overnight at room temperature. Next day, the 
poly-D-lysine solution was removed and washed twice with sterile autoclaved RO 
water. The vessels were dried for at least 2 hr before use. 
 
2.10. Transient transfection  
HepG2, Huh7 and HeLa cells were transfected using LipofectamineTM LTX whereas 
HEK293FT and HEK293-hTLR3 cells were transfected using LipofectamineTM 2000 
(Invitrogen, Carlsbad, U.S.A.). 
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One day prior to transfection, cells were seeded into either 24-well or T-25 flasks 
(Iwakie Glass, Japan) at a density of 6 x 104 cells/cm2 of culture vessel surface area. 
For immunofluorescence studies, cover-slips were first placed into the wells under 
aseptic conditions prior to the seeding of cells (Table 2-9).  
 
Table 2-9: Transient transfection set-up for HepG2, Huh7 and HeLa cells 
 
Application 





Surface Area (cm 2) 25 2 2 
No. of cells seeded 1.5 x 106 1.2 x 105 1.2 x 105 
Single 
transfection 
Plasmid DNA 8.5 µg 700 ng - 
Double 
transfection 
DENV-sNS1-V5 4.25 µg 350 ng - 
STAT3-GFP 4.25 µg 350 ng - 
Firefly luc reporter - - 150 ng* 
Renilla luc (pRL-TK) - - 5 ng* 
Triple 
transfection 
NS protein-V5 - - 750 ng 
Firefly luc reporter - - 150 ng 
Renilla luc (pRL-TK) - - 5 ng 
Opti-MEM® I 1 ml 100 µl 100 µl 
Plus reagent 6.25 µl 0.5 µl 0.5 µl 
LipofectamineTM LTX 25 µl 2 µl 2 µl 
Co-IP: Co-immunoprecipitation assay; WB: Western blot analysis; IFA: 
Immunofluorescence assay; DLA: Dual luciferase assay. *: For double transfection 
in DLA, 0.125 µl of plus reagent, 50 µl of  Opti-MEM® I and 0.5µl of 
LipofectamineTM LTX were used.  
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For the transfection of HepG2, Huh7 and HeLa cells, the DNA and plus reagents 
were first diluted in Opti-MEM® I reduced serum medium without serum (Gibco, 
Invitrogen, NY, U.S.A.) and incubated for 5 min at room temperature (Table 2-9). 
LipofectamineTM LTX (Table 2-9) was then added and the solution was incubated for 
30 min at room temperature to allow the DNA-liposome complex to form. After the 
30 min incubation, the growth medium was aspirated and the DNA-liposome 
complex was added. The cells were then incubated at 37 ºC for 6 hr in a humidified 
incubator (Thermo Fisher Scientific, Massachusetts, USA) with 95 % air and 5 % 
CO2. Following the 6 hr incubation, the DNA-liposome complex was removed and 
replaced with growth medium to reduce the toxicity of the liposome complex on the 
cells. The cells were then incubated at 37 ºC in an atmosphere of 95 % air and 5 % 
CO2 for the indicated timing before the cells were harvested or fixed for the end 
point experiments.  
 
For the transfection of HEK293FT and HEK293-hTLR3 cells, the DNA and 
LipofectamineTM 2000 were separately diluted in Opti-MEM® I in separate tubes 
and incubated for 5 min (Table 2-10). After 5 min, the DNA and LipofectamineTM 
2000 were mixed and incubated for 20 min. The DNA-liposome complex was then 
added directly to the vessels containing growth medium. The cells were incubated at 
37 ºC for the indicated timing before the cells were harvested or fixed for the end 
point experiments.  
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Table 2-10: Transient transfection set-up for HEK293FT and HEK293-hTLR3 cells 
 
Application 
Co-IP & WB IFA DLA 






Surface Area (cm 2) 25 2 2 
No. of cells seeded 1.5 x 106 1.2 x 105 1.2 x 105 
Single 
transfection 
Plasmid DNA 10 µg 800 ng - 
Double 
transfection 
DENV-sNS1-V5 5 µg 400 ng - 
STAT3-GFP 5 µg 400 ng - 
Firefly luc reporter - - 150 ng* 
Renilla luc (pRL-TK) - - 5 ng* 
Triple 
transfection 
NS protein-V5 - - 750 ng 
Firefly luc reporter - - 150 ng 
Renilla luc (pRL-TK) - - 5 ng 
Opti-MEM® I 2 x 500 µl 2 x 50 µl 2 x 50 µl 
LipofectamineTM 2000 25 µl 2 µl 2 µl 
Co-IP: Co-immunoprecipitation assay; WB: Western blot analysis; IFA: 
Immunofluorescence assay; DLA: Dual luciferase assay. *: For double transfection 
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2.11. Generation of stable cell lines 
The effective G418, Geneticin® (Invitrogen, Carlsbad, U.S.A.) killing concentration 
was first determined by treating HepG2 cells over a range of G418 concentrations 
(750 µg/ml - 2000 µg/ml) for up to 7 days. The effective killing concentration was 
determined to be 2000 µg/ml for 7 days. 
 
HepG2 cells were then transiently transfected with DENV-sNS1-V5 as described in 
Section 2.10. One day post transfection, the cells were reseeded into 90-mm culture 
dish (Corning Inc., New York, USA) and the growth medium (Appendix 1d) was 
replaced with selection medium (growth medium containing 2000 µg/ml of G418) 
for the selection of positive clones which have taken up the DENV-sNS1-V5 plasmid. 
Selection medium were changed every other day to maintain antibiotic selection. 
Isolated colonies of cells were passaged for about 5 – 7 passages in selection medium 
before they were frozen down as described in Section 2.1.2. Positive clones were 
confirmed by Western Blot analysis (Section 2.18) of cell lysates using mouse anti-
V5 antibodies (Invitrogen, Carlsbad, U.S.A.) to detect for the integration of the 
sNS1-V5 fusion gene into the stable clones. 
 
2.12. Antibodies 
The antibodies and concentrations used for various applications are summarized in 
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Table 2-11: Antibodies information 







Cell Signalling Technology, 
Danvers, U.S.A 
#9139 1:1000 1:200 
NS1 Mouse 
Dr. Prida Malasit (Medical 
Molecular Biology Unit, 
Faculty of Medicine, Siriraj 
Hospital, Mahidol University, 
Bangkok, Thailand) 
- 1:500 - 
GFP Rabbit 
Sigma-Aldrich, St. Louis, 
U.S.A. 




AB3792 1:1000 - 
V5 Mouse Invitrogen, Carlsbad, U.S.A. R960-25 1:1000 1:400 
IRF-3 Rabbit 
Santa Cruz Biotechnology, 
Santa Cruz, U.S.A. 








Bioworld Technology, MN, 
USA 
BS5082 1:1000 - 
Total-IKK Rabbit 
Santa Cruz Biotechnology, 
Santa Cruz, U.S.A. 





Cell Signalling Technology, 
Danvers, U.S.A 
#3033 1:250 - 
Total-NF-kB Rabbit 
Santa Cruz Biotechnology, 
Santa Cruz, U.S.A. 
sc-372 1:1000 - 
viperin Mouse 
Hycult Biotech Inc., PA, 
U.S.A. 
MaP.VIP 1:1000 - 




WB: Western blot analysis; IFA: Immunofluorescence assay 
Materials and Methods 
59 | P a g e  
 
2.13. Immunofluorescence assay 
At the indicated timing post-polyinosine-polycytidylic acid (pIC) treatment (Section 
2.19) or post-transfection (Section 2.10), the medium was first aspirated and the cells 
were washed once with PBS (Appendix 1h). Next, the cells were fixed with 4 % 
formaldehyde (Appendix 8a) for 20 min at room temperature. After three washes 
with PBS, excess formaldehyde was quenched by incubation with 50 mM glycine 
(Appendix 8b) for 5 min at room temperature.  
 
Next, three washes with PBS were done before the cells were permeabilize with 0.2 % 
Triton-X-100 (Appendix 8c) for 10 min at room temperature. The cells were then 
washed three times with PBS and blocked with 5 % normal goat non-immune serum 
(PAA Laboratories, GmbH, Austria) for 1 hr in 37 ºC incubator (Thermo Fisher 
Scientific, Massachusetts, USA) with a humidity atmosphere of 95% and 5% carbon 
dioxide. After the blocking step, the cells were washed three times by incubating the 
cells with PBS for 5 min with shaking (70 rpm) (Labnet Intl. Inc., Edison, USA) at 
room temperature. 
 
Next, primary antibody staining (Table 2-11) was carried out at 4 ºC in a fridge 
overnight. After primary antibody staining, the cells were washed three times with 
PBS by shaking for 5 min each. Following the three washes, secondary antibody 
staining was performed at 37 ºC for 2 hr. Three washes with PBS and 5 min 
incubation with shaking during each wash were conducted prior to staining the 
nucleus with 4, 6-diamidino-2-phenylindole (DAPI) (Invitrogen Corp., Carlsbad, 
USA) for 10 min at room temperature (Appendix 8d). Next, the cells were washed 
three times with PBS prior to mounting the cover-slips (Marlenfeld, Lauda-
Materials and Methods 
60 | P a g e  
 
Königshofen, Germany) on glass slides using ProLong® Gold (Invitrogen, Carlsbad, 
U.S.A.). 
 
Confocal images were captured using the A1R fast laser scanning confocal 
microscope (Nikon, Japan) or the FluoView 1000 confocal microscope (Olympus, 
Japan). Widefield immunofluorescence images were captured using IX81 inverted 
microscope (Olympus, Japan). 
 
 
2.14. Cell lysis 
At the indicated timing post-pIC treatment (Section 2.18) or post-transfection 
(Section 2.10), the medium was first aspirated and the cells were washed once with 
PBS (Appendix 1h). 
 
For co-immunoprecipitation assay (Section 2.15), following washing with PBS, the 
cells in T-25 flasks (Iwaki Glass, Japan) were lysed using 350 µl of ice-cold trition-
X-100 lysis buffer (150 mM NaCl, 1% Triton X-100, 50 mM Tris-HCl, pH 8.0) 
containing a cocktail of complete, mini protease inhibitors (Roche, Mannheim, 
Germany) (Appendix 9a). Cells were scraped off the culture vessel and transferred to 
microfuge tubes. The cells were then incubated on ice for 1 hr with occasional 
mixing at 15-min intervals. Next, the cell debris was removed by centrifugation 
(Sigma Laborzentrifugen GmbH., Germany) at 10000 x g for 10 min. The 
supernatant containing the cell lysate was transferred to a new microfuge tube and 
used for co-immunoprecipitation (Section 2.15). 
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For phospho-protein assay (Section 2.3), following washing with PBS, the cells were 
lysed using the cell lysis buffer containing complete, mini protease inhibitor and 
phosphatase inhibitors (factor 1 and factor 2) from the Bio-PlexTM cell lysis kit (Bio-
Rad Laboratories, Hercules, U.S.A.). Cells were scraped off the culture vessel and 
transferred to microfuge tubes. The cells were then incubated on ice for 1 hr with 
occasional mixing at 15-min intervals. Next, the cell debris was removed by 
centrifugation at 10000 x g for 10 min.  
 
2.15. Co-immunoprecipitation assay 
Two methods of co-immunoprecipitation were used. The first method uses 
magnetically labelled protein G microbeads (Miltenyi Biotec, Bergisch Gladbach, 
Germany) to bind the antibody-antigen immune complexes. A magnetic field was 
then used to separate the protein G bound immune complexes from the unbound 
proteins in the cell lysates. The second method uses column immobilized protein G 
(Pierce, Rockford, U.S.A.). The protein G bound immune complexes were separated 
from the unbound proteins in the cell lysates using centrifugation. 
 
For magnetic separation, the cell lysates harvested (Section 2.14) were incubated 
with 100 µl of protein G magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, 
Germany) and 2 µg of either mouse anti-V5 or mouse anti-NS1 antibodies overnight 
at 4 ºC on a rotating shaker . On the following day, the µ separation column 
(Miltenyi Biotec, Bergisch Gladbach, Germany) was first placed in the magnetic 
field of the μMACS™ Separator and rinsed with 200 µl of lysis buffer (Appendix 9a). 
The elution buffer (Miltenyi Biotec, Bergisch Gladbach, Germany) was pre-heated to 
95 ºC. Next, the magnetically-labelled cell lysates were applied onto the column and 
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allowed to pass through by gravity flow. The flow-through was collected in fresh 
microfuge tubes. This was followed by four washes with 200 µl of lysis buffer 
(Appendix 9a) each. The column was washed one more time with 100 µl of a low-
salt wash buffer (Miltenyi Biotec, Bergisch Gladbach, Germany) to remove residual 
salt and detergent which may interfere with subsequent sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) analysis (Section 2.17). Next, 20 µl 
of pre-heated elution buffer was added to the column and incubated for 5 min at 
room temperature. Lastly, 50 µl of elution buffer was added and the eluates were 
collected in new microfuge tubes and used for SDS-PAGE (Section 2.17) and 
Western Blot analysis (Section 2.18).  
 
For centrifugal separation, the antibody protein G complex was first formed. The 
ImmunoPure® immobilized protein G (100 µl) was first applied onto Handee™ spin 
cup columns and centrifuged (Sigma Laborzentrifugen GmbH., Germany) at 5000 x 
g for 1 min. All centrifugation steps were carried under this condition. Next, the 
columns were washed twice by adding 400 µl of BupH™ Modified Dulbecco’s PBS 
(Pierce, Rockford, U.S.A.) to the columns followed by centrifugation and discarding 
the flowthrough. Next, 10 µg of mouse anti-NS1 diluted in 400 µl BupH™ Modified 
Dulbecco’s PBS was added to each column and incubated with protein G from kit 
(Pierce, Rockford, U.S.A.) on the column for 2 hr at 4 ºC on a rotating shaker (N-
Biotek, Gyeonggi, Korea). After incubation, the columns were washed three times by 
adding 400 µl of with BupH™ Modified Dulbecco’s PBS to the columns followed 
by centrifugation and discarding the flow-through. 
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The cell lysates harvested (Section 2.14) were then applied to the column containing 
the protein G-anti-NS1 protein immune complex and incubated at 4 ºC overnight. 
After the overnight incubation, the columns were centrifuged and the flow-through 
was collected in fresh microfuge tubes. Next, the columns were washed three times 
by adding 500 µl of BupH™ Modified Dulbecco’s PBS to the columns followed by 
centrifugation and discarding the flow-through. Lastly, 190 µl of ImmunoPure® 
Elution Buffer was added to the column and centrifuged. The eluates were collected 
in new microfuge tubes and used for SDS-PAGE (Section 2.17) and Western Blot 
analysis (Section 2.18).  
 
2.16. Protein quantitation 
The cell lysates harvested (Section 2.14) were quantitated for protein content using 
the DC protein assay (Bio-Rad Laboratories, Hercules, CA, U.S.A.). First, 6 dilutions 
of immunoglobulin G protein standards (0.2 mg/ml, 0.4 mg/ml, 0.8 mg/ml, 1.0 
mg/ml, 1.25 mg/ml and 1.5 mg/ml) were prepared. Next, 2- and 4- fold serial 
dilutions of the cell lysates (Section 2.14) were prepared. Next, 5 µl of protein 
standards and cell lysates were added into each well of clear microtiter plates (Nunc, 
Thermo Fisher Scientific, Denmark). After the samples were added into the wells, 25 
µl of reagent A’ were added to each well. Reagent A’ was prepared by adding 20 µl 
of reagent S to each ml of reagent A. This was followed by the addition of 200 µl of 
reagent B to each well and incubated for 15 min. After 15 min incubation, 
absorbance readings were measured at 750 nm using Infinite® 200 microplate reader 
(Tecan, Switzerland). 
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2.17. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
The cell lysates and co-immunoprecipitation eluates were resolved by SDS-PAGE 
using 10 % Tris-glycine gels (Appendix 9b). Three parts of samples were added to 
one part of SDS loading dye (4x) (Appendix 9c) and heated at 100 ºC for 5 min prior 
to loading into the polyacrylamide gels. The cathode and anode buffers used are 
specified in Appendix 9d. A constant voltage of 200 V was applied for 30 min to 
resolve the gels. The PageRulerTM prestained protein ladder (Fermentas Life Sciences, 
Burlington, Canada) was loaded for each gel for the estimation of protein size. 
 
2.18. Western Blot analysis 
The protein samples resolved using SDS-PAGE (Section 2.17) were transferred onto 
polyvinylidene fluoride (PVDF) membranes using the iBlot® Dry Blotting System 
(Invitrogen, Carlsbad, U.S.A.) according to the manufacturers protocol. Briefly, the 
gel was cut and placed on the anode stack (bottom) containing the PVDF membrane. 
Next, the filter paper was placed above the gel and bubbles were removed using a 
roller to flatten the gel and filter paper. The cathode stack (top) was then placed on 
the filter paper. Following which, the entire stack was placed into the iBlot® Dry 
Blotting System (Invitrogen, Carlsbad, U.S.A.) and the transfer was performed using 
program 3 for 7 min.  
 
The blots containing the transferred protein were then blocked with 5 % milk in PBS 
(Appendix 1h) for 1 hr at room temperature with gentle shaking. The blots were 
briefly washed once with PBS before incubating with primary antibodies (Table 
2-11), which were diluted in 5 % milk in PBS, overnight at 4 ºC with gentle shaking.  
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On the next day, the primary antibodies solutions were removed and the blots were 
washed thrice with Tris-buffered saline Tween-20 (TBST) (Appendix 9e). For each 
wash, the blots were incubated with TBST for 5 min with shaking. Staining with 
horseradish peroxidise-conjugated goat anti-mouse or anti-rabbit secondary 
antibodies (Pierce, Thermo Scientific, Rockford, U.S.A.) was then performed for 1 ½ 
hr at room temperature with gentle shaking. This was followed by three washes with 
TBST similar to that after primary antibodies staining.  
 
The blots were then incubated with either the SuperSignal® West Pico or Dura 
extended duration chemiluminescent substrate (Pierce, Thermo Scientific, Rockford, 
U.S.A.) for 5 min. Next, the blots were developed at various exposure timings using 
CL-XposureTM clear blue x-ray films (Thermo Scientific, Rockford, U.S.A.). 
 
2.19. Polyinosine-polycytidylic acid treatment 
For dual luciferase assays (Section 2.21), HEK293-hTLR3 and HeLa cells were 
treated with either 10 µg/ml or 20 µg/ml of polyinosine-polycytidylic acid (pIC) 
(Invivogen, San Diego, U.S.A.), respectively for 6 hr before the cells lysates were 
harvested. For phospho-protein assay (Section 2.3), immunofluorescence assays 
(Section 2.13) and Western blot analysis (Section 2.18) the cells were treated with 20 
µg/ml of pIC for 4 hr before the cells were either fixed or harvested. For real-time 
RT-PCR (Section 2.22), the cells were treated with 20 µg/ml of pIC for 24 hr before 
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2.20. STAT3 activation studies 
For immunofluorescence assay (Section 2.13), mock-infected and DENV-infected 
Huh7 cells were treated with either 100 ng/ml of IL6 (Biosource, Invitrogen, 
Carlsbad, U.S.A.) or 1000 units of IFNα (Biosource, Invitrogen, Carlsbad, U.S.A.) 
for 30 min to activate STAT3. Nuclear localization of STAT3 protein is indicative of 
STAT3 protein activation.  
 
2.21. Dual luciferase assay 
At the indicated timing post-infection (Section 2.2.4), post-transfection (Section 2.10) 
or post-pIC treatment (Section 2.19), the medium was aspirated and the cells were 
washed once with PBS (Appendix 1h). Next, 100 µl of passive lysis buffer was 
added and incubated for 15 min with shaking to lyse the cells. The cell lysates were 
then transferred to microfuge tubes and frozen down at -80 ºC until they were used 
for dual luciferase assay.  
 
The stored cell lysates were thawed on ice, following which, 20 µl of the cell lysates 
were added to each well. Three biological replicates were performed for each test 
condition. The firefly and Renilla luciferase activity was then determined using the 
dual luciferase reporter assay system (Promega, Madison, U.S.A.) and GlomaxTM 
multi-detection system with auto-injectors (Promega, Madison, U.S.A.). Briefly, 100 
µl of luciferase assay reagent II (LAR II) was added to each well. The luciferase 
activity was measured over 10 sec following a 2-sec delay after the addition of LAR 
II. Next, 100 µl of Stop & Glo® was added to each well and read over 10 sec 
following a 2-sec delay after the addition of Stop & Glo®. The firefly luciferase 
activity was normalized against that of Renilla luciferase activity and the resultant 
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normalized relative luciferase activity were expressed in arbitrary relative luciferase 
units (RLU). 
 
2.22. Real-time RT-PCR 
Total RNA were isolated (Section 2.4) from transiently transfected (Section 2.10) 
HeLa cells at 6 hr or 24 hr post pIC-treatment (Section 2.19). First strand cDNA was 
then synthesized from 1 µg of total RNA (Section 2.5). The first strand cDNA was 
diluted by a factor of 100 just prior to use. Following which, real-time RT-PCR was 
conducted using the SYBR GreenER qPCR SuperMix for ABI PRISM (Invitrogen, 
Carlsbad, U.S.A.). Each reaction well consists of 10 µl of SYBR GreenER qPCR 
SuperMix (2x), 1 µl of first strand cDNA, 0.4 µl of forward primer, 0.4 µl of reverse 
primer and 8.2 µl of DEPC water (Appendix 3a). The primers used are listed in Table 
2-12. Readings were acquired using an ABI PRISM 7000 real-time PCR system 
(Applied Biosystems, California, U.S.A.). The thermal cycling conditions are shown 
in Appendix 10. Hypoxanthine phosphoribosyltransferase (HPRT) and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used as housekeeping 
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Table 2-12: List of primers used for real-time RT-PCR 
Clone/ 
Fragment 
Primer Name Primer Sequence  
CCL5 
CCL5 F 5’- ATCCTCATTGCTACTGCCCTC -3’ 
CCL5 R 5’- GCCACTGGTGTAGAAATACTCC -3’ 
IRF1 
IRF1 F 5’- ATGCCCATCACTCGGATGC -3’ 
IRF1 R 5’- CCCTGCTTTGTATCGGCCTG -3’ 
IRF7 
IRF7 F 5’- GAGCCGTACCTGTCACCCT -3’ 
IRF7 R 5’- GGGCCGTATAGGAACGTGC -3’ 
ISG56 
ISG56 F 5’- GGTGACCTGGGGCAACTTT -3’ 
ISG56 R 5’- CCCGTTCATAATTCTTTCCTCCA -3’ 
Mx1 
Mx1 F 5’- TCCCACCCTCTATTACTGAATGG -3’ 
Mx1 R 5’- GGGAAGGGCAACTCCTGAC -3’ 
OAS1 
OAS1 F 5’- AGAAATACCCCAGCCAAATCTCT -3’ 
OAS1 R 5’- TGAGGAGCCACCCTTTACCA -3’ 
viperin 
Viperin F 5’- TTCACTCGCCAGTGCAACTAC -3’ 
Viperin R 5’- CGGTCTTGAAGAAATGGCTCT -3’ 
HPRT 
HPRT F 5’- TGACACTGGCAAAACAATCA -3’ 
HPRT R 5’- GGTCCTTTTCACCAGCAAGCT -3’ 
GAPDH 
GAPDH F 5’- TGCACCACCAACTGCTTAGC -3’ 






Statistical analyses were done using a two-tailed Student’s t test. The only exception 
was in Figure 5-10b where hypothesis testing for differences in proportion was 
performed. The data for t test were expressed as the mean ± standard errors of the 
mean (SEM) while the results for hypothesis testing for differences in proportion 
were presented as 95% confidence intervals. P-values of less than 0.05 (*) and p-
values between 0.05 and 0.10 (#) were considered significant. 
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3. Results 
3.1. Choice of cell lines as in vitro model for dengue virus 
infection 
Prior to conducting any downstream experiments, it is imperative that the in vitro 
disease model chosen is relevant and reflective of DENV in humans. The in vitro 
cell-based model chosen must be able to support DENV replication. Several cell 
lines, namely HepG2, Huh7, HeLa and HEK293-hTLR3, were tested for their 
abilities to support DENV replication. HepG2 and Huh7 cells are of hepatic lineages. 
HeLa cells are of epithelial origins. HEK293-hTLR3 cells, which stably-express 
human TLR3, are of fibroblastic sources. 
 
All the tested cell lines were found to be susceptible to DENV infection (Figure 3-1). 
Peak virus production was observed at 48 hr for HepG2, Huh7 cell and HeLa cells 
(Figure 3-1). Maximum virus titre was obtained at between 72 – 96 hr for HEK293-
hTLR3 cells (Figure 3-1).  
 
As all the tested cell-lines were able to support DENV replication, they were chosen 
as in vitro models for subsequent experiments in this study. Different cell lines were 
chosen for different downstream experiments, depending on their transfection 
efficiencies, strength of adherence to glass coverslips and availability of reagents for 
that particular experiment. For instance, HeLa and HEK293-hTLR3 cells were 
preferred to HepG2 and Huh7 for transfection studies due to the higher transfection 
efficiencies. For immunofluorescence assays, HeLa, HepG2 and Huh7 were 
preferred to HEK293-hTLR3 because of the stronger adherent properties to glass 
surfaces. When the availability of certain reagents was limited, experiments were 
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conducted mainly in HeLa cells, which have high transfection efficiency and strong 
adherent properties. This use of several cell lines of different origins across different 
experiments served also to eliminate cell line specific effects of any phenomenon 
that would be observed subsequently in the downstream experiments. In addition, 
hepatic cell lines such as HepG2 and Huh7 are also representative target cells for 
DENV infection as liver pathology are observed clinically in some cases of dengue 



















Figure 3-1: HepG2, Huh7, HeLa and HEK293-hTLR3 cells support dengue 
virus replication. 
HepG2, Huh7, HeLa and HEK293-hTLR3 cells were infected with dengue virus type 
2 (DENV2) at a multiplicity of infection (MOI) of 1. Virus supernatants were then 
collected 0, 24, 48, 72, 96, 120 and 144 hr post-infection. Plaque assays were 
performed to determine the plaque forming unit (PFU) of the virus supernatants. Two 
independent experiments were conducted and the data are presented as mean Log10 
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3.2. Signal transduction pathway profiling of dengue virus 
infection 
Viral pathogenesis is the result of the intricate interplay between numerous viral and 
host factors. These virus-host interactions determine virus infectivity, host cell 
susceptibility and eventually the disease outcome (Baron and Albrecht, 1996). Virus-
host interplay involves, but is not limited to, the modulation of numerous cellular 
signalling pathways. Hence, the initial part of this study aims to profile and identify 
novel signalling pathways, if any, implicated in DENV infection.  
 
Since DENV infection has been reported to induce inflammation (Huerta-Zepeda et 
al., 2008), innate immune responses (Kurane and Ennis, 1988) and apoptosis 
(Despres et al., 1996; Matsuda et al., 2005), pathways which are known to regulate 
these cellular processes were studied for their involvements during DENV infection. 
The signalling pathways investigated in this study were namely NF-κB, Jak/STAT, 
PI3K/Akt and MAPK signal transduction pathways. The MAPK pathway can be 
further classified into 3 sub-pathways, namely Erk, p38 MAPK and SAPK/JNK. 
 
To examine the regulation of these pathways, a multiplex signal transduction 
pathway profiling assay was conducted to screen for pathways differentially 
modulated during DENV infection. This profiling assay integrates the well 
established technology of flow cytometry and enzyme-linked immunosorbent assay 
(ELISA) to allow for the simultaneous detection and more importantly the 
quantification of the amount of phosphorylated signal transduction proteins present 
in the cell lysates. 
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This signal transduction pathway profiling assay utilizes the knowledge that cellular 
signal transductions are tightly regulated by a series of phosphorylation and de-
phosphorylation of key signalling proteins and transcriptional factors (Kufe et al., 
2003). The phosphorylation and dephosphorylation are brought about by kinases and 
phosphatases, respectively (Kufe et al., 2003). These phosphorylated signal 
transduction proteins control the transcription and translation of specific downstream 
effector genes (Kufe et al., 2003). Hence by studying the extent of phosphorylation 
of key signalling molecules in a certain pathway, the differential regulation of the 
pathway can be analyzed.  
 
A total of 19 different phosphorylated (p-) signal transduction proteins were 
examined. The signal transduction proteins investigated are namely Akt, ATF2, 
CREB, Erk, GSK-3, HSP27, IκB, IRS-1, JNK, p38 MAPK, MEK1, p53, p70 S6 
Kinase, p90RSK, Src, STAT2, STAT3, TrkA and Tyk2. The grouping of these signal 
transduction proteins into the NF-κB, Jak/STAT, PI3K/Akt, Erk, p38 MAPK and 
SAPK/JNK signalling pathways are listed in Table 3-1. Due to the cross-talk and 
intricate nature of cellular signalling, some of signal transduction proteins 
investigated are known to play regulatory roles across several pathways (Kufe et al., 
2003).  
 
As different pathways may be implicated during different stages of the DENV 
replication cycle within the cells, 4 different timings (6 hr, 24 hr, 48 hr and 72 hr) 
post-infection were chosen to reflect the cellular events occurring during early, early-
mid, mid and late infection, respectively.  
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HeLa cells, which support DENV replication, were chosen as the in vitro model for 
this study. The results were grouped according to their respective signalling 
pathways (Section 3.2.1 - 3.2.4) for easier and clearer analysis of the signal 
transduction pathways implicated during DENV infection.  
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3.2.1. Analysis of NF-κB signalling during dengue virus infection  
The transcription factor NF-κB is a key signal transduction protein that is important 
for the signal transduction of several pathways such as SAPK/JNK (Spiegelman et 
al., 2001), p38 MAPK (Kato et al., 2003), G protein-coupled receptors (GPCR)/Src 
(Funakoshi-Tago et al., 2005; Jalal and Kone, 2006; Lee et al., 2007) and PI3K/Akt 
(Kane et al., 1999). NF-κB is normally present in the cytosol as an inactive complex 
with IκB. Activation of NF-κB signalling involves the phosphorylation of IκB, 
leading to the proteasome degradation of IκB. The degradation of IκB frees up NF-
κB to translocate to the nucleus where it exerts its effect as a transcription factor to 
regulate the expression of downstream genes (Alberts, 2002). Hence, to study the 
signal transduction of NF-κB pathway during DENV infection, the regulation of 
upstream pathways such as SAPK/JNK, p38 MAPK, GPCR/Src and PI3K/Akt was 
investigated. In addition, p-IκB levels were examined as a surrogate marker to gauge 
the extent of activation of NF-κB signalling. 
 
As shown in Figure 3-2a, there was a significant increase in the activation of 
upstream JNK at 72 hr post-infection in the DENV-infected samples relative to the 
mock-infected samples. The amount of p-p38 MAPK was not significantly altered by 
DENV infection across all time points although there appeared to be about 4 fold 
increase in the amount of p-p38 MAPK in the DENV-infected samples as compared 
to the mock-infected samples at 72 hr post-infection (Figure 3-2b). Similar to JNK, 
Src activation was elevated at 72 hr post-infection (Figure 3-2c). Src activation, 
however, was inhibited initially during early infection at 6 hr post-infection (Figure 
3-2c). Unlike JNK and Src, there was no increase in the activation of Akt at 72 hr 
Results 
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post-infection (Figure 3-2d). Akt activation was instead observed to be down-
regulated at 24 hr post-infection (Figure 3-2d).   
 
The level of downstream IκB phosphorylation (Figure 3-2e), and consequently NF-
κB activation, was found to be similar to that of Src activation (Figure 3-2c). IκB 
phosphorylation levels were observed to be significantly decreased at 6 hr post-
infection and elevated at 72 hr post-infection in DENV-infected HeLa cells as 



















77 | P a g e  
 
Figure 3-2: Analysis of NF-κB signalling during dengue virus infection. 
HeLa cells were either mock-infected (-) or infected with DENV (+) at MOI = 1. At 
6, 24, 48 and 72 hr post-infection, the cells lysates were harvested. 50 µg of each 
lysate was assayed for the amount of (a) p-JNK, (b) p-p38 MAPK, (c) p-Src, (d) p-
Akt and (e) p-IκB-α present. Two independent experiments were conducted and the 
results are presented as fluorescence intensity ± SEM. * and # denotes statistically 
significant difference at p < 0.05 and 0.05 < p < 0.10, respectively between the 
mock- and DENV-infected samples. Red and green bars represent statistically 
significant down-regulation and up-regulation, respectively of the signal transduction 
protein in DENV-infected samples as compared to mock-infected samples (black 
bars). Blue bars represent no significant changes in the amount of signal transduction 
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3.2.2. Analysis of Jak/STAT signalling during dengue virus 
infection 
After investigating the NF-κB signal transduction pathway, the effects of DENV 
infection on Jak/STAT signalling, which acts downstream of NF-κB via IFNα/β 
signal transduction (Taniguchi and Takaoka, 2002), were examined.  
 
At 6 hr post-infection, the activation of upstream Src was found to be inhibited in 
DENV-infected samples as compared to mock-infected samples (Figure 3-3a). 
Conversely, Src activation levels were elevated at 72 hr post-infection (Figure 3-3a). 
Activation of upstream Tyk2 in Jak/STAT signal transduction was also observed to 
be increased at 72 hr post-infection (Figure 3-3b). 
 
Similar to upstream Tyk2 (Figure 3-3b), downstream STAT2 activation was elevated 
at 72 hr post-infection (Figure 3-3c). In addition, STAT2 activation was slightly 
raised at 24 hr post-infection in DENV-infected samples (Figure 3-3c). As shown in 
Figure 3-3d, STAT3 activation was down-regulated in DENV-infected HeLa cells at 
6 hr post-infection and then slightly up-regulated at 24 hr post-infection. The initial 
inhibition profile of downstream STAT3 activation (Figure 3-3d) at 6 hr post-

















- + - + - + - +























- + - + - + - +
























- + - + - + - +

























- + - + - + - +
















































 Down-regulation No Change Up-regulation Mock-infected 
 
 
Figure 3-3: Analysis of Jak/STAT signalling during dengue virus infection. 
HeLa cells were either mock-infected (-) or infected with DENV (+) at MOI = 1. At 
6, 24, 48 and 72 hr post-infection, the cells lysates were harvested. 50 µg of each 
lysate was assayed for the amount of (a) p-Src, (b) p-Tyk2, (c) p-STAT2, and (d) p-
STAT3 present. Two independent experiments were conducted and the results are 
presented as fluorescence intensity ± SEM. * and # denotes statistically significant 
difference at p < 0.05 and 0.05 < p < 0.10, respectively between the mock- and 
DENV-infected samples. Red and green bars represent statistically significant down-
regulation and up-regulation, respectively of the signal transduction protein in 
DENV-infected samples as compared to mock-infected samples (black bars). Blue 
bars represent no significant changes in the amount of signal transduction protein 
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3.2.3. Analysis of PI3K/Akt signalling during dengue virus infection 
Next, the PI3K/Akt pathway, which is one of the critical pathways controlling cell 
survival (Dudek et al., 1997; Franke et al., 1997), was investigated for its 
involvement during DENV infection. It was observed that Akt activation, measured 
by the levels of p-Akt, was significantly decreased at 24 hr post-infection in DENV-
infected samples as compared to mock-infected samples (Figure 3-4a). This 
reduction in Akt activation, however, did not result in any corresponding modulation 
of the levels of p-GSK-3α/β (Figure 3-4b), p-p70 S6 Kinase (Figure 3-4c) and p-
CREB (Figure 3-4d) at 24 hr post-infection.  
 
The level of p70 S6 kinase activation was decreased at 6 hr post-infection (Figure 
3-4c) while the levels of GSK-3α/β (Figure 3-4b) and CREB (Figure 3-4d) activation 
were increased at 72 hr post-infection in DENV-infected HeLa cells relative to 
mock-infected HeLa cells. On the contrary, the Akt activation levels at 6 and 72 hr 















- + - + - + - +























- + - + - + - +




















- + - + - + - +

























- + - + - + - +















































 Down-regulation No Change Up-regulation Mock-infected 
 
 
Figure 3-4: Analysis of PI3K/Akt signalling during dengue virus infection. 
HeLa cells were either mock-infected (-) or infected with DENV (+) at MOI = 1. At 
6, 24, 48 and 72 hr post-infection, the cells lysates were harvested. 50 µg of each 
lysate was assayed for the amount of (a) p-Akt, (b) p-GSK-3α/β, (c) p-p70 S6 Kinase 
and (d) p-CREB present. Two independent experiments were conducted and the 
results are presented as fluorescence intensity ± SEM. * and # denotes statistically 
significant difference at p < 0.05 and 0.05 < p < 0.10, respectively between the 
mock- and DENV-infected samples. Red and green bars represent statistically 
significant down-regulation and up-regulation, respectively of the signal transduction 
protein in DENV-infected samples as compared to mock-infected samples (black 
bars). Blue bars represent no significant changes in the amount of signal transduction 
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3.2.4. Analysis of MAPK signalling during dengue virus infection 
3.2.4.1. Analysis of Erk signalling during dengue virus infection 
Following the analysis of PI3K/Akt signalling during DENV infection, the effects of 
DENV infection on MAPK signalling pathway were investigated. First, the 
involvement of Erk sub-pathway of MAPK signal transduction during DENV 
infection was studied. The Erk signalling pathway can receive signals from various 
upstream activators such as GPCR (Lodish, 2000), receptor tyrosine kinase (RTK) 
(Lodish, 2000), Src (Daulhac et al., 1999) and TrkA (Miranda et al., 2010). The Ras 
small G-protein links these upstream receptors and kinases to the downstream Erk 
signalling (Kufe et al., 2003). 
 
As shown in Figure 3-5a, the upstream Src activation was inhibited at 6 hr post-
infection but up-regulated at 72 hr post-infection. Unlike Src (Figure 3-5a), the 
activation of another upstream kinase, TrkA was significantly elevated only at 24 hr 
post-infection (Figure 3-5b).  
 
Despite the modulation of upstream Src (Figure 3-5a) and TrkA (Figure 3-5b) during 
DENV infection, the activation levels of downstream MEK1 (Figure 3-5c) and 
Erk1/2 (Figure 3-5d) were not significantly changed. Correspondingly, the activation 
level of p90RSK, downstream of Erk, was not significantly altered during DENV 
infection (Figure 3-5e). 
 
Other known downstream targets of Erk signalling, however, were found to be 
differentially regulated during DENV infection. For instance, downstream CREB  
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Figure 3-5: Analysis of Erk signalling during dengue virus infection. 
HeLa cells were either mock-infected (-) or infected with DENV (+) at MOI = 1. At 
6, 24, 48 and 72 hr post-infection, the cells lysates were harvested. 50 µg of each 
lysate was assayed for the amount of (a) p-Src, (b) p-TrkA, (c) p-MEK1, (d) p-
Erk1/2, (e) p-p90RSK, (f) p-CREB, (g) p-STAT3 and (h) p-p70 S6 Kinase present. 
Two independent experiments were conducted and the results are presented as 
fluorescence intensity ± SEM. * and # denotes statistically significant difference at p 
< 0.05 and 0.05 < p < 0.10, respectively between the mock- and DENV-infected 
samples. Red and green bars represent statistically significant down-regulation and 
up-regulation, respectively of the signal transduction protein in DENV-infected 
samples as compared to mock-infected samples (black bars). Blue bars represent no 
significant changes in the amount of signal transduction protein between the mock 
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activation was significantly increased at 72 hr post-infection (Figure 3-5f). STAT3 
activation was first down-regulated at 6 hr post-infection and then up-regulated at 24 
hr post-infection (Figure 3-5g). Similar to Src (Figure 3-5a) and STAT3 (Figure 
3-5g), the activation level of p70 S6 Kinase was also reduced at 6 hr post-infection 
(Figure 3-5h). 
 
3.2.4.2. Analysis of p38 MAPK signalling during dengue virus 
infection 
Second, the implication of p38 MAPK sub-pathway of MAPK signalling during 
DENV infection was examined. From Figure 3-6a, it could be observed that the level 
of upstream p38 MAPK activation was not significantly changed at all the time 
points tested.  
 
Similar to that of p38 MAPK (Figure 3-6a), the activation profiles of downstream 
p53 (Figure 3-6b) and CREB (Figure 3-6c) were also elevated at 72 hr post-infection. 
On the contrary, the regulation of another downstream signal transduction protein, 
ATF2 (Figure 3-6d), was different from that of upstream p38 MAPK (Figure 3-6a). 
ATF2 was found to be up-regulated at 24 hr post-infection (Figure 3-6d). There were 
also no significant changes in HSP27 activation (Figure 3-6e), downstream of p38 
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Figure 3-6: Analysis of p38 MAPK signalling during dengue virus infection. 
HeLa cells were either mock-infected (-) or infected with DENV (+) at MOI = 1. At 
6, 24, 48 and 72 hr post-infection, the cells lysates were harvested. 50 µg of each 
lysate was assayed for the amount of (a) p38 MAPK, (b) p-p53, (c) p-CREB, (d) p-
ATF2 and (e) p-HSP27 present. Two independent experiments were conducted and 
the results are presented as fluorescence intensity ± SEM. * and # denotes statistically 
significant difference at p < 0.05 and 0.05 < p < 0.10, respectively between the 
mock- and DENV-infected samples. Red and green bars represent statistically 
significant down-regulation and up-regulation, respectively of the signal transduction 
protein in DENV-infected samples as compared to mock-infected samples (black 
bars). Blue bars represent no significant changes in the amount of signal transduction 
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3.2.4.3. Analysis of SAPK/JNK signalling during dengue virus 
infection 
Third and last, the effects of DENV infection on SAPK/JNK sub-pathway of MAPK 
signalling were investigated. Upstream JNK activation level was significantly up-
regulated at 72 hr post-infection in DENV-infected samples as compared to mock-
infected samples (Figure 3-7a). 
 
Correspondingly, downstream p53 activation level was also significantly raised at 72 
hr post-infection (Figure 3-7b). Unlike p53, the regulation of other downstream 
signal transduction proteins such as ATF2 (Figure 3-7c), STAT3 (Figure 3-7d) and 
IRS-1 (Figure 3-7e) differ from that of upstream JNK. ATF2 activation levels 
(Figure 3-7c) were increased at 24 hr post-infection whereas there were no 
significant changes in JNK activation levels at that same time point (Figure 3-7a). 
STAT3 activation was down-regulated at 6 hr post-infection and then up-regulated at 
24 hr post-infection (Figure 3-7d). There were no significant changes in the level of 
activation of downstream IRS-1 (Figure 3-7e) at all time points investigated despite 
the elevation of JNK activation levels at 72 hr post-infection (Figure 3-7a). 
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Figure 3-7: Analysis of SAPK/JNK signalling during dengue virus infection. 
HeLa cells were either mock-infected (-) or infected with DENV (+) at MOI = 1. At 
6, 24, 48 and 72 hr post-infection, the cells lysates were harvested. 50 µg of each 
lysate was assayed for the amount of (a) p-JNK, (b) p-p53, (c) p-ATF2, (d) p-STAT3 
and (e) p-IRS-1 present. Two independent experiments were conducted and the 
results are presented as fluorescence intensity ± SEM. * and # denotes statistically 
significant difference at p < 0.05 and 0.05 < p < 0.10, respectively between the 
mock- and DENV-infected samples. Red and green bars represent statistically 
significant down-regulation and up-regulation, respectively of the signal transduction 
protein in DENV-infected samples as compared to mock-infected samples (black 
bars). Blue bars represent no significant changes in the amount of signal transduction 
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3.3. Generation of mammalian expression plasmids 
3.3.1. Generation of dengue virus non-structural proteins 
mammalian expression plasmids 
After establishing the implication of NF-κB (Section 3.2.1), Jak/STAT (Section 
3.2.2), PI3K/Akt (Section 3.2.3) and MAPK (Section 3.2.4) signal transduction 
pathways during DENV infection, the next key scientific question to answer is what 
are the mechanisms involved in the regulation of these pathways by DENV. A 
plausible approach to answer this question is to screen the individual viral 
components, which comprise of the viral RNA, and the structural and non-structural 
(NS) proteins (Chambers et al., 1990a), for their ability to modulate these pathways. 
 
In the recent years, it was brought to light that self-duplicating sub-genomic DENV 
RNA, referred to as replicons, were able to modulate various signalling pathways 
such as IFNα/β signalling (Jones et al., 2005) and STAT2 signalling (Mazzon et al., 
2009).  These replicons express all the DENV NS proteins, which is necessary for 
the replication of the sub-genomic RNA replicons. These results suggested that either 
the DENV sub-genomic RNA or the NS proteins were responsible for the regulation 
of the various signalling pathways. Hence, as an initial screen, the DENV NS 
proteins were examined for their ability to modulate these pathways.  
 
To screen for the ability of each individual DENV NS protein to modulate the 
various pathways, it was necessary to first generate mammalian expression plasmids, 
which express the individual DENV NS proteins in mammalian cells. The open 
reading frame of each of the individual DENV NS protein was first cloned into the 
pcDNA3.1 mammalian expression vector upstream of V5 and poly-histidine (p-HIS) 
Results 
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tags (Figure 3-8a). Other than the seven NS proteins, two additional constructs, 
namely ER-targeted NS1 (sNS1) and NS2B-3 were also created (Figure 3-8b). These 
plasmids were named as DENV-sNS1-V5, DENV-NS1-V5, DENV-NS2A-V5, 
DENV-NS2B-V5, DENV-NS2B-3-V5, DENV-NS3-V5, DENV-NS4A-V5, DENV-
NS4B-V5 and DENV-NS5-V5. The DENV-sNS1-V5 plasmid encodes DENV NS1 
protein with the endoplasmic reticulum (ER) targeting signal sequences from the C-
terminus of the DENV envelope (E) protein. This ER targeting sequence has been 
found to be essential for the correct post-translational glycosylation of NS1 protein 
(Falgout and Markoff, 1995) which is important for viral replication (Tajima et al., 
2008). NS2B-3 denotes the fusion construct expressing the NS3 protease with NS2B 
protein as a co-factor, both of which were found to be indispensible for the cleavage 
of the DENV polyprotein into the individual functional proteins (Falgout et al., 
1991).  
 
Colony PCR, followed by agarose gel electrophoresis, was used to screen for 
positive clones of the DENV NS proteins mammalian expression construct (Figure 
3-9). Based on the sequence of DENV NGC strain (GenBank Accession: M29095) 
published on NCBI, the calculated sizes of sNS1, NS1, NS2A, NS2B, NS2B-3, NS3, 
NS4A, NS4B and NS5 genes were 1140 bp, 1056 bp, 654 bp, 390 bp, 2244 bp, 1854 
bp, 381 bp, 813 bp and 2700 bp, respectively. The observed sizes of the colony PCR 
products for sNS1 (Figure 3-9a), NS1 (Figure 3-9b), NS2A (Figure 3-9c), NS2B 
(Figure 3-9d), NS2B-3 (Figure 3-9e), NS3 (Figure 3-9f), NS4A (Figure 3-9g), NS4B 
(Figure 3-9h) and NS5 (Figure 3-9i) genes matched that which were calculated. All 
positive clones with the correct PCR band sizes were sequenced and analysed using 
BLAST to further verify the integrity of their sequences before using them for 
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94 | P a g e  
 
subsequent downstream experiments. Where possible, multiple clones for each 
plasmid were sequenced and the one which showed the highest match under BLAST 
analysis were chosen. In addition, the translated amino acid sequences of the clones 
were also checked to confirm that there were no amino acid changes as compared to 














Figure 3-8: Generation of dengue virus non-structural protein mammalian 
expression plasmids.  
(a) The individual NS proteins were cloned into pcDNA3.1 vector upstream of V5 
and p-HIS Tags as shown. (b) PCR products of DENV NS proteins that were 
amplified from DENV2 infectious clone are shown. Other than the seven NS proteins, 
two additional constructs namely, sNS1 and NS2B-3 genes were created. The sNS1 
gene denotes NS1 protein with ER targeting signal sequences contributed by 28 
amino acids from the C-terminus of the DENV E protein. The NS2B-3 gene denotes 
the fusion construct expressing the NS3 protease with NS2B as a co-factor. 100 bp 
and 1 kb denote 100 bp and 1 kb DNA ladders, respectively. The molecular sizes (in 













































Figure 3-9: Colony PCR screening of dengue virus non-structural proteins 
mammalian expression constructs. 
For each DENV NS protein construct, six colonies were picked for colony PCR 
screening. The PCR products were resolved by agarose gel electrophoresis. The 
calculated sizes of the PCR bands for (a) DENV-sNS1-V5 (1140 bp), (b) DENV-
NS1-V5 (1056 bp), (c) DENV-NS2A-V5 (654 bp), (d) DENV-NS2B-V5 (390 bp), (e) 
DENV-NS2B-3-V5 (2244 bp), (f) DENV-NS3-V5 (1854 bp), (g) DENV-NS4A-V5 
(381 bp), (h) DENV-NS4B-V5 (813 bp) and (i) DENV-NS5-V5 (2700 bp) genes 
were verified by comparing against the 1 kb or 100 bp DNA ladder. Positive clones 
with the correct sizes were sequenced to further confirm the integrity of their 
sequences. The relevant molecular sizes (in number of bp) of the 1 kb DNA ladder 
were indicated by the arrow-heads on the right. 
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3.3.2. Generation of West Nile virus non-structural 1 protein 
positive control plasmids 
In addition to the DENV NS proteins mammalian expression plasmids, NS1 protein 
constructs of KUNV and WENV were also produced (Figure 3-10a). Both variants of 
NS1 proteins, with (sNS1) and without (NS1) the ER targeting sequences were 
generated (Figure 3-10b). These plasmids were named as KUNV-sNS1-V5, KUNV-
NS1-V5, WENV-sNS1-V5 and WENV-NS1-V5. As WNV NS1 protein was found 
to inhibit TLR3-mediated signal transduction (Wilson et al., 2008), which acted 
upstream of NF-κB (Chiron et al., 2009; Jiang et al., 2003) and Jak/STAT signalling 
(Taniguchi and Takaoka, 2002), the KUNV and WENV sNS1 proteins served as 
positive controls for the down-regulation of these pathways. The plasmids encoding 
KUNV and WENV NS1 proteins without the ER targeting sequences were used to 
investigate the importance of ER targeting, and consequently proper post-
translational modification, on the regulatory effect of WNV NS1 protein on NF-κB 
and Jak/STAT signalling. 
 
From the deposited sequences of KUNV (GenBank Accession: D00246) and WENV 
(GenBank Accession: NC_001563) in NCBI, the PCR product of KUNV sNS1, 
KUNV NS1, WENV sNS1 and WENV NS1 genes were calculated to be 1128 bp, 
1056 bp, 1128 bp and 1056 bp, respectively. These matched the PCR bands of the 
positive clones, which were resolved by agarose gel electrophoresis (Figure 3-10c – 
f). Positive clones with the correct PCR band sizes were sequenced to verify the 
integrity of their sequences. Clones with incorrect PCR band sizes such as those in 
lane 2 for WENV-sNS1-V5 (Figure 3-10e) and lane 3 for WENV-NS1-V5 (Figure 
3-10f) were not chosen for sequencing.  
Results 





















Figure 3-10: Generation of West Nile virus non-structural 1 protein mammalian 
expression plasmids. 
(a) West Nile virus (WNV) NS1 proteins were cloned into pcDNA3.1 vector 
upstream of V5 and p-HIS Tags as shown. (b) RT-PCR products of KUNV and 
WENV NS1 proteins that were amplified from KUNV and WENV viral RNA are 
shown. The sNS1 gene denotes NS1 protein with ER targeting signal sequences 
contributed by the C-terminus of the WNV E protein. (c - f) Colony PCR screening 
of positive clones of KUNV and WENV NS1 proteins mammalian expression 
constructs. For each construct, five colonies were picked for colony PCR screening. 
The PCR products were resolved by agarose gel electrophoresis. The calculated sizes 
of the PCR bands for (c) KUNV-sNS1-V5 (1128 bp), (d) KUNV-NS1-V5 (1056 bp), 
(e) WENV-sNS1-V5 (1128 bp) and (f) WENV-NS1-V5 (1056 bp) genes were 
verified by comparing against the 1 kb or 100 bp DNA ladder. Positive clones with 
the correct sizes were sequenced to further confirm the integrity of their sequences. 
The relevant molecular sizes (in number of bp) of the 1 kb DNA ladder were 
indicated by the arrow-heads on the right. 
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3.3.3. Dengue virus and West Nile virus non-structural proteins 
expression plasmids functionally expressed the respective NS 
proteins 
Prior to using these constructs, it was also necessary to test their expression in 
mammalian cells. This was achieved by transfecting these constructs into HEK293-
hTLR3 cells and subjecting the cell lysates to Western Blot analysis. As shown in 
Figure 3-11, all the DENV-NS proteins-V5 plasmids, as well as the KUNV-sNS1-V5 
and WENV-sNS1-V5 plasmids were functionally expressing the various NS proteins.  
 
The recombinant DENV, KUNV and WENV sNS1-V5 fusion proteins were 
observed to be between 40 – 55 kDa in size (Figure 3-11a). DENV NS2A-V5 and 
NS2B-V5 proteins were found to be resolved at about 30 kDa and 25 kDa, 
respectively (Figure 3-11b). DENV NS2B-3-V5 and NS3-V5 recombinant proteins 
were both resolved at about 70 kDa (Figure 3-11a). DENV NS4A-V5 and NS4B-V5 
proteins were observed to be about 25 kDa and 35 kDa, respectively when resolved 
using SDS-PAGE (Figure 3-11b). DENV-NS5-V5 protein and LacZ control were 
found to be about 100 kDa in size (Figure 3-11a). The size of the soluble NS proteins, 
namely NS1, NS2B-3, NS3 and NS5 matched those reported in literature (Li et al., 
1999; Perera and Kuhn, 2008). The sizes of the hydrophobic NS proteins, namely 
NS2A, NS2B, NS4A and NS4B were found to be slightly higher than published data 
(Liu et al., 2010; Perera and Kuhn, 2008). This could be due to the V5 and p-HIS tag 
which were cloned downstream of the NS protein constructs (Figure 3-8a). 
 
It was also observed that the soluble NS proteins namely NS1, sNS1, NS2B-3, NS3 
and NS5 (Figure 3-11a) were expressed at higher levels than the hydrophobic NS 
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proteins such as NS2A, NS2B, NS4A and NS4B (Figure 3-11b) as the bands for the 
hydrophobic NS proteins were only visualized when a chemiluminescent substrate of 














Figure 3-11: Dengue virus and West Nile virus non-structural protein plasmids 
functionally express the respective NS proteins.  
HEK293-hTLR3 cells were transfected with the individual NS protein mammalian 
expression plasmids. 24 hr post transfection, the cells lysates were harvested and 
subjected to SDS-PAGE and Western Blot analysis using mouse anti-V5 (MαV5) 
primary antibodies followed by horseradish peroxidise-conjugated goat anti-mouse 
secondary antibodies. The blots with the soluble NS proteins, namely NS1, NS2B-3, 
NS3 and NS5, and LacZ control were developed using (a) the SuperSignal West 
(Pico) Chemiluminescent Substrate. The blots with the hydrophobic NS proteins, 
namely NS2A, NS2B, NS4A and NS4B were developed using (b) SuperSignal West 
(Dura) Extended Duration Chemiluminescent Substrate with higher sensitivity. The 
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3.4. Effects of dengue virus non-structural proteins on 
modulating cellular signal transduction 
After generating and verifying the functional expression of the DENV NS protein 
mammalian expression plasmids, each of the DENV NS proteins were tested for their 
ability to modulate NF-κB, Jak/STAT, PI3K/Akt and MAPK signal transduction 
pathways, which were found to be implicated during DENV infection (Section 3.2). 
This was done by transfecting each of the DENV NS protein plasmid into HeLa cells 
and examining the phosphorylation and activation levels of the signal transduction 
proteins involved in NF-κB, Jak/STAT, PI3K/Akt and MAPK signalling.  
 
Other than transfecting the individual NS proteins plasmid, it was also necessary to 
simulate the environment of replicating RNA, and consequently signal transductions 
which occur during DENV infection. The hallmark of DENV replication is the 
presence of dsRNA intermediates (Urcuqui-Inchima et al., 2010). As such, the 
cellular context of replicating RNA can be simulated by treating the cells with 
polyinosine-polycytidylic acid (pIC), which is an analog of dsRNA.  
 
3.4.1. NF-κB signalling is not modulated by dengue virus non-
structural proteins 
First, the DENV NS proteins were examined for their ability to modulate NF-κB 
signal transduction in the presence of dsRNA analog pIC. All 4 upstream pathways, 
namely p38 MAPK (Kato et al., 2003), SAPK/JNK (Spiegelman et al., 2001), 
GPCR/Src (Funakoshi-Tago et al., 2005; Jalal and Kone, 2006; Lee et al., 2007) and 
PI3K/Akt (Kane et al., 1999), which can trigger NF-κB activation, were first 
analyzed to investigate any regulatory effects mediated by DENV NS proteins.  
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As shown in Figure 3-12a, the activation of upstream p38 MAPK was significantly 
inhibited in DENV NS1 and WENV sNS1 proteins-expressing cells as compared to 
LacZ control protein-expressing cells. For the other upstream signal transduction 
proteins of NF-κB signalling such as JNK (Figure 3-12b), Src (Figure 3-12c) and Akt 
(Figure 3-12d), there were no significant difference in the levels of activation 
between the DENV NS and LacZ proteins-expressing cells.  
 
The lowered activation of p38 MAPK, however, translated to a reduced 
phosphorylation of IκB only in WENV sNS1 protein-expressing cells but not in 
DENV NS1 protein-expressing cells (Figure 3-12e). The level of activation of IκB 
was not significantly changed in all the DENV NS protein-expressing cells relative 
to the LacZ control protein-expressing cells (Figure 3-12e).  
 
The targeting of WENV sNS1 protein to the ER was also found to be important for 
the inhibitory effect of WENV sNS1 protein on NF-κB signalling as removal of ER 
targeting sequence resulted in the abolishment of this inhibitory effect as observed in 
WENV NS1 protein-expressing cells (Figure 3-12e). These results indicated that the 
modulation of NF-κB signal transduction pathway, which was observed during 
DENV infection (Section 3.2.1), was not mediated by the DENV NS proteins.  
Results 
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Figure 3-12: NF-κB signalling is not modulated by dengue virus non-structural 
proteins. 
HeLa cells were transfected with the various DENV, KUNV and WENV NS protein 
and LacZ control plasmids. At 24 hr post-transfection, the cells were treated with 20 
µg/ ml of pIC for 4 hr. Following which, the cell lysates were harvested. 50 µg of 
each lysate was assayed for the amount of (a) p-p38 MAPK, (b) p-JNK, (c) p-Src, (d) 
p-Akt and (e) p-IκB-α present. Two independent experiments were conducted and 
the results are presented as fluorescence intensity ± SEM. * and # denotes statistically 
significant difference at p < 0.05 and 0.05 < p < 0.10, respectively between the LacZ 
control- and NS proteins-expressing cells. Red and green bars represent statistically 
significant down-regulation and up-regulation, respectively of the signal transduction 
protein in DENV NS protein-expressing cells as compared to LacZ control protein-
expressing cells (black bars). Blue and yellow bars represent no significant changes 
in the amount of signal transduction protein in DENV NS  and WNV NS1 proteins-
expressing cells, respectively.  
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3.4.2. Dengue virus non-structural 1 (sNS1) protein inhibits 
Jak/STAT signalling 
Second, the DENV NS proteins were screened for their regulatory effect on 
Jak/STAT signalling. The Jak/STAT signalling pathway can receive stimulus from 
several upstream pathway including Src (Levy and Darnell, 2002), IL6 (Mackiewicz 
et al., 1992) and IFNα/β (Ho and Ivashkiv, 2006) signal transduction pathway. As 
shown in Figure 3-13a, upstream Src activation was not significantly changed in 
DENV NS protein-expressing cells versus LacZ control protein-expressing cells. 
This suggested that Src activation was not modulated by any of the DENV NS 
proteins. 
 
Although upstream Src activation (Figure 3-13a) was not modulated by DENV NS 
proteins, downstream Tyk2 activation was inhibited by DENV sNS1 protein as 
compared to LacZ control in the presence of pIC dsRNA analog (Figure 3-13b). For 
the other DENV NS proteins, there were no significant differences observed in the 
level of Tyk2 activation. Similar to DENV sNS1 protein, inhibition of Tyk2 
activation was observed in WENV sNS1 protein positive control samples (Figure 
3-13b). WNV sNS1 protein was used as positive control because it was reported to 
inhibit TLR3 signalling (Wilson et al., 2008) which would lead to a corresponding 
down-regulation of downstream Tyk2 activation. The sNS1 protein of KUNV, a 
close relative of WNV, however, did not exhibit the same inhibitory effect on Tyk2 
activation (Figure 3-13b).  
 
In addition to the inhibition of upstream Tyk2 activation (Figure 3-13b), DENV 
sNS1 protein was also found to significantly reduce the activation of downstream 
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STAT2 (Figure 3-13c) and STAT3 (Figure 3-13d) in response to pIC dsRNA 
treatment. In contrast, the other DENV NS protein-expressing cells did not show any 
significant changes in the levels of STAT2 (Figure 3-13c) and STAT3 (Figure 3-13d) 
activation. Like DENV sNS1, both KUNV and WENV sNS1 protein positive 
controls also inhibited the activation of STAT2 (Figure 3-13c) and STAT3 (Figure 
3-13d).  It should be noted that the level of inhibition on STAT2 (Figure 3-13c) and 
STAT3 (Figure 3-13d) by DENV sNS1 protein was greater than that on Tyk2 (Figure 
3-13b). 
 
It should be highlighted that the inhibition of Tyk2 (Figure 3-13b), STAT2 (Figure 
3-13c) and STAT3 (Figure 3-13d) activation was only seen in DENV and WENV 
sNS1 proteins-expressing cells, but not in their corresponding NS1 protein-
expressing cells, which lack the ER targeting sequences. This indicated that for both 
DENV and WENV, proper targeting of their NS1 proteins to the ER is essential for 
their inhibitory effect on Tyk2 (Figure 3-13b), STAT2 (Figure 3-13c) and STAT3 
(Figure 3-13d) activation. The same phenomenon was also observed for KUNV 
sNS1 and NS1 proteins in terms on their inhibition of STAT2 (Figure 3-13c) and 
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Figure 3-13: Dengue virus non-structural 1 (sNS1) protein inhibits Jak/STAT 
signalling. 
HeLa cells were transfected with the various DENV, KUNV and WENV NS protein 
and LacZ control plasmids. At 24 hr post-transfection, the cells were treated with 20 
µg/ ml of pIC for 4 hr. Following which, the cell lysates were harvested. 50 µg of 
each lysate was assayed for the amount of (a) p-Src, (b) p-Tyk2 (c) p-STAT2 and (d) 
p-STAT3 present. Two independent experiments were conducted and the results are 
presented as fluorescence intensity ± SEM. * and # denotes statistically significant 
difference at p < 0.05 and 0.05 < p < 0.10, respectively between the LacZ control- 
and NS proteins-expressing cells. Red and green bars represent statistically 
significant down-regulation and up-regulation, respectively of the signal transduction 
protein in DENV NS protein-expressing cells as compared to LacZ control protein-
expressing cells (black bars). Blue and yellow bars represent no significant changes 
in the amount of signal transduction protein in DENV NS and WNV NS1 proteins-
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3.4.3. PI3K/Akt signalling is not modulated by dengue virus non-
structural proteins 
Next, the regulation of PI3K/Akt signal transduction by DENV NS proteins was 
investigated. From Figure 3-14a, it was observed that upstream Akt activation level 
was not significantly changed by all the DENV NS proteins relative to LacZ control. 
This was also the case for the KUNV and WENV sNS1 proteins controls (Figure 
3-14a).  
 
Similar to upstream Akt, there were also no significant differences in the levels of 
downstream GSK-3α/β (Figure 3-14b), p70 S6 kinase (Figure 3-14c) and CREB 
(Figure 3-14d) between the DENV NS protein-expressing cells and LacZ control 
protein-expressing cells. There was only a slight activation of p70 S6 kinase (Figure 
3-14c) by WENV NS1 protein. These findings suggested that DENV NS proteins did 
not modulate Akt signalling in the presence of pIC dsRNA analog.  
 
3.4.4. Effects of dengue virus non-structural proteins on MAPK 
signalling 
3.4.4.1. Effects of dengue virus non-structural proteins on Erk 
signalling 
Following the investigation of the involvement of DENV NS proteins in PI3K/Akt 
signalling, the involvement of DENV NS proteins in MAPK signal transduction was 
studied. Firstly, the DENV NS proteins were screened for regulatory effects on Erk 
sub-pathway of MAPK signalling. 
 
Results 
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Figure 3-14: PI3K/Akt signalling is not modulated by dengue virus non-
structural proteins. 
HeLa cells were transfected with the various DENV, KUNV and WENV NS protein 
and LacZ control plasmids. At 24 hr post-transfection, the cells were treated with 20 
µg/ ml of pIC for 4 hr. Following which, the cell lysates were harvested. 50 µg of 
each lysate was assayed for the amount of (a) p-Akt, (b) p-GSK-3α/β (c) p-p70 S6 
Kinase and (d) p-CREB present. Two independent experiments were conducted and 
the results are presented as fluorescence intensity ± SEM. * and # denotes statistically 
significant difference at p < 0.05 and 0.05 < p < 0.10, respectively between the LacZ 
control- and NS proteins-expressing cells. Red and green bars represent statistically 
significant down-regulation and up-regulation, respectively of the signal transduction 
protein in DENV NS protein-expressing cells as compared to LacZ control-protein-
expressing cells (black bars). Blue and yellow bars represent no significant changes 
in the amount of signal transduction protein in DENV NS and WNV NS1 proteins-
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From Figure 3-15a, it was observed that upstream Src was not differentially 
modulated by DENV NS proteins. Similarly, there were also no significant changes 
in the levels of TrkA activation between the DENV NS proteins and LacZ control 
(Figure 3-15b). 
 
MEK1 activation, which is downstream of GPCR/Ras signal transduction but 
upstream of Erk, was found to be up-regulated by DENV sNS1 protein (Figure 
3-15c). This up-regulation, however, did not translate to up-regulation in downstream 
Erk1/2 in DENV sNS1 protein-expressing HeLa cells (Figure 3-15d). For the other 
DENV NS proteins, there was no observed differential regulation in the levels of 
activation of both MEK1 (Figure 3-15c) and Erk (Figure 3-15d). 
 
Downstream p90RSK (Figure 3-15e), CREB (Figure 3-15f) and p70 S6 kinase 
(Figure 3-15g) were also not differentially regulated by DENV NS proteins as 
compared to LacZ control. Downstream p70 S6 kinase activation was only found to 
be slightly elevated in WENV NS1 protein-expressing cells (Figure 3-15g). STAT3 
activation, on the contrary, was reduced in DENV, KUNV and WENV sNS1 
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Figure 3-15: Effects of dengue virus non-structural proteins on Erk signalling. 
HeLa cells were transfected with the various DENV, KUNV and WENV NS protein 
and LacZ control plasmids. At 24 hr post-transfection, the cells were treated with 20 
µg/ ml of pIC for 4 hr. Following which, the cell lysates were harvested. 50 µg of 
each lysate was assayed for the amount of (a) p-Src, (b) p-TrkA, (c) p-MEK1, (d) p-
Erk1/2, (e) p-p90RSK, (f) p-CREB, (g) p-p70 S6 Kinase and (h) p-STAT3 present. 
Two independent experiments were conducted and the results are presented as 
fluorescence intensity ± SEM. * and # denotes statistically significant difference at p 
< 0.05 and 0.05 < p < 0.10, respectively between the LacZ control and NS proteins-
expressing cells. Red and green bars represent statistically significant down-
regulation and up-regulation, respectively of the signal transduction protein in DENV 
NS protein-expressing cells as compared to LacZ control protein-expressing cells 
(black bars). Blue and yellow bars represent no significant changes in the amount of 
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3.4.4.2. Effects of dengue virus non-structural proteins on p38 
MAPK signalling 
Secondly, DENV NS proteins were examined for regulatory effects on the p38 
MAPK sub-pathway of MAPK signal transduction. As shown in Figure 3-16a, 
upstream p38 MAPK was found to be down-regulated in DENV NS1 and WENV 
sNS1 proteins-expressing cells.  
 
Conversely, this down-regulation of upstream p38 MAPK activation did not lead to 
any corresponding reduction in the activation of ATF2 (Figure 3-16b), p53 (Figure 
3-16c), CREB (Figure 3-16d) and HSP27 (Figure 3-16e) in DENV NS1 and WENV 
sNS1 proteins-expressing cells. ATF2 activation level was slightly reduced in DENV 
NS3 protein-expressing HeLa cells (Figure 3-16b). For all the other DENV NS 
proteins, the level of ATF2 activation was not differentially regulated as compared to 
LacZ control (Figure 3-16b). There were also no observed differences in the 
activation of p53 (Figure 3-16c), CREB (Figure 3-16d) and HSP27 (Figure 3-16e) 
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Figure 3-16: Effects of dengue virus non-structural proteins on p38 MAPK 
signalling. 
HeLa cells were transfected with the various DENV, KUNV and WENV NS protein 
and LacZ control plasmids. At 24 hr post-transfection, the cells were treated with 20 
µg/ ml of pIC for 4 hr. Following which, the cell lysates were harvested. 50 µg of 
each lysate was assayed for the amount of (a) p38 MAPK, (b) p-ATF2, (c) p-p53, (d) 
p-CREB, and (e) p-HSP27 present. Two independent experiments were conducted 
and the results are presented as fluorescence intensity ± SEM. * and # denotes 
statistically significant difference at p < 0.05 and 0.05 < p < 0.10, respectively 
between the LacZ control- and NS proteins-expressing cells. Red and green bars 
represent statistically significant down-regulation and up-regulation, respectively of 
the signal transduction protein in DENV NS protein-expressing cells as compared to 
LacZ control protein-expressing cells (black bars). Blue and yellow bars represent no 
significant changes in the amount of signal transduction protein in DENV NS and 
WNV NS1 proteins-expressing cells, respectively.   
Results 
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3.4.4.3. Effects of dengue virus non-structural proteins on 
SAPK/JNK signalling 
Lastly, the regulatory effects of DENV NS proteins on SAPK/JNK signal 
transduction were investigated. The level of upstream JNK activation was not 
significantly changed in all the DENV NS protein-expressing HeLa cells as 
compared to the LacZ control protein-expressing HeLa cells (Figure 3-17a). 
 
Similar to JNK (Figure 3-17a), no significant differences in the levels of activated 
p53 (Figure 3-17b) and IRS-1 (Figure 3-17c) were observed between all the DENV 
NS and LacZ control proteins-expressing cells. Downstream ATF2 activation was 
observed to be reduced in DENV NS3 protein-expressing cells while the other 
DENV NS protein-expressing cells did not show any significant changes in the level 
of ATF2 activation (Figure 3-17d). Unlike the other signal transduction proteins in 
SAPK/JNK signalling, STAT3 activation was found to be significantly decreased in 
DENV, KUNV and WENV sNS1 proteins-expressing cells as compared to LacZ 
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Figure 3-17: Effects of dengue virus non-structural proteins on SAPK/JNK 
signalling. 
HeLa cells were transfected with the various DENV, KUNV and WENV NS protein 
and LacZ control plasmids. At 24 hr post-transfection, the cells were treated with 20 
µg/ ml of pIC for 4 hr. Following which, the cell lysates were harvested. 50 µg of 
each lysate was assayed for the amount of (a) p-JNK, (b) p-p53, (c) p-IRS-1, (d) p-
ATF2 and (e) p-STAT3 present. Two independent experiments were conducted and 
the results are presented as fluorescence intensity ± SEM. * and # denotes statistically 
significant difference at p < 0.05 and 0.05 < p < 0.10, respectively between the LacZ 
control- and NS proteins-expressing cells. Red and green bars represent statistically 
significant down-regulation and up-regulation, respectively of the signal transduction 
protein in DENV NS protein-expressing cells as compared to LacZ control protein-
expressing cells (black bars). Blue and yellow bars represent no significant changes 
in the amount of signal transduction protein in DENV NS and WNV NS1 proteins-
expressing cells, respectively.  
Results 
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4. Results 
4.1. Screening of interaction domains between dengue virus non-
structural 1 and STAT3α/β proteins in yeast-two-hybrid 
system 
Experimental data from Section 3.2.2 revealed that DENV was implicated in the 
modulation of Jak/STAT signalling. In addition, DENV sNS1 protein was 
responsible for the down-regulation of Jak/STAT signal transduction (Section 3.4.2). 
Recent study reported that recombinant DENV sNS1 protein interacted with an N-
terminally truncated form of STAT3β protein (Chua et al., 2005). In light of these 
findings, it is possible that the interaction of DENV NS1 protein with STAT3β 
protein could be the mechanism responsible for the observed reduction of STAT3 
protein activation (Section 3.4.2). Hence, the aim of this chapter was to investigate 
the interaction between DENV NS1 and STAT3α/β proteins to further elucidate the 
mechanism of action behind the down-regulation of Jak/STAT signal transduction by 
DENV sNS1 protein. 
 
4.1.1. Generation of yeast-two-hybrid constructs 
The well-established yeast-two-hybrid technique, which allows for the sensitive 
detection of protein interactions (Estojak et al., 1995; Guarente, 1993), was initially 
used to screen for the interaction domains between DENV NS1 and STAT3α/β 
proteins. To utilize the yeast-two-hybrid system, the DENV NS1 and truncated 
STAT3α/β genes were cloned into the pGBKT7 bait vector (Figure 4-1a) and 
pGADT7 prey vector (Figure 4-1b), respectively.  
 
Results 



















Figure 4-1: Schematics of dengue virus non-structural 1 protein and truncated 
STAT3α/β yeast-two-hybrid constructs. 
(a) The full length open reading frame of DENV2 NGC NS1 gene is cloned into 
pGBKT7 bait vector as a fusion protein to the GAL4 DNA binding domain (BD). (b) 
Full length STAT3α and 3 truncated STAT3β constructs (STAT3β-∆C574, STAT3β-
∆C321 and STAT3β-∆C116) were cloned into pGADT7 prey vector as fusion 
proteins to the GAL4 activation domain (AD). The schematic of ∆N40-STAT3β, 
which lacked 40 amino acids from the N-terminus and was reported to interact with 
DENV NS1 protein (Chua et al., 2005), is also shown. The amino acid positions of 
the domains are indicated above the diagram of each construct.  
 
 
As shown in Figure 4-1a, the full length open reading frame of DENV2 NS1 protein 
was cloned into the pGBKT7 vector which expressed DENV NS1 protein as a fusion 
protein to the GAL4 DNA BD. The construct was named as BD-NS1 plasmid. A 
BD-sNS1 variant, encoding NS1 protein with the ER targeting sequences, was not 
created as the ER targeting signal sequences would be cleaved off by host signalase 
causing the GAL4 BD to be cleaved off from NS1 protein. This would make the BD-
sNS1 construct invalid for the yeast-two-hybrid screen as NS1 would not be 
expressed as a fusion protein to the GAL4 BD. 
Results 
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Full length STAT3α and truncated STAT3β genes were cloned into pGADT7 prey 
vector, which expressed the various STAT3 protein truncations as fusion proteins to 
the GAL4 AD (Figure 4-1b). These STAT3 plasmids were named as AD-STAT3α, 
AD- STAT3β-∆C574, AD- STAT3β-∆C321 and AD- STAT3β-∆C116, respectively. 
The truncated STAT3β constructs, namely STAT3β-∆C574, STAT3β-∆C321 and 
STAT3β-∆C116, sequentially excluded the known functional domains from the C-
terminus of the STAT3β gene (Figure 4-1b). As shown in Figure 4-1b, STAT3β-
∆C574 construct excluded the SH2 domain from STAT3β gene. The DNA binding 
and SH2 domains of STAT3β gene were deleted in STAT3β-∆C321 construct 
(Figure 4-1b). Finally, the coiled-coil, DNA binding and SH2 domains of STAT3β 
gene were removed to form STAT3β-∆C116 construct (Figure 4-1b). 
 
The DENV-sNS1-V5 plasmid (Section 3.3.1) was used as a template for the PCR 
amplification of DENV NS1 gene (Figure 4-2a). The DENV NS1 amplicon was then 
cloned into pGBKT7 bait vector using restriction endonuclease. Colony PCR was 
performed to screen for positive clones of BD-NS1 protein plasmid, which should 
have PCR products of about 1055 bp in size (Figure 4-2b). All positive clones with 
the correct size of 1055 bp (lanes 1 – 4, 6) (Figure 4-2b) were sequenced to confirm 
the integrity of their sequences. The clone in lane 5 showed incorrect PCR product 
size and hence was not chosen for sequencing (Figure 4-2b). 
 
For the full length AD-STAT3α and AD-truncated STAT3β plasmids, RT-PCR was 
first performed to amplify the respective STAT3α and truncated STAT3β genes from 
the total RNA of MRC-5 lung fibroblasts (Figure 4-3a). Next, these amplified 
products were cloned into pGADT7 prey vector using restriction endonuclease. 
Results 
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Positive clones of AD-STAT3α (Figure 4-3b), AD-STAT3β-∆C574 (Figure 4-3c), 
AD-STAT3β-∆C321 (Figure 4-3d) and AD-STAT3β-∆C116 (Figure 4-3e) plasmids 
were identified using colony PCR screening. The molecular sizes of the PCR bands 
of the positive clones of AD-STAT3α, AD-STAT3β-∆C574, AD-STAT3β-∆C321 
and AD-STAT3β-∆C116 plasmids were 2309 bp (Figure 4-3b), 1721 bp (Figure 
4-3c), 971 bp (Figure 4-3d) and 350 bp (Figure 4-3e), respectively. Similar to BD-
NS1 protein plasmid, all positive clones with correct PCR band sizes for AD-
STAT3α and AD-truncated STAT3β constructs were sequenced to ensure their 














Figure 4-2: Generation of BD-NS1 protein plasmid. 
(a) PCR product of DENV NS1 protein that was amplified from DENV-sNS1-V5 
(Section 3.3.1) is shown. (b) Colony PCR screening of positive clones of BD-NS1 
(1055 bp). Six colonies were picked for colony PCR screening. The PCR products 
were resolved by agarose gel electrophoresis. Positive clones with the correct sizes 
were sequenced to further confirm the integrity of their sequences. 100 bp and 1 kb 
denotes the 100 bp and 1 kb DNA ladder. The relevant molecular sizes (in number of 



























Figure 4-3: Generation of AD-STAT3α and truncated STAT3β constructs. 
(a) RT-PCR products of STAT3α and truncated STAT3β genes that were amplified 
from the total RNA of MRC-5 cells are shown. (b - e) Colony PCR screening of (b) 
AD-STAT3α (2309 bp), (c) AD-STAT3β-∆C574 (1721 bp), (d) AD-STAT3β-∆C321 
(971 bp) and (e) AD-STAT3β-∆C116 (350 bp). Six colonies per construct were 
picked for colony PCR screening. The PCR products were resolved by agarose gel 
electrophoresis. Positive clones with the correct sizes were sequenced to further 
confirm the integrity of their sequences. 100 bp and 1 kb denote the 100 bp and 1 kb 
DNA ladder. The relevant molecular sizes (in number of bp) of the 100 bp and 1 kb 
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4.1.2. Yeast-two-hybrid constructs do not exhibit autonomous 
activation of HIS3 reporter gene 
Prior to the use of the BD-NS1 protein and AD-STAT3 constructs for interaction 
domain screening in a yeast-two-hybrid system, it was essential to verify that the 
constructs did not auto-activate the reporter genes which can lead to false positive 
results. These reporter genes, namely HIS3, ADE2 and MEL1, were controlled by the 
GAL4 transcription factor upstream activating sequences in AH109 yeast cells 
(James et al., 1996).  
 
To determine the suitability of the BD-NS1 protein and AD-STAT3 plasmids for use 
in yeast-two-hybrid system, auto-activation assays were performed. Briefly, each 
plasmid was transformed into AH109 yeast cells, which are auxotrophic for adenine, 
histidine, leucine and tryptophan. Next, dilutions of the transformed yeast cells were 
spotted onto minimal synthetic dropout agar lacking histidine. Normally, no growth 
should be observed on dropout plates if the test plasmid does not autonomously 
activate the HIS3 reporter gene, which controls the expression of histidine. Growth 
on the histidine dropout agar indicates autonomous activation of HIS3 reporter gene 
by the test plasmid, which would render the test plasmid unsuitable for use in yeast-
two-hybrid interaction studies.    
 
The BD-p53 and AD-T co-transformed yeast cells, which expressed the known 
interactors of murine p53 and SV40 large T antigen (Iwabuchi et al., 1993; Li and 
Fields, 1993), respectively, were used as positive control to ensure that the 
functionality of the HIS3 reporter was intact in the AH109 yeast cells. Indeed, the 
BD-p53 and AD-T co-transformed yeast cells exhibited growth up to 10-2 dilution 
Results 
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(Figure 4-4), indicating an intact HIS3 reporter. The empty BD and AD plasmids co-
transformed yeast cells, which served as negative control, showed no growth (Figure 
4-4). This confirmed that the HIS3 reporter was tightly regulated and can only be 
activated when the BD and AD fusion proteins interacted, as in the case of BD-p53 
and AD-T positive control. 
 
After confirming the functionality of the auto-activation assay, the BD-NS1 protein 
and AD-STAT3 plasmids were tested for autonomous activation of the HIS3 reporter 
gene. As shown in Figure 4-4, there was no growth observed even at neat 
concentration for the BD-NS1 protein, AD-STAT3α, AD-STAT3β-∆C574, AD-
STAT3β-∆C321 and AD-STAT3β-∆C116 constructs singly-transformed AH109 
yeast cells on histidine dropout plates. This showed that all these constructs did not 
auto-activate the HIS3 reporter gene and thus are suitable for use in the yeast-two-






























Figure 4-4: BD-NS1 protein and AD-STAT3 constructs do not exhibit 
autonomous activation of HIS3 reporter gene.  
AH109 yeast cells were singly or co-transformed with the various plasmids as stated 
on the right. Serial dilutions (indicated at the top) of the transformed yeast cells were 
then spotted on histidine dropout plates. Growth indicates the activation of the 
histidine reporter gene. The BD-p53 and AD-T co-transformed yeast cells expressing 
the BD-murine p53 and AD-large T antigen fusion proteins, respectively are used as 
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4.1.3. Dengue virus non-structural 1 protein interacts with STAT3β 
protein through the coiled-coil domain in a yeast-two-hybrid 
system 
After ascertaining the suitability of the BD-NS1 protein and the various AD-STAT3 
constructs, a yeast-two-hybrid interaction domain screen was carried out. Growth of 
blue colonies, which were indicative of positive interactions, was observed for the 
BD-p53 and AD-T positive control co-transformants (Figure 4-5a) whereas no 
growth was observed for the BD and AD empty vector negative control co-
transformants (Figure 4-5b).  
 
The intensity of blue colouration of the colonies is reflective of the strength of 
interaction. Blue colouration is imparted by the activation of MEL1 gene that 
produces galactosidase. Galactosidase will cleave the alpha-galactoside substrate in 
the media and produce a blue chromogenic byproduct.  As shown in Figure 4-5c, the 
BD-NS1 and AD-STAT3α co-transformed yeast cells showed sparse growth of blue 
colonies on the QDO plates with x-α-gal, indicating a weak interaction between 
DENV NS1 protein and STAT3α protein in the yeast-two-hybrid system.  
 
From Figure 4-5d and Figure 4-5e, it was observed that the BD-NS1 and AD-
STAT3β-∆C574, and BD-NS1 protein and AD-STAT3β-∆C321 co-transformants, 
respectively exhibited abundant growth of blue colonies, similar to that of the BD-
p53 and AD-T positive control co-transformants (Figure 4-5a). These results 
indicated that exclusion of the SH2 domain of STAT3β in AD-STAT3β-∆C574 
(Figure 4-1b) and DNA binding domain of STAT3β in AD-STAT3β-∆C321 
Results 
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constructs (Figure 4-1b) did not abolish the interaction between DENV NS1 protein 
and STAT3β protein. 
 
In contrast, the BD-NS1 and AD-STAT3β-∆C116 plasmids co-transformed yeast 
cells did not show any growth on QDO plates with x-α-gal (Figure 4-5f), like that of 
the BD and AD empty vector negative control co-transformants (Figure 4-5b). This 
suggested that exclusion of the coiled-coil domain of STAT3β in AD-STAT3β-
∆C116 plasmid resulted in no interactions with BD-NS1 and thus no activation of the 
reporter genes as shown (Figure 4-5f). These results pointed towards the coiled-coil 











Figure 4-5: Dengue virus non-structural 1 protein interacts with STAT3β 
protein through the coiled-coil domain.  
Ah109 yeast cells were co-transformed with (a) BD-p53 and AD-T, (b) BD and AD 
empty vector, (c) BD-NS1 and AD-STAT3α, (d) BD-NS1 and AD-STAT3β-∆C574, 
(e) BD-NS1 and AD-STAT3β-∆C321, and (f) BD-NS1 and AD-STAT3β-∆C116 
plasmids. The co-transformants were plated on -Trp/-Leu/-His/-Ade nutrient dropout 
(QDO) plates with x-α-gal. For each co-transformant, 2 representative colonies are 
shown. Positive interactions between the BD and AD fusion proteins lead to the 
activation of the LacZ reporter gene resulting in blue colonies. The BD-p53 and AD-
T co-transformant is used as positive control and the BD and AD empty vector co-
transformant is used as negative control. 
Results 
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4.2. Investigation of dengue virus non-structural 1 protein and 
STAT3α/β protein interactions in mammalian cells 
Next, after the yeast-two-hybrid screen, it was necessary to verify the interactions 
between DENV NS1 and STAT3α/β proteins in mammalian cells. First, the 
interaction of endogenous STAT3α protein with DENV NS1 protein was 
investigated as this was not shown before in the context of mammalian cells. Next, as 
the published result of DENV NS1 protein and STAT3β interaction focused primarily on 
an N-terminally truncated form of STAT3β (Chua et al., 2005), the interaction between 
DENV NS1 protein and full length STAT3β was also examined.  
 
4.2.1. Generation of dengue virus non-structural 1 (sNS1) protein 
stable cell line  
For the purpose of studying the interactions between DENV NS1 protein and 
endogenous STAT3α protein, HepG2 cell line stably-expressing DENV sNS1 
(HepG2-sNS1-V5) or the empty vector (HepG2-vector) were generated. As the 
DENV-sNS1-V5 plasmid encodes a neomycin resistance gene, stably-transfected cell 
lines can be selected using Geneticin® (G418). First, the effective killing 
concentration of HepG2 by G418 was determined. The HepG2 cell monolayers were 
found to be intact at concentrations of G418 below 1250 µg/ml (Figure 4-6a – d), 
indicating that HepG2 cells are not susceptible to G418 at these concentrations. At 
1500 µg/ml of G418 (Figure 4-6e), viable cells were still observed. At 2000 µg/ml of 
G418 (Figure 4-6f), no cells survived (cell death indicated by rounding of cells). 
Hence, to ensure complete elimination of cells that did not integrate the DENV-
sNS1-V5, 2000 µg/ml of G418 was used for subsequent stable cell line selection in 
HepG2 cells.  
Results 























































Figure 4-6: Effective killing concentration of HepG2 cells by G418. 
HepG2 cells were either (a) untreated or treated with (b) 750 µg/ml, (c) 1000 µg/ml, 
(d) 1250 µg/ml, (e) 1500 µg/ml or (f) 2000 µg/ml of G418. Medium containing the 
respective concentrations of G418 were changed every other day. After 7 days, the 
cell monolayers were visualized using phase contrast under an Olympus IX81 
inverted microscope. Rounded morphology of the cells indicates effective killing by 
G418 whereas intact cell monolayers show ineffective killing. 
Results 
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Next, using this effective killing concentration of G418, HepG2 cells, which were 
transiently-transfected with DENV-sNS1-V5 plasmid or the empty vector, were 
selected for stable clones with integrated sNS1-V5 gene into their genomes. As 
shown in Figure 4-7, HepG2-sNS1-V5 stable clones 2, 4 and 5 stably-expressed the 
sNS1-V5 fusion protein as observed in Western Blot analysis. Since HepG2-sNS1-
V5 stable clone 2 showed the most intense band in Western Blot, it was chosen for 






Figure 4-7: HepG2-sNS1-V5 stable clones 2, 4 and 5 stably-express dengue virus 
non-structural 1 (sNS1) protein. 
HepG2 cells were transfected with DENV-sNS1-V5 and selected with 2000 µg/ml of 
G418. Isolated clones (C1 – C6) were passaged separately. After 5 passages, a 
portion of the cells were harvested and subjected to Western Blot analysis using 
mouse anti-V5 antibodies. Presence of sNS1-V5 protein bands indicates integration 
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4.2.2. Generation of STAT3α-GFP and STAT3β-GFP constructs 
In addition to creating HepG2 stable cell lines expressing sNS1 protein, it was also 
necessary to generate full length STAT3α and STAT3β mammalian expression 
plasmids as there is no available specific antibody that differentiates between 
endogenous full length STAT3α protein and STAT3β protein.  
 
The full length STAT3α and STAT3β genes were cloned into the pcDNA3.1/CT-
GFP-TOPO vector as fusion proteins to green fluorescent protein (GFP) (Figure 4-8). 
The full length STAT3α gene was amplified from the total RNA of MRC-5 (Figure 
4-9a). Positive clones, with PCR products of about 2309 bp were selected using 
colony PCR screening (Figure 4-9b). The full length STAT3β gene was synthesized 
from two separately synthesized shorter PCR fragments, STAT3β-left and STAT3β-right 
(Figure 4-10a), using overlapping PCR (Figure 4-10b). Colony PCR screening revealed 
positive clones with PCR bands of about 2165 in agarose gel electrophoresis (Figure 
4-10c). Clone with incorrect PCR band size such as that in lane 6 for STAT3β-GFP 
(Figure 4-10c) was not chosen for sequencing. All the positive clones of STAT3α-GFP 

















Figure 4-8: Schematics of STAT3α-GFP and STAT3β-GFP constructs. 
The open reading frame of full length STAT3α and STAT3β genes were cloned into 
the pcDNA3.1/CT-GFP-TOPO vector as a fusion protein to green fluorescent protein 













Figure 4-9: Generation of STAT3α-GFP plasmid. 
(a) RT-PCR product of STAT3α gene that was amplified from MRC-5 total RNA is 
shown. (b) Colony PCR screening of positive clones of STAT3α-GFP (2309 bp). Six 
colonies were selected for colony PCR and the PCR products were resolved by 
agarose gel electrophoresis. Positive clones with sizes around 2309 bp were 
sequenced to further confirm their sequence integrities. 1 kb denotes 1 kb DNA 
ladder. The relevant molecular sizes (in number of bp) of the 1 kb DNA ladder are 





















Figure 4-10: Generation of STAT3β-GFP construct. 
(a) PCR products of STAT3β-left and STATβ-right fragments are shown. STAT3β-
left fragment was amplified from STAT3α-GFP and STAT3β-right was generated 
using ∆N40-STAT3β-GFP (Chua et al., 2005) as template. (b) Full length STAT3β 
PCR fragment was synthesized from STAT3β-left and STATβ-right using 
overlapping PCR. (c) Colony PCR screening of positive clones of STAT3β-GFP 
plasmid (2165 bp). Six colonies were picked for colony PCR screening. The PCR 
products were resolved by agarose gel electrophoresis. Positive clones with sizes 
around 2165 bp were sequenced to further confirm the integrity of their sequences. 1 
kb denotes the 1 kb DNA ladder. The relevant molecular sizes (in number of bp) of 
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4.2.3. Dengue virus non-structural 1 (sNS1) protein does not co-
localize with STAT3α 
After generating the STAT3-GFP constructs, the localizations of both DENV sNS1 
and STAT3α-GFP proteins in co-transfected HepG2 cells were examined. Co-
localization of DENV sNS1 and STAT3α proteins would indicate a possible 
interaction in mammalian cells. As shown in Figure 4-11a, STAT3α-GFP plasmid 
was functional and expressed STAT3α-GFP protein in the cytosol. DENV sNS1-V5 
protein was also found to be localized in the cytosol (Figure 4-11b). Although both 
STAT3α-GFP (Figure 4-11a) and DENV sNS1-V5 (Figure 4-11b) proteins were 
localized in the cytosol, there was no co-localization observed between STAT3α-
GFP and DENV sNS1-V5 proteins in HepG2 cells (co-transfected with both the 
STAT3α-GFP and DENV-sNS1-V5 plasmids) (Figure 4-11c). These results 






















Figure 4-11: Dengue virus non-structural 1 (sNS1) protein does not co-localize 
with STAT3α protein.  
HepG2 cells were transfected with either (a) STAT3α-GFP plasmid, (b) DENV-
sNS1-V5 plasmid or (c) both plasmids. 36 hr post-transfection, the cells were fixed, 
permeabilized, probed sequentially with mouse anti-V5 primary antibodies and 
Alexa Fluor® 594 conjugated goat anti-mouse secondary antibodies, stained with 
DAPI and viewed under the Nikon A1R confocal microscope. (a) STAT3α-GFP 
protein and (b) DENV sNS1-V5 protein expressions are shown. (c) DENV sNS1 
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4.2.4. Dengue virus non-structural 1 (sNS1) protein does not co-
immunoprecipitate with endogenous STAT3α in mammalian 
cells 
To confirm that DENV sNS1 protein does not interact with endogenous STAT3α 
protein, co-immunoprecipitation studies were conducted using HepG2-sNS1-V5 
(Section 4.2.1) and HEK293T-sNS1-HA cell lines (Section 2.1) which stably-
expressed sNS1 proteins. HEK293T-sNS1-HA cell line, kindly provided by Dr. Prida 
Malasit (Section 2.1), was generated using a DENV-sNS1-HA plasmid different 
from the DENV-sNS1-V5 used thus far.  
 
The whole cell lysates (WCL) of HepG2-vector and HepG2-sNS1-V5 cells were first 
probed with anti-V5 antibodies confirm expression sNS1-V5 protein in HepG2-
sNS1-V5 cells (Figure 4-12a). Similarly, specific DENV sNS1-HA protein band was 
observed in the WCL of HEK293T-sNS1-HA cells but not HEK293T-vector cells 
(Figure 4-12b), showing the intact expression of DENV sNS1-HA in HEK293T-
sNS1-HA cells. Endogenous STAT3α expression was also found in all the cell lines 
used as shown by the presence of STAT3α protein bands in the WCL (Figure 4-12c 
and d).  
 
From Figure 4-12a, it was observed that pull-down of STAT3α protein in HepG2-
sNS1-V5 cells using anti-STAT3 antibodies did not result in the co-
immunoprecipitation of DENV sNS1-V5 protein as shown by the absence of protein 
bands in Western Blots. Similar results were also obtained for HEK293T-sNS1-HA 
cells (Figure 4-12b).  
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Reciprocal pull-down of DENV sNS1-V5 protein using anti-V5 antibodies also did 
not lead to the co-immunoprecipitation of STAT3α in both HepG2- sNS1-V5 (Figure 
4-12c) and HEK293T-sNS1-HA cells (Figure 4-12d). These results indicated that 




























Figure 4-12: Dengue virus non-structural 1 (sNS1) protein does not co-
immunoprecipitate with endogenous STAT3α protein.  
Pull-down of endogenous STAT3α protein did not co-immunoprecipitate DENV 
sNS1-V5 protein in (a) HepG2-sNS1-V5 and (b) HEK293T-sNS1-HA stable cell 
lines. Reciprocal pull-down of DENV sNS1-V5 did not co-immunoprecipitate 
endogenous STAT3α protein in (c) HepG2-sNS1-V5 and (b) HEK293T-sNS1-HA 
stable cell lines. HepG2-vector and HEK293T-vector stable cell lines expressing the 
empty vector serve as negative controls. Immunoprecipitations (IP) were performed 
using anti-STAT3, anti-V5 and anti-NS1 antibodies as indicated. Western Blot (WB) 
analysis of the whole cell lysates (WCL) and IP eluates were done using the same 
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4.2.5. Dengue virus non-structural 1 (sNS1) protein does not co-
immunoprecipitate with full length STAT3α and STAT3β in 
mammalian cells 
Next, the interaction between DENV sNS1 protein and full length STAT3β protein 
was examined. In addition, as a further confirmation that DENV sNS1 protein does 
not interact with STAT3α protein, the interaction between DENV sNS1 protein and 
recombinant STAT3α-GFP protein was also investigated. Two immunoprecipitation 
methods, namely the protein G-conjugated magnetic bead and the protein G-
conjugated sepharose bead immunoprecipitation methods, were used to eliminate any 
non-specific binding effects by the beads, which may lead to false positive results. 
 
From Figure 4-13a and b, it was observed that specific protein bands were obtained 
for DENV sNS1-V5, STAT3α-GFP and STAT3β-GFP proteins in the WCL of 
DENV-NS1-V5, STAT3α-GFP and STAT3β-GFP singly-transfected HEK293FT 
cells, respectively, indicating that all the three plasmids were functionally expressing 
the respective proteins. For both the protein G-conjugated magnetic bead (Figure 
4-13a) and the protein G-conjugated sepharose bead (Figure 4-13b) 
immunoprecipitation methods, the pull-down of DENV sNS1-V5 protein using 
mouse anti-NS1 antibodies was successful. This was indicated by the detection of 
specific sNS1-V5 protein bands in the immunoprecipitated eluates of DENV-sNS1-
V5 singly-transfected, DENV-sNS1-V5 and STAT3α-GFP co-transfected, and 




























Figure 4-13: Dengue virus non-structural 1 (sNS1) protein does not co-
immunoprecipitate with full length STAT3α and STAT3β proteins.  
Pull-down of DENV sNS1-V5 protein did not co-immunoprecipitate full length 
STAT3α-GFP and STAT3β-GFP proteins using both (a) protein G-conjugated 
magnetic beads and (b) protein G-conjugated sepharose beads immunoprecipitation 
(IP) methods. HEK293FT cells were either mock-transfected or transfected with 
DENV-NS1-V5, STAT3α-GFP, STAT3β-GFP as indicated. 24 hr post-transfection, 
the cell lysates were harvested and immunoprecipitated with mouse anti-NS1 
antibodies Next, the whole cell lysates (WCL) and IP eluates were subjected to 
Western Blot (WB) analysis using rabbit anti-GFP and mouse anti-V5 antibodies.  
Results 
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No STAT3β-GFP protein band was observed in the immunoprecipitated eluates of 
both the STAT3β-GFP singly-transfected, and DENV-sNS1-V5 and STAT3β-GFP 
co-transfected samples for both the protein G-conjugated magnetic bead (Figure 
4-13a) and the protein G-conjugated sepharose bead (Figure 4-13b) methods. These 
findings indicated that DENV sNS1 protein did not interact with full length STAT3β 
protein. 
 
As shown in Figure 4-13a, STAT3α-GFP protein bands were detected in the 
immunoprecipitated eluates of both the STAT3α-GFP singly-transfected, and 
DENV-sNS1-V5 and STAT3α-GFP co-transfected samples using the protein G-
conjugated magnetic bead immunoprecipitation method. This seemed to be due to a 
non-specific interaction obtained using the protein G-conjugated magnetic bead 
immunoprecipitation method.  This was because if the co-immunoprecipitation was 
due to true interactions between NS1 and STAT3α proteins, no STAT3α-GFP 
protein bands should be observed for the STAT3α-GFP singly-transfected cells 
(Figure 4-13b). Furthermore, when using the protein G-conjugated sepharose bead 
immunoprecipitation method, no protein bands were observed in the 
immunoprecipitated eluates of similarly transfected samples (Figure 4-13b). These 
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5. Results 
5.1. Dengue virus infection does not inhibit IFNα- and IL6-
induced STAT3α activation 
In the previous chapter (Section 4.1), it was proposed that the interaction between 
DENV sNS1 protein and STAT3α/β protein could possibly be the mechanism of 
action behind the observed reduction of Jak/STAT signal transduction (Section 3.4.2). 
However, this hypothesis was shown to be untrue as DENV sNS1 protein did not 
interact with both full length STAT3α and STAT3β in mammalian cells (Section 4.2). 
Hence, the observed down-regulation of Jak/STAT signalling by DENV sNS1 
protein (Section 3.4.2) in the presence of pIC dsRNA analog must be due to another 
mechanism.  
 
Viral dsRNA is one of the key pathogen-associated molecular patterns (PAMPs) 
found in virus-infected cells (Alexopoulou et al., 2001; Honda and Taniguchi, 2006; 
Wang et al., 2004b) known to trigger the activation of interferon regulatory factor 3 
(IRF3) through TLR3 signalling (Honda et al., 2006) which in turn induced the 
transcription and translation of IFNα/β (Taniguchi and Takaoka, 2002). Viral dsRNA 
can also induce IFNα/β expression through retinoic-acid-inducible gene I (RIG-I), 
melanoma-differentiation-associated gene 5 (MDA5) and IFN-inducible dsRNA-
dependent protein kinase (PKR) signalling (Honda and Taniguchi, 2006). Secreted 
IFNα/β in turn act in an autocrine or paracrine manner by binding to IFNα/β 
receptors to trigger the activation of the Jak/STAT signalling and subsequently 
downstream ISGs (Honda and Taniguchi, 2006).  As there are many intermediary 
signal transduction proteins involved in the induction of Jak/STAT signalling in 
Results 
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response to dsRNA, all these intermediary signalling molecules represent different 
points at which DENV could exert its effect through its sNS1 protein.  
 
The initial part of this chapter aims to delineate whether the mechanism of action of 
DENV on Jak/STAT signal transduction is upstream or downstream of IFNα/β 
signalling. To achieve this, the effect of DENV2 infection on IFNα- and IL6-induced 
STAT3 protein activation, as indicated by STAT3 protein nuclear localization, was 
investigated.  
 
As shown in Figure 5-1a, STAT3 protein localization was diffused throughout the 
cells in mock-infected and untreated Huh7 cells. IFNα treatment led to the nuclear 
localization and activation of STAT3 protein in most of the cells (Figure 5-1b). 
Likewise, treating the Huh7 cells with IL6 also resulted in the nuclear localization of 
STAT3 protein (Figure 5-1c). These results showed that IFNα- and IL6-induced 
STAT3 protein activation was functional in Huh7 cells.  
 
From Figure 5-1d, it was observed that DENV infection (untreated) resulted in some 
STAT3 protein activation as shown by the nuclear localization of STAT3 protein in 
about 50 % of the cells. IFNα treatment of DENV-infected cells led to the strong 
activation of STAT3 protein as seen by the intense nuclear localization (Figure 5-1e), 
similar to that observed in mock-infected IFNα-treated cells (Figure 5-1b). Treatment 
with IL6 of DENV-infected cells also caused extensive nuclear localization (Figure 
5-1f), like those observed in mock-infected IL6-treated cells (Figure 5-1c). These 
findings indicated that DENV infection did not inhibit IFNα- and IL6-induced 
STAT3 protein activation.  
 
Results 


























Figure 5-1: Dengue virus infection does not inhibit IFNα- and IL6-induced 
STAT3α protein activation. 
Huh7 cells were either (a – c) mock-infected or (d – f) infected with DENV2 at MOI 
= 1. 24 hr post-infection, the cells were then subjected to (a and d) no treatment, (b 
and e) 1000 units of IFNα treatment for 30 min or (c and f) 100 ng/ml IL6 treatment 
for 30 min. Next, the cells were fixed, permeabilized, probed sequentially with 
mouse anti-STAT3 protein primary antibodies and Alexa Fluor® 488-conjugated 
goat anti-mouse antibodies, stained with DAPI and viewed under the Olympus IX81 
inverted microscope. Sub-cellular localizations of STAT3α protein (green) and 
nucleus (blue) are shown. Nuclear localization of STAT3 indicates activation of 
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5.2. Establishment of an IFNβ promoter luciferase reporter assay 
Since DENV did not inhibit IFNα- and IL-6-induced STAT3α protein activation 
(Section 5.1), it is most likely that DENV acts upstream of IFNα/β to modulate 
Jak/STAT signalling. To investigate whether DENV modulates Jak/STAT signalling 
through mechanism upstream of IFNα/β signalling, an IFNβ promoter luciferase 
reporter assay was developed. If DENV acted upstream of IFNα/β signalling, it 
should modulate the activation of IFNβ promoter.  
 
To create IFNβ promoter luciferase reporter, the 110 bp (IFNβ-110) and 300 bp 
(IFNβ-300) IFNβ promoter sequences upstream of the transcriptional start site of 
IFNβ messenger RNA were cloned into pGL4 vector upstream of the firefly 
luciferase reporter gene (Figure 5-2). As shown in Figure 5-2, both the IFNβ-110 and 
IFNβ-300 promoters were designed to contain all 4 known cis response elements, 
namely positive regulatory domains (PRD) I – IV, which regulate the transcription 
and expression of the IFNβ gene (Honda et al., 2006).  
 
The IFNβ-300 promoter region was first amplified from total genomic DNA 
extracted from HEK293FT cells (Figure 5-3a). Next, the IFNβ-110 and IFNβ-300 
were amplified (Figure 5-3b) and cloned into pGL4 using RE cloning. From colony 
PCR screening (Figure 5-3c), it was observed that all the clones of IFNβ-110-pGL4 
and IFNβ-300-pGL4 showed PCR bands of about 200 bp and 400 bp, respectively. 
This differed from the expected size of 110 and 300 bp for IFNβ-110-pGL4 and 
IFNβ-300-pGL4, respectively. Nonetheless, sequencing results of these clones 
showed that their sequences were intact and no additional sequence was found. 
Results 
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Hence, these IFNβ-110-pGL4 and IFNβ-300-pGL4 clones were used for downstream 














Figure 5-2: Schematics of IFNβ-110-pGL4 and IFNβ-300-pGL4 constructs. 
The 110 bp and 300 bp IFNβ promoter sequences upstream of the transcriptional 
start site of IFNβ messenger RNA, which is found on the complementary strand of 
chromosome 9, were cloned into pGL4 vector upstream of the firefly luciferase 
reporter gene using NheI and BglII restriction endonuclease cloning. Both IFNβ-110-
pGL4 and IFNβ-300-pGL4 contain 4 cis elements, namely positive regulatory 


































Figure 5-3: Generation of IFNβ-110-pGL4 and IFNβ-300-pGL4 plasmids. 
(a) PCR product of the 300 bp IFNβ promoter region (IFNβ-300) that was primed out 
from total genomic DNA extracted from HEK293FT cells is shown. (b) The 110 bp 
(IFNβ-110) and 300 bp (IFNβ-300) IFNβ promoter regions were then amplified 
using the PCR product of IFNβ-300 from (a). Two different sets of primers for 
gateway (G) and restriction endonuclease (RE) cloning were used. RE cloning was 
eventually used to insert the IFNβ promoter sequences into pGL4 vector. (c) Colony 
PCR screening of positive clones of IFNβ-110-pGL4 and IFNβ-300-pGL4 plasmids. 
Six colonies were selected for colony PCR and the PCR products were resolved by 
agarose gel electrophoresis. Positive clones, with sizes around 110 bp and 300 bp for 
IFNβ-110-pGL4 and IFNβ-300-pGL4 plasmids, respectively, were sequenced to 
further confirm their sequence integrity. 100 bp denotes 100 bp DNA ladder. The 
relevant molecular sizes (in number of bp) of the 100 bp DNA ladder are indicated 
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5.2.1. IFNβ promoter luciferase reporter constructs are 
functionally activated by dengue virus infection 
Prior to the use of the IFNβ promoter firefly luciferase reporter constructs (IFNβ-
110-pGL4 and IFNβ-300-pGL4) in further downstream studies, it was necessary to 
first test their functionality. Since it is known that virus infection leads to NF-κB 
induction (Honda et al., 2006), enhanced type I IFN production (Biron, 1999) and 
activation of downstream genes which are regulated by IFN-stimulated response 
elements (ISRE) (Taniguchi and Takaoka, 2002), virus-induced activation was used 
to test the functionality of the IFNβ-110-pGL4 and IFNβ-300-pGL4 plasmids.  
 
As shown in Figure 5-4, both the IFNβ-110-pGL4 and IFNβ-300-pGL4 plasmids 
were functionally induced by DENV infection similar to that of the NF-κB-Luc and 
ISRE-Luc positive controls. It should be noted that the magnitude of fold changes 
induced by DENV, was in the ascending order from NF-κB, IFNβ-300-pGL4, IFNβ-
110-pGL4 to ISRE-Luc. This was consistent with the amplification effect of 
upstream NF-κB on IFNβ promoter, which in turn led to the amplification of 
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Figure 5-4: The IFNβ promoter constructs are functionally-induced by dengue 
virus infection.  
IFNβ promoter, NF-κB-Luc and ISRE-Luc activity are functionally-induced by 
DENV infection. The IFNβ-110-pGL4, IFNβ-300-pGL4, NF-κB-Luc and ISRE-Luc 
plasmids were each co-transfected into HEK293-hTLR3 cells with pRL-TK Renilla 
luciferase vector as transfection control. 24 hr post-transfection, the cells were either 
mock-infected (-) or infected with DENV (+) at MOI = 1. 24 hr post-infection, the 
cells were harvested and the cell lysates were analysed for firefly and Renilla 
luciferase activity. The firefly luciferase activity is normalized against the Renilla 
luciferase activity to give the normalized relative luciferase activity (nRLA). Results 
are expressed as fold changes of the nRLA of the DENV-infected samples (green 
bars) relative to that of the mock-infected samples (black bars) for each of the 
plasmids. Data are presented as mean fold changes ± SEM of three independent 
samples (n = 3). * denotes statistically significant difference (p < 0.05) between 
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5.2.2. Optimization of the IFNβ promoter luciferase reporter assay 
Before using the IFNβ promoter luciferase reporter system for downstream 
experiments, it was necessary to optimize the experimental conditions. These 
parameters were namely the treatment time and concentration of pIC dsRNA analog, 
and the ratio of pRL-TK Renilla luciferase to IFNβ-110-pGL4 firefly luciferase 
plasmids.  
 
It was found that the IFNβ promoter was significantly activated following 6 hr of 
induction (Figure 5-5a). Longer incubations of 24 hr did not result in increased 
induction of the IFNβ-100 promoter (Figure 5-5a). Next it was also observed that 
both 10 µg/ml and 20 µg/ml of pIC were required for optimal activation of the IFNβ-
110 promoter (Figure 5-5b). Both the 1:30 and 1:10 ratio of pRL-TK Renilla 
luciferase vector to IFNβ-110-pGL4 firefly luciferase vector showed similar levels of 
induction of the IFNβ-100 promoter (Figure 5-5c). Hence, the optimum conditions 
used for subsequent studies were 6 hr treatment with pIC at a concentration of 10 
µg/ml or more on cells transfected with pRL-TK Renilla luciferase vector to IFNβ-
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Figure 5-5: Optimization of the IFNβ promoter luciferase reporter assay.  
HEK293-hTLR3 cells were co-transfected with pRL-TK, IFNβ-110-pGL4 (at a ratio 
of 1 pRL-TK: 10 IFNβ-110) and either DENV-sNS1-V5 or LacZ control plasmids. 
24 hr post-transfection, the transfected cells were (a) treated with 20 µg/ml pIC for 
various time periods indicated and (b) treated with various concentrations of pIC 
(µg/ml) for 6 hr before the lysates were harvested and analyzed for luciferase activity. 
(c) HEK293-hTLR3 cells were co-transfected with 1:30 or 1:10 ratio of pRL-TK to 
IFNβ-110, and either DENV-sNS1-V5 or LacZ control plasmids. 24 hr post-
transfection, the cells were treated with 20 µg/ml pIC for 6 hr before the cell lysates 
were harvested and analyzed for luciferase activity. The firefly luciferase activity is 
normalized to the Renilla luciferase activity. The results are expressed as fold 
changes of the normalized relative luciferase activity of the pIC-treated samples 
relative to that of the untreated samples. Data are expressed as mean fold changes ± 
SEM of two independent samples (n = 2). * denotes statistically significant 
difference (p < 0.05) between the pIC-treated and untreated samples. Optimal 
conditions for IFNβ promoter luciferase reporter assay are determined to be 6 hr 
treatment with pIC ( ≥ 10 µg/ml) on cells transfected with pRL-TK and IFNβ-110-
pGL4 at a ratio of 1:30. 
Results 
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5.3. Dengue virus infection inhibits pIC-induced activation of 
IFNβ promoter, NF-κB and ISRE reporters 
Next, the effects of DENV infection on pIC-induced activation of IFNβ promoter, 
NF-κB and ISRE reporters were assessed. This was done to study whether the 
observed modulation of downstream Jak/STAT signalling (Section 3.2.2) was 
attributed to DENV actions upstream of IFNα/β signalling. 
 
As shown in Figure 5-6a, pIC treatment on HEK293-hTLR3 cells, which were 
transfected with IFNβ-110-pGL4 plasmid, resulted in about 10-fold increase in 
expression of firefly luciferase reporter. DENV infection significantly reduced this 
induction to about 2 folds (Figure 5-6a). Similarly, the pIC-induced activation of 
IFNβ-300-pGL4 was significantly lowered in DENV-infected samples relative to that 
of mock-infected ones (Figure 5-6b). Lastly, as compared to mock-infected samples, 
the activation of NF-κB-Luc (Figure 5-6c) and ISRE-Luc (Figure 5-6d) by pIC was 
also inhibited in DENV-infected samples. These findings indicated that DENV acted 
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Figure 5-6: Dengue virus infection inhibits pIC-induced activation of IFNβ 
promoter, NF-κB and ISRE reporters.   
HEK293-hTLR3 cells were co-transfected with pRL-TK and either (a) IFNβ-110-
pGL4, (b) IFNβ-300-pGL4, (c) NF-κB-Luc or (d) ISRE-Luc. 24 hr post-transfection, 
the cells were either mock-infected or infected with DENV at MOI = 1. 24 hr post-
infection, the cells were either untreated or treated with 10 µg/ml pIC for 6 hr. 
Following which, the cell lysates were harvested and analyzed for luciferase activity. 
The firefly luciferase activity is normalized to the Renilla luciferase activity. The 
respective normalized relative luciferase activities of the respective untreated 
samples are set as 1. The results are expressed as fold changes of the normalized 
relative luciferase activity of the pIC-treated samples relative to their respective 
untreated samples. Data are shown as mean fold change over respective untreated 
control ± SEM of three independent samples (n = 3). * denotes statistically 
significant difference (p < 0.05) between DENV-infected and mock-infected samples. 
The pIC-induced activation of IFNβ promoter, NF-κB-Luc and ISRE-Luc is reduced 
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5.4. Effects of dengue virus non-structural proteins on IFNβ 
promoter activity in response to pIC stimulation 
Having shown that DENV acted upstream of IFNα/β signalling to modulate 
Jak/STAT signalling (Section 5.3), next, the mechanism was investigated. To study 
this, DENV NS proteins were screened for their abilities to regulate IFNβ promoter 
activity in response to pIC stimulation.  
 
From the IFNβ promoter luciferase reporter assay screening, it was found that DENV 
sNS1 protein significantly inhibited the pIC-induced activation of the IFNβ-110 
promoter as compared to the LacZ vector control in both HEK293-hTLR3 (Figure 
5-7a) and HeLa (Figure 5-7b) cells. Both KUNV and WENV-sNS1 proteins positive 
controls, which were reported to inhibit IFNα/β signalling through the TLR3 
pathway (Wilson et al., 2008), also significantly reduced the pIC-induced activation 
of IFNβ-110 promoter as compared to the LacZ vector control in HEK293-hTLR3 
(Figure 5-7a) and HeLa (Figure 5-7b) cells. It was also observed that when the ER 
targeting signal peptides of DENV, KUNV and WENV sNS1 proteins were excluded 
(as shown in the DENV, KUNV and WENV NS1 samples), the inhibitory effect on 
IFNβ promoter activation was attenuated in both HEK293-hTLR3 (Figure 5-7a) and 
HeLa (Figure 5-7b) cells. 
 
Inconsistent results, however, were obtained for DENV NS2B and NS5 proteins. 
Both DENV NS2B and NS5 proteins were shown to activate IFNβ promoter activity 
in HEK293-hTLR3 cells (Figure 5-7a) but DENV NS2B protein showed no 
significant changes in IFNβ promoter activity while DENV NS5 protein decreased 
IFNβ promoter activation in HeLa cells (Figure 5-7b). These results suggested that  
Results 
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Figure 5-7: Effects of dengue virus non-structural protein on IFNβ promoter 
activity in response to pIC stimulation.  
Cells were co-transfected with IFNβ-110-pGL4, pRL-TK, and the individual DENV, 
KUNV and WENV NS proteins plasmids. 24 hr post-transfection, HEK293-hTLR3 
and HeLa cells were treated with 10 µg/ml and 20 µg/ml pIC, respectively for 6 hr 
and the cell lysates were harvested. For HeLa cells, 20 µg/ml of pIC were used 
(instead of 10 µg/ml) so as to maintain consistencies with earlier experiments 
(Section 3.4). Luciferase activity in the lysates was analyzed and the firefly 
luciferase activity was normalized to the Renilla luciferase activity. The LacZ control 
protein-expressing cells were used as vector control and KUNV sNS1- and WENV 
sNS1 proteins-expressing cells were used as positive controls. The normalized 
relative luciferase activity (nRLA) of the LacZ vector control is set as 1 fold. The 
results are expressed as fold changes of the nRLA of the NS proteins-expressing cells 
relative to that of the LacZ vector control. Data are shown as mean fold change over 
LacZ control ± SEM of three independent samples (n = 3). * denotes statistically 
significant difference (p < 0.05) between the NS protein-expressing cells and the 
LacZ control protein-expressing cells. Red and green bars represent statistically 
significant down-regulation and up-regulation, respectively in DENV NS protein-
expressing cells as compared to LacZ control protein-expressing cells (black bars). 
Blue and yellow bars represent no significant changes in DENV and WNV (KUNV 
and WENV) NS proteins-expressing cells, respectively. IFNβ-110-pGL4 promoter 
activity is reduced in DENV, KUNV and WENV sNS1 protein-expressing cells in 
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there may be differential cell-type specific effects for DENV NS2B and NS5 proteins 
on IFNβ promoter activity in response to pIC treatment. For the other DENV NS 
proteins such as NS2A, NS2B-3, NS3, NS4A and NS4B proteins, no significant 
changes in IFNβ promoter activity were detected as compared to the LacZ control in 
both cell lines (Figure 5-7a and b). 
 
5.5. Effects of dengue virus non-structural proteins on TLR3 
signalling 
5.5.1. Effects of dengue virus non-structural 1 (sNS1) protein on 
pIC-induced NF-κB activation 
In the previous section, it was found that DENV inhibited pIC-induced activation of 
IFNβ promoter through sNS1 protein (Section 5.4). It would be of interest to further 
dissect the underlying mechanism by which DENV sNS1 inhibited pIC-induced 
activation of IFNα/β signalling. Since pIC dsRNA analog is known to trigger IFNα/β 
signalling via the TLR3 pathway involving the activation of NF-κB and IRF3 
(Honda and Taniguchi, 2006; Taniguchi and Takaoka, 2002), it would be logical to 
next examine the effects of DENV NS proteins on NF-κB and IRF3 activation. This 
will further elucidate the mode of action of DENV sNS1 protein inhibition of IFNα/β 
signalling.  
 
The effects of DENV NS protein on NF-κB have been examined in Section 3.4.1 by 
studying the levels of p-IκB as a surrogate marker for activation of NF-κB signalling. 
However, to further verify that DENV sNS1 does not regulate NF-kB signalling, 
Western Blot analysis was performed to directly detect for the levels of activated NF-
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κB (p-NF-κB). In addition, the levels of upstream phosphorylated IκB kinase (IKK) 













Figure 5-8: Western Blot analysis of IKK and NF-κB phosphorylation and 
expression levels. 
HeLa cells were transfected with DENV-sNS1-V5, DENV-NS1-V5 and LacZ 
control plasmids as indicated. sNS1 and NS1 denote NS1 protein with and without 
the ER targeting signal sequences, respectively. 24 hr post-transfection, the cells 
were treated with 20 µg/ml of pIC for 4 hr, following which, the cell lysates were 
harvested. These conditions were used to maintain consistency with earlier 
experiments (Section 3.4). For each lysate, 30 µg of total protein was resolved by 
SDS-PAGE and subjected to Western Blot (WB) analysis using anti-p-IKK, anti-
total-IKK, anti-p-NF-κB and anti-total-NF-κB and anti-actin antibodies. Detection of 
actin was used to show equal loading across samples. Protein levels of p-IKK, total-
IKK, p-NF-κB, total-NF-κB and actin are shown. DENV sNS1 protein does not 




As shown in Figure 5-8, similar intensities of p-IKK and total-IKK protein bands 
were obtained for all the DENV sNS1, DENV NS1 and LacZ control proteins-
expressing cells. There were also no apparent differences observed in the amount of 
p-NF-κB and total-NF-κB between the DENV sNS1 and LacZ control proteins-
expressing cells (Figure 5-8). Similar results were obtained for DENV NS1 and LacZ 
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control proteins-expressing cells (Figure 5-8). Equal loading was shown across the 
samples by the similar intensities of actin protein bands (Figure 5-8). These results 




5.5.2. Effects of dengue virus non-structural proteins on IRF3 
activation 
To investigate the effects of DENV NS proteins on IRF3 activation, HeLa cells were 
transiently transfected with the various DENV, KUNV, WENV NS proteins and 
LacZ control constructs and treated with pIC to trigger the activation and nuclear 
localization of IRF3. The cells were then stained for NS protein and LacZ control 
expressions, and IRF3 sub-cellular localization. Typically, IRF3 is localized in the 
cytosol and the nucleus in its inactive and activated forms, respectively.  
 
IRF3 activation upon pIC treatment was shown to be intact within HeLa cells as 
indicated by the nuclear localization of IRF3 in pIC-treated LacZ control protein-
expressing cells (Figure 5-9a). In both KUNV (Figure 5-9b) and WENV sNS1 
proteins-expressing cells (Figure 5-9c), it was found that the IRF3 was localized 
mainly in the cytosol indicating the inhibition of pIC-induced activation of IRF3 by 
KUNV and WENV sNS1. This result was similar to the published data of Wilson 
and colleagues (2008) showing that WNV sNS1 protein inhibited IRF3 nuclear 
localization and activation. However, in this study, it was observed that not all cells 
expressing KUNV (Figure 5-9b) and WENV sNS1 proteins (Figure 5-9c) showed 
this inhibition of pIC-induced activation of IRF3.  Likewise, only a sub-population of  
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Figure 5-9: Effects of Dengue virus non-structural proteins on IRF3 nuclear 
localization.  
HeLa cells were transfected with (a) LacZ control, (b) KUNV-sNS1-V5, (c) WENV-
sNS1-V5, (d) DENV-sNS1-V5, (e) KUNV-NS1-V5, (f) WENV-NS1-V5, (g) 
DENV-NS1-V5, (h) DENV-NS2A-V5, (i) DENV-NS2B-V5, (j) DENV-NS2B-3-V5, 
(k) DENV-NS3-V5, (l) DENV-NS4A-V5, (m) DENV-NS4B-V5 and (n) DENV-
NS5-V5 plasmids expressing the various flavivirus NS proteins or LacZ control. 24 
hr post-transfection, the cells were treated with 20 µg/ml of pIC for 4 hr. The cells 
were stained for NS proteins expression, IRF3 sub-cellular localization and nucleus 
using V5-epitode-specific antibody, IRF3-specific antibody and DAPI, respectively. 
Red, green and blue indicate NS protein expression, IRF3 expression and nucleus, 
respectively. Nuclear localization of IRF3 indicates IRF3 activation. Representative 
V5-positive cells showing IRF3 nuclear localization and IRF3 cytosolic localization 
are indicated by pointed and blunt arrows, respectively. Inhibition of pIC-induced 
IRF3 nuclear localization is seen in KUNV, WENV and DENV sNS1 proteins-
expressing cells. In cells expressing the other NS proteins and LacZ control proteins, 
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DENV sNS1 protein-expressing cells exhibited inhibition of pIC-induced IRF3 
nuclear localization (Figure 5-9d).  
 
IRF3 was found to be mainly localized to the nucleus in pIC-treated KUNV (Figure 
5-9e), WENV (Figure 5-9f) and DENV NS1 proteins-expressing cells (Figure 5-9g), 
indicating that proper ER targeting is essential for the observed reduction of pIC-
induced activation of IRF3 by KUNV (Figure 5-9b), WENV (Figure 5-9c) and 
DENV sNS1  (Figure 5-9d) proteins. The other NS proteins, namely NS2A (Figure 
5-9h), NS2B (Figure 5-9i), NS2B-3 (Figure 5-9j), NS3 (Figure 5-9k), NS4A (Figure 
5-9l), NS4B (Figure 5-9m) and NS5 (Figure 5-9n) did not appear to inhibit pIC-
induced IRF3 nuclear localization as IRF3 were localized to the nucleus in HeLa 
cells expressing these NS proteins.  
 
As there is a mixed population of cells exhibiting differential IRF3 sub-cellular 
localization amongst the NS proteins-expressing cells, to obtain a more accurate 
representation of the extent of inhibition, the NS and LacZ control proteins-
expressing cells were counted to obtain the proportion of cells showing IRF3 
activation (Figure 5-10a). It was found that the proportion of cells showing IRF3 
nuclear localization were significantly reduced in DENV, KUNV and WENV sNS1 
proteins-expressing cells relative to LacZ control proteins-expressing cells (Figure 
5-10b). Consistent with the results obtained in Figure 5-9, exclusion of the ER 
targeting peptide in the KUNV (Figure 5-9e), WENV (Figure 5-9f) and DENV NS1 
(Figure 5-9g) proteins-expressing cells led to the abolishment of their inhibitory 
effects on pIC-induced IRF3 activation (Figure 5-10b). In DENV NS2B-3 protein-
expressing cells, there was a slight enhancement in the proportion of cells with IRF3 
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nuclear localization (Figure 5-10b). For all the other NS proteins (NS2A, NS2B, NS3, 
NS4A, NS4B and NS5), there were no observable changes in the proportion of cells 
with activated IRF3 (Figure 5-10b). These findings suggested that DENV sNS1 











































172 | P a g e  
 
Figure 5-10: Dengue virus and West Nile virus non-structural 1 (sNS1) proteins 
inhibit pIC-induced IRF3 nuclear localization.  
HeLa cells were transfected with mammalian expression plasmids expressing the 
various flavivirus NS proteins or LacZ control as indicated. 24 hr post-transfection, 
the cells were treated with 20 µg/ml of pIC for 4 hr. The cells were stained for NS 
proteins expression, IRF3 sub-cellular localization and nucleus using V5-epitode-
specific antibody, IRF3-specific antibody and DAPI, respectively. (a) Cells 
expressing NS proteins are scored for IRF3 cytosolic (inactive) or nuclear 
localization (activated). At least 100 V5-positive cells were counted for each 
construct. Results are presented as percentage of cells with IRF3 localization in the 
cytosol (orange bars) and in the nucleus (purple bars). (b) Differences in the 
percentage of cells showing IRF3 nuclear localization (Pnucleus) in the NS protein-
expressing cells as compared to that of the LacZ control protein-expressing cells 
[Pnucleus(NS proteins) – Pnucleus(LacZ vector control)]. Bars indicate the 95% 
confidence interval of [Pnucleus(NS proteins) – Pnucleus(LacZ vector control)]. 
Hypothesis testing for difference in proportion is conducted and * denotes p-value < 
0.05 between the NS and LacZ control proteins-expressing cells. Red and green 
squares represent statistically significant decrease and increase, respectively in the 
percentage of cells showing IRF3 nuclear localization in DENV NS protein-
expressing cells as compared to LacZ control protein-expressing cells(black squares). 
Blue and yellow squares represent no significant changes in the percentage of cells 
showing IRF3 nuclear localization in DENV and WNV (KUNV and WENV) NS 
proteins-expressing cells, respectively. Percentage of cells with IRF3 localization is 
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5.6. Effects of dengue virus non-structural proteins on the 
transcription of IFN-inducible genes 
Once the upstream mode of action of DENV sNS1 protein was streamlined, 
investigation was performed to determine the downstream effects of DENV sNS1 
protein inhibition of pIC-induced IFNα/β signalling.  Seven pIC-inducible genes, 
downstream of IFNα/β, were studied to confirm that the inhibition of pIC-induced 
IFNα/β signalling by DENV sNS1 protein translated to a similar inhibitory effect on 
the transcription of downstream genes. These genes were namely CCL5, IRF1, IRF7, 
ISG56, Mx1, OAS1 and viperin. The transcript levels of GAPDH and HPRT 
housekeeping genes were also analyzed for normalization purposes. KUNV and 
WENV sNS1, known to inhibit IFNα/β signalling (Wilson et al., 2008), were used as 
positive controls. 
 
Firstly, CCL5 transcript level was observed to be significantly down-regulated in 
DENV-sNS1, NS3, KUNV sNS1 and NS1, and WENV sNS1 and NS1 proteins-
expressing cells relative to those expressing LacZ control at 6 hr post-pIC-treatment 
(Figure 5-11a). However, the inhibition of pIC-induced CCL5 transcription was only 
maintained in DENV, KUNV and WENV sNS1 proteins-expressing cells treated 
with pIC for 24 hr (Figure 5-11b). In cells expressing DENV NS2B-3 proteins, 
CCL5 transcript level was significantly up-regulated at both 6 hr (Figure 5-11a) and 
24 hr post-pIC-treatment (Figure 5-11b).  
 
Secondly, as shown in Figure 5-11c, there were no significant changes in the amount 
of IRF1 transcripts in all the flavivirus NS proteins-expressing cells as compared to 
LacZ control protein-expressing cells at 6 hr post-pIC-treatment. In contrast,  
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Figure 5-11: Effects of dengue virus non-structural proteins on the transcription 
of CCL5, IRF1, IRF7 and ISG56. 
Real-time analysis was performed for (a and b) CCL5, (c and d) IRF1, (e and f) IRF7 
and (g and h) ISG56. HeLa cells were transfected with mammalian expression 
plasmids expressing the various flavivirus NS proteins or LacZ control as indicated. 
24 hr post-transfection, the cells were treated with 20 µg/ml of pIC for 6 hr or 24 hr 
as indicated. After pIC treatment, the total RNA was extracted and subjected to real-
time PCR. The obtained Ct (threshold cycle) values were analyzed using qbasePLUS 
(Biogazelle) and normalized against GAPDH and HPRT housekeeping genes. Data 
are shown as mean calibrated normalized relative quantity (CNRQ) ± SEM of two 
independent biological replicates (n = 2). Students’ T-test was performed. * and # 
denotes p-value < 0.05 and 0.05 < p-value <0.10, respectively between the NS 
protein-expressing cells and the LacZ vector control. Red and green bars represent 
statistically significant down-regulation and up-regulation, respectively in the 
transcription of genes in DENV NS protein-expressing cells as compared to LacZ 
control protein-expressing cells (black bars). Blue and yellow bars represent no 
significant changes in the transcription of genes in DENV and WNV (KUNV and 
WENV) NS proteins-expressing cells, respectively. (a) Transcript level of CCL5 (6 
hr post-pIC-treatment) is reduced in DENV sNS1, DENV NS3, KUNV sNS1, 
KUNV NS1, WENV sNS1 and WENV NS1 proteins-expressing cells but is 
increased in DENV NS2B-3 protein-expressing cells. (b) CCL5 transcript level (24 
hr post-pIC-treatment) is reduced in DENV, KUNV and WENV sNS1 proteins-
expressing cells but is increased in DENV NS2B-3 protein-expressing cells. (c) IRF1 
transcript level (6 hr post-pIC-treatment) is not significantly changed in all the NS 
proteins-expressing cells. (d) Level of IRF1 transcripts (24 hr post-pIC-treatment) is 
significantly lowered in DENV sNS1, DENV NS1, KUNV sNS1 and WENV sNS1 
proteins-expressing cells. (e) IRF7 transcript level (6 hr post-pIC-treatment) is 
significantly reduced in DENV sNS1, NS4B, KUNV sNS1, WENV sNS1 and 
WENV NS1 proteins-expressing cells. (f) Amount of IRF7 transcripts (24 hr post-
pIC-treatment) is decreased in DENV, KUNV, WENV sNS1 proteins-expressing 
cells. (g) Level of ISG56 transcripts (6 hr post-pIC-treatment) is lowered in DENV 
sNS1 protein-expressing cells but elevated in DENV NS2B and KUNV NS1 
proteins-expressing cells. (h) ISG56 transcript level (24 hr post-pIC-treatment) is 
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treatment of cells using pIC for 24 hr caused a reduction in IRF1 transcript levels in 
cells transfected with DENV-sNS1-V5, DENV-NS1-V5, KUNV-sNS1-V5 and 
WENV-sNS1-V5 plasmids (Figure 5-11d).  
 
Thirdly, from Figure 5-11e, it was observed that in cells transfected with DENV-
sNS1-V5, DENV-NS4B-V5, KUNV-sNS1-V5, WENV-sNS1-V5 and WENV-NS1-
V5 plasmids, the level of IRF7 transcripts was significantly lowered at 6 hr post-pIC 
treatment. When subjected to longer incubation with pIC (up to 24 hr), inhibition of 
pIC-induced IRF7 transcription (Figure 5-11f) were only observed in DENV, KUNV 
and WENV sNS1 proteins-expressing cells.  
 
Fourthly, the copy number of ISG56 transcripts was only found to be significantly 
lowered in DENV-sNS1-V5-transfected cells at 6 hr post-pIC-treatment (Figure 
5-11g). In contrast, the level of ISG56 transcripts was up-regulated in DENV NS2B 
and KUNV NS1 proteins-expressing cells (Figure 5-11g) at 6 hr. At 24 hr post-
infection, the transcript level of ISG56 was reduced in cells transfected with DENV-
sNS1-V5, KUNV-sNS1-V5 and WENV-sNS1-V5 plasmids (Figure 5-11h).  
 
The Mx1 transcription was significantly down-regulated at both 6 hr (Figure 5-12a) 
and 24 hr (Figure 5-12b) post-pIC-treatment in cells expressing DENV sNS1 and 
KUNV sNS1 proteins relative to those expressing LacZ control. For WENV sNS1 
proteins-expressing cells, Mx1 transcripts level was only significantly reduced at 6 hr 
(Figure 5-12a) but not at 24 hr (Figure 5-12b) post-pIC-treatment. 
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As shown in Figure 5-12c and d, the quantity of OAS1 transcripts was significantly 
lowered in DENV-sNS1-V5, DENV-NS5-V5 and KUNV-sNS1-V5-transfected 
samples at both 6 hr (Figure 5-12c) and 24 hr (Figure 5-12d) post-pIC-treatment. The 
amount of OAS1 was significantly reduced in cells transfected with WENV-sNS1-
V5 at 6 hr post-pIC-treatment (Figure 5-12c).  
 
Lastly, the level of viperin transcripts was found to be significantly down-regulated 
in cells expressing DENV, KUNV and WENV sNS1 proteins at 6 hr post-pIC 
treatment (Figure 5-12e). At 24 hr post-pIC-treatment, no statistically significant 
changes in the amount of viperin transcripts were observed (Figure 5-12f).  
 
To conclude, DENV sNS1 protein, as well as KUNV and WENV sNS1 protein 
positive controls consistently inhibited the transcription of all seven pIC-inducible 
genes at 6 hr, 24 hr or both timings post-pIC treatment (Figure 5-11 and Figure 5-12). 
On the contrary, only certain genes were specifically regulated by other DENV NS 
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Figure 5-12: Effects of dengue virus non-structural proteins on the transcription 
of Mx1, OAS1 and viperin. 
Real-time analysis was performed for (a and b) Mx1 and (c and d) OAS1 and (e and f) 
viperin. HeLa cells were transfected with mammalian expression plasmids 
expressing the various flavivirus NS proteins or LacZ control as indicated. 24 hr 
post-transfection, the cells were treated with 20 µg/ml of pIC for 6 hr or 24 hr as 
indicated. After pIC treatment, the total RNA was extracted and subjected to real-
time PCR. The obtained Ct (threshold cycle) values were analyzed using qbasePLUS 
(Biogazelle) and normalized against GAPDH and HPRT housekeeping genes. Data 
are shown as mean calibrated normalized relative quantity (CNRQ) ± SEM of two 
independent biological replicates (n = 2). Students’ T-test was performed. * and # 
denotes p-value < 0.05 and 0.05 < p-value <0.10, respectively between the NS 
proteins transfected samples and the LacZ vector control. Red and green bars 
represent statistically significant down-regulation and up-regulation, respectively in 
the transcription of genes in DENV NS protein-expressing cells as compared to LacZ 
control protein-expressing cells (black bars). Blue and yellow bars represent no 
significant changes in the transcription of genes in DENV and WNV (KUNV and 
WENV) NS protein proteins-expressing cells, respectively. (a) Mx1 transcript level 
(6 hr post-pIC-treatment) is reduced in DENV, KUNV and WENV sNS1 proteins-
expressing cells. (b) Mx1 transcript level (24 hr post-pIC-treatment) is lowered in 
DENV and KUNV sNS1 proteins-expressing cells. (c) The amount of OAS1 
transcripts (6 hr post-pIC-treatment) is decreased in DENV sNS1, DENV NS5, 
KUNV sNS1 and WENV sNS1 proteins-expressing cells. (d) The amount of OAS1 
transcripts (24 hr post-pIC-treatment) is decreased in DENV sNS1, DENV NS5 and 
KUNV sNS1 proteins-expressing cells. (e) Viperin transcript level (6 hr post-pIC-
treatment) is lowered in DENV, KUNV, WENV sNS1 proteins-expressing cells. (f) 
No statistically significant changes in Viperin transcript level (24 hr post-pIC-
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5.6.1. Dengue virus non-structural 1 protein down-regulate viperin 
protein expression level 
Recently, it was reported that over-expression of viperin attenuated DENV 
replication (Fink et al., 2007; Jiang et al., 2010). Hence, it would be of interest to 
investigate if DENV sNS1 expression could inhibit the protein expression of viperin 
as a strategy to evade host innate immune responses.  
 
As shown in Figure 5-13, the intensities of the viperin protein bands, detected by 
both rabbit and mouse anti-viperin antibodies, were reduced in DENV, KUNV and 
WENV sNS1-expressing cells relative to those expressing LacZ control. The 
intensities of the viperin protein bands were observed to be similar in cells 
transfected with DENV-NS1-V5, KUNV-NS1-V5 and WENV-NS1-V5 plasmids as 
compared to those transfected with LacZ control plasmid (Figure 5-13). Equal 
loading across samples were demonstrated by similar intensities of the actin protein 
bands (Figure 5-13).  
 
These results indicated that DENV, KUNV and WENV sNS1 proteins down-regulate 
pIC-induced viperin protein expression. Functional ER targeting and consequently 
proper processing of DENV, KUNV and WENV sNS1 proteins was important for 
























Figure 5-13: Western Blot analysis of viperin protein expression levels. 
HeLa cells were transfected with DENV-, KUNV- and WENV-sNS1 and DENV-, 
KUN- and WENV-NS1-V5, and LacZ control plasmids as indicated. sNS1 and NS1 
denote NS1 protein with and without the ER targeting signal sequences, respectively. 
24 hr post-transfection, the cells were treated with 20 µg/ml of pIC for 4 hr, 
following which, the cell lysates were harvested. For each lysate, 30 µg of total 
protein was resolved by SDS-PAGE and subjected to Western Blot (WB) analysis 
using rabbit anti-viperin, mouse anti-viperin and mouse anti-actin antibodies. 
Detection of actin was used to show equal loading across samples. Protein levels of 
viperin and actin are shown. Viperin protein expression levels are down regulated in 
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6. Discussion 
Viral pathogenesis is defined as the series of events involving the intricate interplay 
between a plethora of viral and host factors that lead to the development of disease. 
These virus-host interactions play crucial roles in determining virus infectivity, host 
cell susceptibility and the severity of disease (Baron and Albrecht, 1996). In recent 
years, it was brought to light that replicon-bearing cells of flaviviruses such as 
DENV (Jones et al., 2005), KUNV (Guo et al., 2005; Liu et al., 2005) and WNV 
(Scholle and Mason, 2005) inhibited IFNα/β signal transduction pathway. These 
replicon-containing cells mimic viral RNA replication and native expression of all 
the NS proteins during a natural DENV infection.  
 
Further elucidation into the mechanisms of action identified several NS proteins, 
namely NS2B, NS4A and NS4B, to be responsible for interfering with Jak/STAT 
signalling pathway downstream of IFNα/β signal transduction (Jones et al., 2005; 
Munoz-Jordan et al., 2003). Emerging evidences also showed that DENV NS3 serine 
protease, when expressed together with its co-factor NS2B protein, modulate the 
XBP1 unfolded protein response pathway (Yu et al., 2006). Recently, it was reported 
that DENV NS5 protein binds to tight junction protein implicating it in signalling 
pathways that regulate vascular permeability (Ellencrona et al., 2009). These 
discoveries pointed towards the role of DENV NS proteins in the pathogenesis of 
DENV infection via the modulation of various signalling pathways within the host 
cells. To date, there are still a multitude of host signalling pathways whose 
involvements during DENV infection are not clearly defined.  
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Empirical evidences generated from this study offered novel insights into the 
modulation of dsRNA-induced IFNα/β innate immune signalling by DENV. The 
study also identified DENV sNS1 protein as the key player in immunological 
regulation during DENV infection. Based on the findings of this study, a model for 
the proposed mechanism of action of DENV sNS1 protein on IFNα/β signal 
transduction is put forth (Figure 6-1). As depicted in Figure 6-1i to v, there are five 
possible positions at which DENV sNS1 protein can act to antagonize IRF3 
activation, which was demonstrated in this study (Section 5.5.2). Alcon-LePoder and 
colleagues (2005) reported that secreted DENV sNS1 protein can be endocytosed 
into liver cells and targeted to late endosomes, where TLR3 are typically found 
(Matsumoto et al., 2003). DENV infection was also shown to be increased in cells 
pre-incubated with secreted DENV sNS1 protein (Alcon-LePoder et al., 2005).  
 
As DENV sNS1 protein has been shown to be co-localized with viral dsRNA 
intermediates during DENV replication (Mackenzie et al., 1996), it is possible that 
the endocytosed DENV sNS1 protein interacts with viral dsRNA and prevent it from 
binding to and initiating TLR3 signalling (Figure 6-1i). The endocytosed DENV 
sNS1 protein might directly act on TLR3 to block the dsRNA-triggered TLR3 
signalling pathway (Figure 6-1ii). Cytosolic DENV sNS1 protein could also disrupt 
the complex mediating the signal transduction of TLR3 activation to IRF3 (Figure 6-
1iii). As proposed in Figure 6-1iii, cytoplasmic DENV sNS1 protein could possibly 
interact with any one of the components of the complex such as TLR3, Trif, TRAF3, 
NAP1 or TBK1. Another probable mode of action is that DENV sNS1 protein binds 
to IRF3 and prevent its activation through phosphorylation by TBK1 (Figure 6-1iv). 
Finally, DENV sNS1 protein might sequester IRF3 through binding and hinder 
Discussion 
189 | P a g e  
 
nuclear translocation of IRF3 (Figure 6-1v). Nuclear translocation is important for 
IRF3 to activate IFNα, IFNβ and other downstream gene transcription (Taniguchi 
and Takaoka, 2002).    
 
A novel discovery of this study is that DENV sNS1 protein significantly inhibited 
pIC-triggered IRF3 nuclear localization (Figure 5-9d and Figure 5-10), indicating the 
involvement of endosomal TLR3 or cytoplasmic RNA helicases such as RIG-I and 
MDA5. In addition, KUNV and WENV sNS1 proteins were also shown to inhibit 
pIC-initiated IRF3 activation, which is consistent with the study conducted by 
Wilson and colleagues (2008). One critical distinction that was brought up in this 
project but not in previous work is the presence of a mixed population of KUNV 
(Figure 5-9b) and WENV sNS1 proteins-expressing cells (Figure 5-9c) They 
displayed differential IRF3 sub-cellular localization (reflective of IRF3 activation 
status) in response to pIC induction. This mixed population of cells was also 
observed in DENV sNS1-expressing cells as well as in the other NS and LacZ 
control proteins-expressing cells (Figure 5-10a). This disparity could be due to the 
use of exogenously added pIC dsRNA.  The uptake of exogenous pIC among the 
cells is not uniform and thus, this led to a mixed population of cells with dissimilar 
IRF3 activation. This also explained why the heterogeneous pattern of IRF3 
activation was observed in LacZ control-expressing cells (Figure 5-10a). To 
reconcile this issue, NS and LacZ control proteins-expressing cells were scored for 
IRF3 cytosolic (inactive) or nuclear localization (activated). The count in the LacZ 
control protein-expressing cells served as a basal level for the percentage of cells 
which took up pIC and showed IRF3 activation. From the tabulation results (Figure  
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5-10b), it was revealed that DENV, KUNV and WENV sNS1 proteins caused a 
significant attenuation of IRF3 activation response.  
 
The ER targeting signal sequence of DENV sNS1 protein was also found to be 
important for the inhibition of IRF3 nuclear localization (Figure 5-10b). Truncation 
of the ER targeting signal peptide from DENV sNS1 protein (represented as DENV 
NS1 protein) resulted in the abolishment of this inhibition effect (Figure 5-10b). 
Experiments involving IFNβ promoter studies (Figure 5-7), Jak/STAT signalling 
(Figure 3-13), transcriptional induction of ISGs (Figure 5-11 and Figure 5-12) and 
expression of viperin anti-viral protein (Figure 5-13) also showed this same 
abolishment effect when the ER targeting sequence was excluded from the DENV 
sNS1 protein. This shows that proper ER targeting and consequently proper 
processing of DENV sNS1 protein is important for the attenuation IRF3 activation as 
well as the inhibition of downstream IFNα/β and Jak/STAT signalling pathways.  
 
Since dsRNA can also be recognized by cytoplasmic RNA helicases such as RIG-I 
and MDA5 to trigger both downstream NF-κB and IRF3 activation (Honda et al., 
2006; Honda and Taniguchi, 2006; Kang et al., 2002), efforts were also made to 
investigate the NF-κB signalling pathway to further delineate the mode of action of 
DENV sNS1. Firstly, similar levels of upstream IKK activation was seen in both 
DENV sNS1 and LacZ control proteins-expressing cells (Figure 5-8). Next, using p-
IκB levels as a surrogate marker for NF-κB activation, no differential regulation of 
NF-κB signalling was also detected between HeLa cells expressing DENV sNS1 and 
LacZ control proteins (Figure 3-12e). As a final confirmation, direct detection of NF-
kB phosphorylation levels in DENV sNS1 and LacZ control proteins-expressing cells  
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Figure 6-1: Proposed model for the modulation of IFNα/β signalling by DENV 
sNS1 protein during DENV infection. 
Possible mechanisms of action of DENV sNS1 on IFNα/β signal transduction. 
Secreted DENV sNS1 protein was reported to be endocytosed and accumulates in 
late endosomes (Alcon-LePoder et al., 2005). (i) Endocytosed DENV sNS1 protein 
could possibly bind viral dsRNA and prevent it from binding to TLR3 or (ii) DENV 
sNS1 protein could interact with and directly block TLR3. (iii) Cytosolic DENV 
sNS1 protein might inhibit the TLR3-Trif-TRAF3-NAP1-TBK1 protein complex via 
interaction with any of its components. (iv) Another probable mechanism of action is 
that DENV sNS1 protein binds to IRF3 and prevents its phosphorylation. (v) If 
DENV sNS1 interacts with IRF3, it could also prevent IRF3 from translocating into 
the nucleus where it exerts its effect on IFNβ gene transcription. (vi) DENV sNS1 
protein reduces IRF3 nuclear localization and activation. (vii) This in turn leads to 
decreased induction of IFNα/β gene transcription hence (viii) lowering the positive 
feedback and causes (ix) reduction in Jak/STAT signalling. (x) This results in 
decrease in ISGs induction, (xi) lowering the feedback via IRF7 de novo synthesis. 
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also did not show any apparent differences (Figure 5-8). These evidences indicated 
that DENV sNS1 protein does not modulate NF-κB signal transduction. 
Consequently, this suggests that DENV sNS1 protein did not act through RIG-I and 
MDA5 pathways to cause the observed down-regulation of IRF3 activation (Section 
5.5.2) as NF-κB activation should be moderated if DENV sNS1 protein exerts effects 
on RIG-I or MDA5 signalling. These findings pointed towards the mode of action of 
DENV sNS1 on TLR3 signalling.  
 
As illustrated by Figure 6-1vi and vii, the down-regulation of IRF3 activation by 
DENV sNS1 protein would lead to a corresponding decrease in IFNα/β gene 
induction. This lowers the positive feedback response (Figure 6-1viii) and causes the 
attenuation of Jak/STAT signalling (Figure 6-1ix). The reduction in Jak/STAT 
activation would correspondingly decrease the induction of ISGs such as CCL5, 
IRF1, IRF7, ISG56, Mx1, OAS1 and viperin (Figure 6-1x). Consequently, the 
positive feedback via IRF7 de novo synthesis (Figure 6-1xi) to induce IFNα gene 
transcription (Figure 6-1vii) would also be lowered. As the half life of IRF7 is short 
(Sato et al., 2000), the uninterrupted de novo production of IRF7 is important for 
maintaining the feedback on IFNα/β gene induction. This was demonstrated in 
studies which showed that disruption of IRF7 signalling resulted in more severe 
inhibition of IFNα/β gene activation than interference of IRF3 signalling 
(Hata et al., 2001). This provided a novel strategy by which DENV could modulate 
and delay the triggering of the innate immune response through its sNS1 protein by 
first reducing IRF3 activation that would eventually lead to the lowering of IRF7 
feedback and an attenuated IFNα/β innate immune response.   
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Results generated from this study supported this proposed model. It was found that 
DENV infection did not inhibit IFNα and IL6-induced STAT3 activation (Figure 5-
1), indicating that DENV sNS1 protein most likely exert its effect upstream of 
IFNα/β signalling. From Section 5.3, it was also found that DENV infection 
significantly hindered the induction of IFNβ promoter, NF-κB-luc and ISRE-luc by 
pIC (Figure 5-6). The DENV sNS1 protein was shown to be the culprit viral protein 
responsible for repression of pIC-dependent IFNβ promoter activity in both 
HEK293-hTLR3 and HeLa cells (Figure 5-7). Reduction in IFNβ promoter activity 
was also observed in KUNV and WENV sNS1 proteins-expressing cells, which 
acted as positive controls (Figure 5-7). This is coherent with the published data of 
Wilson and colleagues (2008). These evidences indicated that the down-regulation of 
IFNα/β gene induction (Figure 6-1vii) is attributed to sNS1 protein-mediated 
interference in IRF3 activation (Figure 6-1vi).  
 
Positive feedback through Jak/STAT signalling (Figure 6-1viii and ix) was shown to 
be lowered by DENV sNS1 protein as illustrated by the decrease in Tyk2 (Figure 3-
13b), STAT2 (Figure 3-13c) and STAT3 (Figure 3-13d) activation in cells 
expressing DENV sNS1 protein. As IFNα/β signalling through IFNα/β receptors 1/2 
(IFNAR-1/2) is needed for the activation of Jak/STAT signal transduction, this 
attenuation of Jak/STAT signalling (Section 3.4.2) augmented the earlier observation 
that IFNβ gene induction was reduced in DENV sNS1 protein-expressing cells 
(Figure 5-7).  
 
In this study, DENV sNS1 protein expression in HeLa cells was also demonstrated to 
result in diminished transcription of downstream ISRE-regulated ISGs such as CCL5 
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(Figure 5-11a and b), IRF7 (Figure 5-11e and f), ISG56 (Figure 5-11g and h) Mx1 
(Figure 5-12a and b), OAS1 (Figure 5-12c and d) and viperin (Figure 5-12e). 
Attenuation of the GAS-controlled (Meraz et al., 1996) transcription of IRF1 gene 
was also observed in DENV sNS1 protein-expressing cells (Figure 5-11d). These 
transcriptional reductions across a panel of ISRE- and GAS-regulated genes 
strengthened the findings that Jak/STAT signalling activations (Section 3.4.2) were 
attenuated in DENV sNS1 protein-expressing cells.  
 
This is because Tyk2 dependent phosphorylation of STAT2 (Ihle and Kerr, 1995), 
and consequently the formation of ISGF3, has been shown to be essential for 
activating ISRE to induce the transcription of downstream ISGs (Darnell et al., 1994). 
Moreover, STAT3 was also reported to be vital for supporting ISGF3-mediated 
stimulation of ISRE as knock-down of STAT3 resulted in the impairment of the 
induction of ISRE-dependent genes such as OAS and myxovirus resistance protein 2 
(Mx2) by IFNα (Ho and Ivashkiv, 2006; Yang et al., 1998). In addition, the down-
regulation of both ISRE and GAS-regulated genes (Section 5.6) indicated the 
impairment of both ISGF3 and AAF signalling, respectively. This suggested the 
regulation is attributed to the reduction in their common upstream IFNα/β signalling 
via their receptors IFNAR1/2. This is consistent with our proposed model that pIC-
stimulated IRF3 activation is reduced by DENV sNS1 protein (Figure 6-1vi), causing 
IFNα/β gene induction to be lowered (Figure 6-1vii) which leads to the decrease in 
positive feedback IFNα/β signalling via their receptors IFNAR1/2 (Figure 6-1viii). 
 
Finally, viperin anti-viral protein expression levels were demonstrated to be 
decreased in DENV sNS1 protein-expressing cells (Figure 5-13). This confirmed the 
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validity of the gene transcription studies (Section 5.6) as down-regulation of viperin 
gene transcription (Figure 5-12e) led to a corresponding reduction in viperin anti-
viral protein levels. All these experiments showed a consistent down-regulation of 
IFNα/β signalling in DENV sNS1 proteins-expressing cells, leading to the eventual 
attenuation of viperin anti-viral protein expression. More importantly, this decreased 
viperin anti-viral protein expression in DENV sNS1 protein-expressing cells could 
confer a survival advantage for DENV as viperin anti-viral protein was shown to 
suppress DENV infection (Fink et al., 2007; Jiang et al., 2010). This indirect 
inhibition of viperin anti-viral protein expression by DENV sNS1 protein provided 
insights into a novel strategy employed by DENV to suppress the host innate 
immune response.  
 
Recently, in an opposing study, Baronti and colleagues (2010) reported that 
Flavivirus NS1 proteins did not inhibit TLR3 signalling by showing that the mRNA 
levels of IFNβ, and ISGs such as ISG56 and viperin, were not reduced in WNV and 
DENV sNS1 proteins-expressing cells. Differences between the study conducted by 
Baronti and colleagues (2010) and work done in this project might have been 
generated due to the use of different concentrations of pIC. Five times higher 
concentration of pIC was used in their studies as compared to this study. Excessive 
level of pIC could possibly saturate the TLR3 signalling pathway and masked the 
inhibitory effect of sNS1. Although HeLa cells over-expressing TLR3 and IRF3 
were used in their studies, this may not represent the true level of functional TLR3 
that are found in endosomal compartments within the cells as endosomal targeting 
and acidification were reported to be important for TLR3 signalling (Matsumoto et 
al., 2003).  
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In addition, KUNV and WENV sNS1 proteins, shown to inhibit TLR3 signalling by 
Wilson and colleagues (2008), were also demonstrated to down-regulate IRF3 
activation in this study. This indicated the validity of the data generated from this 
study. Nevertheless, the results from all these studies pointed towards a possible 
threshold level of TLR3 stimulation that would show DENV sNS1 protein-mediated 
inhibition of IRF3 activation. Below this threshold level of TLR3 induction, 
inhibition would be observed as in the case of this study and that of Wilson and 
colleagues (2008). Beyond that threshold level of TLR3 activation, inhibition might 
be masked as could be the case in the work of Baronti and colleagues (2010). 
 
This novel mechanism of innate immunity suppression by DENV sNS1 protein could 
also have implications in the triggering of effective adaptive immune responses. 
Type I IFN (IFNα/β) secretion from infected cells is crucial for proper activation and 
maturation of antigen presenting cells such as dendritic cells (Pace et al., 2010; 
Zietara et al., 2009). In this study, down-regulation of IRF3 activation by DENV 
sNS1 protein (Section 5.5.2) was shown to lead to decreased IFNβ gene induction 
(Section 5.4). Hence, this could affect antigen presentation by dendritic cells to T-
lymphocytes to bring about effective adaptive immune responses (Le Bon and Tough, 
2002; Pace et al., 2010; Zietara et al., 2009). In addition, IFNα/β was also shown to 
be important for preventing apoptosis in antigen-activated T-cells (Marrack et al., 
1999). Thus, decrease IFNα/β may lead to increased cell death of activated T-cells, 
rendering them less effective in clearing DENV-infected cells. 
 
It was originally proposed in Chapter 4 that DEN sNS1 protein could moderate 
Jak/STAT signalling (Section 3.4.2) by binding to STAT3α/β proteins and hindering 
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their activation. An interesting finding of this study is that STAT3α/β protein was 
shown to interact with DENV sNS1 protein in the yeast-two-hybrid system (Section 
4.1) but not in the mammalian system (Section 4.2). This is not uncommon of a 
yeast-two-hybrid system as the detection of false positives has been identified as the 
most significant problem of a yeast-two-hybrid system (Knudsen et al., 2002). Hence, 
yeast-two-hybrid results require verification using co-immunoprecipitation and co-
localization studies in the natural environment of the proteins. In the case of this 
study, mammalian cells represent the native environment of DENV sNS1 and 
STAT3α/β proteins.  
 
One of the possible explanations for the false positive results in yeast-two-hybrid 
system is the improper processing of the DENV NS1 protein. Targeting of DENV 
sNS1 protein to the ER in mammalian cells was shown to be critical for proper post-
translational modification of sNS1 protein (Falgout et al., 1989; Jacobs et al., 2000). 
This post-translational modification, involving glycosylation, was reported to be 
critical for proper DENV sNS1 protein function in the DENV replicative complex 
(Lindenbach and Rice, 1999; Mackenzie et al., 1996). Mutation of the glycosylation 
sites on DENV sNS1 protein resulted in defective DENV replication (Crabtree et al., 
2005; Tajima et al., 2008). Studies done to identify cleavage signal peptides and their 
corresponding protease revealed that host signalase, found in the ER lumen, cleaved 
the ER targeting signal peptide away from sNS1 protein (Chambers et al., 1990b). 
During a natural infection, this cleavage occurs after sNS1 protein has translocated 
into the ER (Chambers et al., 1990b). Due to this cleavage of the ER signal peptide 
located at the N-terminus of sNS1, inclusion of the ER targeting sequence in the BD-
sNS1 yeast-two-hybrid construct would mean the cleaving away of both the ER 
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targeting peptide and also the GAL4 BD. This would not form a functional yeast-
two-hybrid construct as sNS1 protein would not be expressed as a fusion protein to 
the GAL4 BD. Hence, only the BD-NS1 construct without the ER signal peptide 
could be used in the yeast-two-hybrid interaction domain screening. This presented a 
limitation to the yeast-two-hybrid system which made the interaction studies in 
mammalian system more crucial in studying the true interactions of DENV sNS1 
protein with any other proteins.  
 
From the interaction studies done in mammalian cells (Section 4.2.4), it was shown 
that DENV sNS1 protein does not interact with endogenous full length STAT3α. 
Recombinant STAT3α-GFP proteins also showed similar results in co-localization 
studies (Section 4.2.3). Recombinant STAT3α-GFP bands, however, were detected 
in the immunoprecipitated eluates of both the STAT3α-GFP singly-transfected and 
DENV-sNS1-V5 and STAT3α-GFP co-transfected samples using the protein G- 
conjugated magnetic beads IP method (Figure 4-13a). This seemed to be due to a 
non-specific interaction obtained using the magnetic beads IP method. This was 
because if co-immunoprecipitation was due to authentic interaction between DENV 
sNS1 and STAT3α proteins, STAT3α-GFP band should not be observed in the 
STAT3α-GFP singly-transfected IP eluates (Figure 4-13a). Furthermore, when the 
pull-down of DENV sNS1 protein was done using the sepharose beads IP method, no 
protein bands were observed for STAT3α-GFP. These results indicated that DENV 
sNS1 protein did not co-immunoprecipitate and interact with full-length STAT3α. 
 
Since the published result of DENV sNS1 protein and STAT3β protein interaction 
focused primarily on an N-terminally truncated form of STAT3β protein (Chua et al., 
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2005), the interaction between DENV sNS1 protein and full length STAT3β was also 
examined in this study. Evidences from co-immunoprecipitation analysis in this 
study revealed that full length STAT3β did not bind to DENV sNS1 protein (Figure 
4-13b). This pointed towards the importance of the N-terminus domain of STAT3β 
protein in mediating interactions with other proteins. This was also the case in many 
known protein-protein interactions involving STAT3 protein. Xu and colleagues 
(1996) showed the significance of the N-terminus domain of STAT3 protein in 
interactions leading to the formation of a stable STAT tetramers. Enhanceosome 
formation brought about by the interaction of STAT3 protein and other proteins of 
the transcriptional machinery also require intact N-terminus domain and tetramer 
formation (Zhang and Darnell, 2001; Zhang et al., 2007). Studies done on STAT4 
protein, a closely related member of STAT3 in the STAT protein family, also 
highlighted the implication of the N-terminus domain in STAT4 protein dimer 
formation (Ota et al., 2004) and interaction with receptors such as IFNAR-2 (Tyler et 
al., 2007). Hence, an N-terminally truncated form of STAT3β protein (Chua et al., 
2005) may not reflect authentic full length STAT3β protein interactions occurring 
within the cell. This could have resulted in the discrepancies in STAT3β protein 
interaction with DENV sNS1 protein between this study (Section 4.2.5) and the work 
of Chua and colleagues (2005).  
 
However, from this study, it is not possible to completely rule out that transient 
interactions do not occur between DENV sNS1 and STAT3 proteins. As the co-
localization and co-immunoprecipitation methods employed in this work revealed 
only snapshots of molecular events happening within the cell, a live cell imaging 
analysis of both DENV sNS1 and STAT3 proteins localizations could reveal possible 
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transient interaction. Additionally, interaction studies between native DENV sNS1 
and endogenous STAT3 proteins could be conducted under the conditions of wild 
type DENV infection across multiple time-points to supplement the results obtained 
from transient transfection studies. Time course experiments involving IFNα and IL6 
treatment (Figure 5-1) could also be performed to rule out the possibly of any 
transient interactions between DENV sNS1 and STAT3 proteins. 
 
In addition to studying the involvement DENV sNS1 protein interaction with 
STAT3α/β proteins in innate immunity evasion, a mapping of signal transduction 
pathways modulated during DENV infection was also performed (Section 3.2). 
Figure 6-2 and Figure 6-3 summarize the signal transduction pathways modulated 
during early DENV infection (6 hr post-infection) and during peak DENV 
production (72 hr post-infection). Notably, some of the differences observed in the 
amount of phosphorylated signalling proteins between the DENV-infected and 
mock-infected samples were comparatively small, despite being statistically 
significant. As statistical calculations are dependent on the deviations between 
experiments, statistically significant results could by chance be obtained if the 
standard errors between replicates are low. Ideally, the likelihood of this scenerio 
could be reduced by conducting more biological replicates instead of duplicates 
which were done in this study. However, due to constraints of limited availability of 
reagents, only duplicate experiments could be performed. To circumvent this issue, 
additional experiments were conducted on upstream and downstream pathways to 
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Figure 6-2: Schematic representation of signal transduction pathways 
modulated during early DENV infection (6 hr post-infection). 
During early infection (6 hr post-infection), the down-regulation of Erk, NF-κB and 
Jak/STAT signalling is seen. Erk signalling is inhibited as shown by the reduction in 
upstream Src and downstream p70 S6 Kinase activation levels. NF-κB signalling 
pathway is also attenuated as seen by the decrease in upstream Src and downstream 
IκB phosphorylation levels. Antagonism of Jak/STAT signalling is also observed as 
shown by the reduction in upstream Src and downstream STAT3 activation levels. 
No regulation of p38 MAPK, SAPK/JNK and PI3K/Akt signalling is seen at 6 hr 
post-infection. Signal transduction molecules showing differential regulation are 
coloured. Green and red arrows indicate up-regulation and down-regulation, 
respectively. The figure is adapted from Alberts (2002); Janeway (2001); Kufe (2003) 
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During early DENV infection, down-regulation of Erk, NF-κB and Jak/STAT 
signalling were seen in this study (Figure 6-2). More specifically, Src and p70 S6 
Kinase activation levels were reduced for Erk signalling (Figure 6-2). Src activation 
regulated the activation of p70 S6 Kinase (Inushima et al., 2001) which in turn 
moderate through phosphorylation the activity of 40S ribosomal S6 protein (Chou 
and Blenis, 1995; Ferrari and Thomas, 1994; Grammer et al., 1996). The 40S 
ribosomal S6 protein is known to control the initiation of cap-dependent translation 
(Dufner and Thomas, 1999). Certain viruses such as poliovirus attenuated cap-
dependent translation to make the critical switch from cap-dependent expression of 
cellular proteins to cap-independent expression of viral proteins (Gradi et al., 1998). 
This switch from cap-dependent translation to cap-independent translation were also 
reported in DENV involving the down-regulation of p70 S6 Kinase phosphorylation 
levels (Villas-Boas et al., 2009). Therefore this could be a strategy of DENV to 
hijack host cellular translational machineries for the synthesis of viral proteins.  
 
NF-κB signalling pathway was also attenuated during early DENV infection as seen 
by the decrease in upstream Src and downstream IκB phosphorylation levels (Figure 
6-2). Antagonism of Jak/STAT signalling was also observed as shown by the 
reduction in upstream Src and downstream STAT3 activation levels (Figure 6-2). 
Sensing of viral RNA through cytoplasmic RNA helicases such as RIG-I (Yoneyama 
et al., 2004) and MDA5 (Yoneyama et al., 2005) induced the activation of NF-κB 
which in turn stimulated downstream IFNα/β production (Lenardo et al., 1989; Li 
and Verma, 2002). IFNα/β plays key roles in cellular anti-viral response by 
mediating the induction of anti-viral genes through Jak/STAT signalling pathway 
(Darnell et al., 1994; Ihle and Kerr, 1995). Thus, this initial inhibition of NF-κB and  
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Figure 6-3: Pictorial representation of signal transduction pathways modulated 
during peak DENV production (72 hr post-infection). 
Significant elevation of SAPK/JNK, NF-κB and Jak/STAT signalling is observed 
during peak virus production (at 72 hr post-infection) in HeLa cells (Figure 3-1). 
Increase in upstream JNK activation levels augments the activation of downstream 
CREB and p53. For NF-κB signal transduction, elevation of upstream Src leads to 
amplification of downstream IkB activation levels. Raised Tyk2 activation during 
peak DENV production enhances STAT2 phosphorylation and activation. No 
activation of Erk is seen even though upstream Src activation level is increased. 
PI3K/Akt and p38 MAPK signal transduction does not appear to be regulated during 
maximum DENV replication. The figure is adapted from Alberts (2002); Janeway 


































207 | P a g e  
 
Jak/STAT signalling could have implications for innate immunity suppression to 
favour DENV replication. 
 
Peak DENV production in HeLa cells was observed to occur around 72 hr post-
infection (Figure 3-1). Among all the time period post-infection, this was also the 
one which showed the most considerable amount of differential activation of the 
various signal transduction pathways (Section 3.2). As illustrated in Figure 6-3, 
significant induction of SAPK/JNK, NF-κB and Jak/STAT signalling is observed 
during peak virus production. Increase in upstream JNK activation levels augmented 
the activation of downstream CREB and p53. Recently, JNK activation was shown to 
be indispensable for DENV replication as inhibition of JNK signalling resulted in 
significant attenuation of virus production (Ceballos-Olvera et al., 2010). The 
apoptotic phenotype during DENV infection has also been attributed to pro-apoptotic 
JNK signal transduction (Hilgard et al., 2004; Morchang et al., 2010). Hence, JNK 
contributes to DENV pathogenesis by supporting DENV replication as well as 
mediating DENV-induced apoptosis. 
 
As depicted in Figure 6-3, elevation of upstream Src led to amplification of 
downstream IkB activation levels, pointing towards the significant induction of NF-
κB signalling during maximum virus replication. Enhanced Jak/STAT signalling 
through Tyk2 and STAT2 activation was also observed during peak DENV 
production. This induction of NF-κB and Jak/STAT signal transduction was 
important for triggering and mediating IFNα/β-induced anti-viral innate immune 
response (Darnell et al., 1994; Ihle and Kerr, 1995; Lenardo et al., 1989; Li and 
Verma, 2002; Sato et al., 2000; Taniguchi and Takaoka, 2002). An interesting 
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phenomenon to highlight is that these host anti-viral innate immune signalling 
pathways were only significantly escalated at 72 hr post-infection after peak virus 
titre was reached. Since a productive infection was achieved, this indicated that 
DENV must have developed certain strategies to evade the innate immune response. 
As discussed earlier, one such mechanism of innate immunity suppression identified 
in this study is the attenuation of dsRNA-induced IRF3 activation by DENV sNS1 
protein.  
 
This evasion of the innate immue system to result in productive infections and high 
virus titres could possibly impact clinical outcomes. Clinical studies done showed 
that high virus titres in the systemic circulation were associated with greater disease 
severity (Libraty et al., 2002a; Murgue et al., 2000; Vaughn et al., 2000). A study 
conducted on Taiwanese patients during an outbreak in 1998 revealed the presense of 
higher levels of viral RNA during defervescence in the blood in DHF patients than in 
DF patients (Wang et al., 2003). In the same study, imunne complexes of dengue 
virus were also isolated during the abatement of fever in DHF patients but not in DF 
patients, thereby implicating higher virus replication in more severe disease outcome 
(Wang et al., 2003).  
 
Several improvements could have been made to the current study to strengthen the 
conclusion obtained. In Section 3.1, DENV infection could have been done at a 
lower MOI of 0.1 to evaluate the permissibility of the various cell lines to DENV 
infection. If these cell lines show different permissibility to DENV infection at a 
lower MOI, a method of standardization would have to be put in place in order to 
make compatible and meaningful comparisons across different experiments 
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conducted using different cell lines. Due to the possible transient nature of protein 
phosphorylation and consequently pathway activation, time points earlier than 6 hr 
post-infection could be performed to reflect the very early events happening and 
identify potential pathways that are differentially modulated just after DENV 
infection (Section 3.2).  In addition, quantitative real time PCR analysis of 
downstream genes could be conducted to confirm the transcriptional regulation of the 
identified pathways.  
 
Future work to further dissect the molecular mechanism of DENV sNS1 protein-
mediated IRF3 inhibition can include interaction studies between DENV sNS1 
protein and the signalling complexes upstream of IRF3. Secreted DENV sNS1 
protein can also be tested for their ability to attenuate IRF3 activation. This would 
narrow down the form of DENV sNS1 protein that is required for IRF3 antagonism. 
Further molecular mapping can also be performed to identify critical residues of 
sNS1 protein that is important for this inhibition effect on innate immune response. 
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7. Conclusion 
In this study, signal transduction pathway mapping revealed the modulation of NF-
κB, Jak/STAT, PI3K/Akt and MAPK signalling during DENV infection. Further 
elucidation of the underlying mechanism identified key roles of DENV sNS1 in the 
immunological suppression of IRF3-mediated IFNα/β innate immune signalling. 
This antagonism of IRF3 activation revealed a novel strategy by which DENV sNS1 
protein aids DENV to evade the innate immune system through the indirect 
inhibition of IRF7 positive feedback as well as the attenuation of viperin anti-viral 
protein expression by DENV sNS1 protein. This implicates targeting DENV sNS1 
protein as a new strategy for anti-viral therapeutic intervention. Molecular mapping 
to identify residues of sNS1 protein critical for this innate immunity inhibition could 
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All the cell culture media, except EMEM, were prepared from powder formulation. 
Firstly, all the various components, excluding the foetal bovine serum and antibiotics, 
were mixed together in 900 ml of autoclaved reverse osmosis (RO) water (resistivity 
of 18.2 MΩ·cm at 25 °C). The pH was then adjusted to 7.2 before filtering through a 
0.2 µm filter. Lastly, foetal bovine serum and antibiotics were added to the desired 
concentration. Foetal bovine serum for the L15 growth media was heat-inactivated at 
56 °C for 30 min before addition into sterile L15 media. 
Preparation of cell culture media and reagents 
 
a) Growth Medium for BHK Cell  
Component Amount Source 
RPMI-1640 1 bottle R4130, Sigma-Aldrich, St. Louis, U.S.A. 
NaHCO3 2.0 g Merck KGaA, Germany 
RO water 900 ml - 
Foetal bovine serum 100 ml PAA Laboratories GmbH, Austria 
 
b) Growth Medium for C6/36 
Component Amount Source 
L15 1 bottle L4386, Sigma-Aldrich, St. Louis, U.S.A. 
RO water 900 ml - 
Heat-inactivated 
foetal bovine serum 
100 ml PAA Laboratories GmbH, Austria 
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c) Growth Medium for HeLa and MRC-5 
Component Amount Source 
EMEM 445 ml 
E15-024, PAA Laboratories, GmbH, 
Austria 
GLUTAMAXTM I (100x) 5 ml Gibco, Invitrogen, NY, U.S.A. 
Foetal bovine serum 50 ml PAA Laboratories, GmbH, Austria 
 
d) Growth Medium for HepG2 and Huh7 
Component Amount Source 
DMEM 1 bottle D1152, Sigma-Aldrich, St. Louis, U.S.A. 
NaHCO3 2.0 g Merck KGaA, Germany 
RO water 900 ml - 
Foetal bovine serum 100 ml PAA Laboratories GmbH, Austria 
 
e) Growth Medium for HEK293FT 
Component Amount Source 
DMEM 1 bottle D1152, Sigma-Aldrich, St. Louis, U.S.A. 
MEM NEAA (100x) 10 ml Gibco, Invitrogen, NY, U.S.A. 
GLUTAMAXTM I (100x) 10 ml Gibco, Invitrogen, NY, U.S.A. 
MEM Sodium Pyruvate 
(100x) 
10 ml Gibco, Invitrogen, NY, U.S.A. 
RO water 870 ml - 
Foetal bovine serum 100 ml PAA Laboratories, GmbH, Austria 
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f) Growth Medium for HEK293-hTLR3 
Component Amount Source 
DMEM 1 bottle D1152, Sigma-Aldrich, St. Louis, U.S.A. 
MEM NEAA (100x) 10 ml Gibco, Invitrogen, NY, U.S.A. 
GLUTAMAXTM I (100x) 10 ml Gibco, Invitrogen, NY, U.S.A. 
MEM Sodium Pyruvate 
(100x) 
10 ml Gibco, Invitrogen, NY, U.S.A. 
RO water 870 ml - 
Foetal bovine serum 100 ml PAA Laboratories, GmbH, Austria 
Blasticidin (10 μg/µl) 1000 µl Gibco, Invitrogen, NY, U.S.A. 
 
g) Growth Medium for HEK293T-sNS1 
Component Amount Source 
RPMI-1640 1 bottle R4130, Sigma-Aldrich, St. Louis, U.S.A. 
NaHCO3 2.0 g Merck KGaA, Germany 
RO water 900 ml - 
Foetal bovine serum 100 ml PAA Laboratories GmbH, Austria 
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h) Phosphate Buffered Saline (PBS) (pH 7.2) 
Component Amount Source 
NaCl 8.0 g BDH Biochemical, Poole, England 
KCL 0.2 g Merck KGaA, Germany 
Na2HPO4 1.15 g Merck KGaA, Germany 
KH2PO4 0.2 g Merck KGaA, Germany 
RO water Top up to 1 L  
The various components were first dissolved in 900 ml of RO water. The pH was 
then adjusted to 7.2 using 1 M HCl or 1 M NaOH solutions. Following which, RO 
water was added until the final volume was 1 L. The PBS was sterilized by 
autoclaving at 121° C for 15 min, 15 lbs. pressure and cooled before use. 
 
i) Trypsin (1x) 
Component Amount Source 
Trypsin (10x) 10 ml Gibco, Invitrogen, NY, U.S.A. 
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Appendix 2 
a) Virus Diluent, Hanks’ Balanced Salts (pH 7.2 - 7.4) 
Preparation of reagents for virus infection and plaque assay 
Component Amount Source 
Hanks’ Balanced Salts 1 bottle H6136, Sigma-Aldrich, St. Louis, U.S.A. 
BSA (cell culture grade) 0.2 g Sigma-Aldrich, St. Louis, U.S.A. 
RO water Top up to 1 L - 
The various components were first dissolved in 900 ml of RO water. The pH was 
then adjusted to 7.2 using 1 M HCl or 1 M NaOH solutions. Following which, RO 
water was added until the final volume was 1 L. 
 
b) Maintenance Media 
All the maintenance media were prepared in similar manner as described in 
Appendix 1 but with variations in the volume of the various components. 
i. Maintenance Media for C6/36 
Component Amount Source 
L15 1 bottle L4386, Sigma-Aldrich, St. Louis, U.S.A. 
RO water 980 ml - 
Heat-inactivated 
foetal bovine serum 
20 ml PAA Laboratories GmbH, Austria 
 
ii. Maintenance Media for Huh7 
Component Amount Source 
DMEM 1 bottle D1152, Sigma-Aldrich, St. Louis, U.S.A. 
NaHCO3 2.0 g Merck KGaA, Germany 
RO water 980 ml - 
Foetal bovine serum 20 ml PAA Laboratories GmbH, Austria 
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iii. Maintenance Media for HEK293-hTLR3 
Component Amount Source 
DMEM 1 bottle D1152, Sigma-Aldrich, St. Louis, U.S.A. 
MEM NEAA (100x) 10 ml Gibco, Invitrogen, NY, U.S.A. 
GLUTAMAXTM I (100x) 10 ml Gibco, Invitrogen, NY, U.S.A. 
MEM Sodium Pyruvate 
(100x) 
10 ml Gibco, Invitrogen, NY, U.S.A. 
RO water 950 ml - 
Foetal bovine serum 20 ml PAA Laboratories, GmbH, Austria 
Blasticidin (10 μg/µl) 1000 µl Gibco, Invitrogen, NY, U.S.A. 
 
iv. Maintenance Media for HeLa 
Component Amount Source 
EMEM 485 ml 
E15-024, PAA Laboratories, GmbH, 
Austria 
GLUTAMAXTM I (100x) 5 ml Gibco, Invitrogen, NY, U.S.A. 
Foetal bovine serum 10 ml PAA Laboratories, GmbH, Austria 
 
c) 0.1M Sodium Hydroxide  
Sodium hydroxide pellets (BDH Ltd., Poole, England) was weighed out to 50 g and 
mixed into 1 L of deionised water (Barnstead, New Hampshire, USA) to create a 1 M 
solution of Sodium Hydroxide. The 1 M solution of Sodium Hydroxide was diluted 
10 times to produce 0.1 M concentrations, for use in adjusting the pH of media. 
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d) Overlay Medium (pH 7.2 - 7.4) 
The overlay medium is made by mixing RPMI (2x) and Carboxymethylcellulose (2x) 
at a 1:1 ratio.  
i. RPMI (2x) 
Component Amount Source 
RPMI-1640 1 bottle R4130, Sigma-Aldrich, St. Louis, U.S.A. 
NaHCO3 2.0 g Merck KGaA, Germany 
RO water 480 ml - 
Foetal bovine serum 20 ml PAA Laboratories GmbH, Austria 
RPMI (2x) was prepared in similar manner as described in Appendix 1 with only 
variations in the volume of the various components. 
ii. CMC (2x) 
Component Amount Source 
Carboxymethylcellulose 
(CMC) 
2.0 g Merck KGaA, Germany 
RO water 100 ml - 
CMC (2x) was autoclaved at 121° C for 15 min, 15 lbs. pressure and cooled before 
use. 
 
e) 1 % Crystal Violet / 20 % Formaldehyde Solution 
Component Amount Source 
Crystal violet powder 5.0 g Sigma-Aldrich, St. Louis, U.S.A. 
37 % Formaldehyde 
solution 
270 ml Merck KGaA, Germany 
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f) Acid Glycine (pH 3.0) solution 
Component Amount Source 
NaCl 8.0 g Sigma-Aldrich, St. Louis, U.S.A. 
KCl 0.38 g Merck KGaA, Germany 
MgCl2.6H2O 0.1 g Merck KGaA, Germany 
CaCl2.2H2O 0.1 g Merck KGaA, Germany 
Glycine 7.5 g Sinopharm Chemical Reagent Co., China 
Autoclaved RO water Final 1 L - 
The various components were dissolved in 850 ml of autoclaved RO water. Next, the 
pH was adjusted to 3 with 5M HCl. Autoclaved RO water was then added to a final 
volume of 1 L. The solution was then filtered through a 0.2 µm filter and stored at 4 
ºC. Solution was warmed to room temperature before use. 
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Appendix 3 
a) DEPC-treated water 
Reagents for first strand cDNA synthesis 
Component Amount Source 
DEPC 1 ml Sigma-Aldrich, St. Louis, U.S.A. 
RO water 1000 ml - 
The DEPC containing RO water was incubated overnight at room temperature with 
stirring. The water was then autoclaved at 121°C for 15 min, 15 lbs. pressure. 
 
b) Nucleic acid mixture 
Component  Volume per reaction 
Total RNA (1 µg/µl) 1 µl 
Random Hexamer (50 ng/ µl) 1 µl 
dNTP mix (10 mM) 1 µl 
DEPC-treated water 7 µl 
 
c) cDNA synthesis mixture 
Component  Volume per reaction 
RT buffer (10x) 2 µl 
MgCl2 (25 mM) 4 µl 
DTT (0.1 M) 2 µl 
RNaseOUT (40 U/μl) 1 µl 
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d) VILOTM cDNA synthesis reaction mixture  
Component  Amount per reaction 
VILOTM reaction mix (5x) 4 µl 
SuperScript® enzyme mix (10x) 2 µl 
RNA 1 µg 
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Appendix 4 
a) LBA broth 
Reagents, reaction setup and conditions for cloning 
Component Final Amount Source 
Tryptone 1 % 10 g Oxoid, Basingstoke, England 
Yeast extract 0.5 % 5 g Oxoid, Basingstoke, England 
NaCl 1 % 10 g BDH, Poole, England 
RO water - 1 L - 
Ampicillin (100 μg/µl)  100 μg/ml 1 ml 
Sigma-Aldrich, St. Louis, 
U.S.A. 
The components, except antibiotics, were completely dissolved and sterilized by 
autoclaving at 121°C for 15 min, 15 lbs. pressure. The solution was cooled down to 
below 55 ºC before the addition of ampicillin. 
 
b) PCR reaction setup for Taq DNA polymerase 
Component 
Volume for full 
reaction (µl) 
Volume for 
Colony PCR (µl) 
ThermoPol Reaction Buffer (10x) 7.5 2.5 
dNTP (10 mM) 1.5 0.5 
Forward Primer (10 µM) 1.5 0.5 
Reverse Primer (10 µM) 1.5 0.5 
cDNA Template 6 - 
Colony pellet - 1 
Taq DNA polymerase 1.5 0.5 
Autoclaved RO water 55.5 19.5 
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c) Thermal cycling conditions for Taq DNA polymerase 
Step PCR for TOPO-TA cloning Colony PCR 
Denaturation 95 ºC for 5 min 95 ºC for 5 min 
Denaturation 95 ºC for 30 s 
32 cycles 
95 ºC for 5 min 
38 cycles 
Annealing 55 ºC for 30 s 55 ºC for 30 s 
Extension 
72 ºC  
(1 min per kb of 
PCR product) 
72 ºC  
(1 min per kb of 
PCR product) 
Final extension 72 ºC for 30 min 72 ºC for 8 min 
Hold 4 ºC 4 ºC 
 
 







Pfu Reaction Buffer (10x) 7.5 - 
Accuprime Pfx Reaction Buffer 
containing dNTP (10x) 
- 5 
dNTP (10 mM) 2.25 - 
Forward Primer (10 µM) 2.25 1.5 
Reverse Primer (10 µM) 2.25 1.5 
DNA Template (10 ng/µl) 3 1 
Pfu DNA polymerase 0.75 0.4 
Autoclaved RO water 54 40.6 
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e) Thermal cycling conditions for Pfu & AccuprimeTM Pfx DNA polymerase 
Step Pfu Pfx 
Denaturation 95 ºC for 2 min 95 ºC for 2 min 
Denaturation 95 ºC for 30 s 
35 cycles 
95 ºC for 30 s 
32 cycles 
Annealing 55 ºC for 30 s 55 ºC for 30 s 
Extension 
72 ºC  
(2 min per kb of 
PCR product) 
72 ºC  
(1 min per kb of 
PCT product) 
Final extension 72 ºC for 8 min 72 ºC for 8 min 
Hold 4 ºC 4 ºC 
 
 
f) PCR reaction setup for AccuprimeTM Taq DNA polymerase high fidelity 
Component 
AccuprimeTM Taq DNA polymerase high 
fidelity reaction volume (µl) 
AccuprimeTM PCR Buffer II 
containing dNTP (10x) 
5 
Forward Primer (10 µM) 1.5 
Reverse Primer (10 µM) 1.5 
Genomic DNA Template 1 
AccuprimeTM Taq high fidelity 0.4 
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g) Thermal cycling conditions for AccuprimeTM Taq DNA polymerase high 
fidelity 
Step 
PCR for AccuprimeTM Taq 
high fidelity 
Denaturation 95 ºC for 5 min 
Denaturation 95 ºC for 30 s 
32 cycles 
Annealing 55 ºC for 30 s 
Extension 
72 ºC  
(1 min per kb of 
PCR product) 
Final extension 72 ºC for 8 min 
Hold 4 ºC 
 
h) TA-TOPOisomerase cloning reaction setup 
Component Volume per Reaction (µl) 
Fresh PCR product 4 
Salt Solution 1 
Autoclaved RO water - 
TOPO® vector 1 
Total 6 
The reaction was incubated at room temperature for 30 min and the entire 6 µl of 
ligated products was used for transformation using One Shot® TOP10 Chemically 
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i) Directional-TOPOisomerase cloning reaction setup 
Component Volume per Reaction (µl) 
Fresh PCR product 0.5 to 4 (use 5 ng per kb of PCR product) 
Salt Solution 1 
Autoclaved RO water Top up to a final volume of 5 
TOPO® vector 1 
Total 6 
The reaction was incubated at room temperature for 30 min and the entire 6 µl of 
ligated products was used for transformation using One Shot® TOP10 Chemically 




j) Restriction endonuclease reaction set-up 
Component PCR product (µl) pGL4 vector(µl) 
RE Buffer B (10x) 7 5 
BSA (10x) 7 5 
Template 49 4 µg 
NheI 2.5 2.5 
BglII 2.5 2.5 
Autoclaved RO water 2 31 
Total 70 50 
Reaction was carried out at 37°C for 4 hours before the RE products were purified 
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k) SOC medium 
Component Final Amount Source 
Tryptone 2 % 20 g Oxoid, Basingstoke, England 
Yeast extract 0.5 % 5 g Oxoid, Basingstoke, England 
NaCl 10 mM 0.58 g BDH, Poole, England 
KCl 2.5 mM 0.186 g Merck KGaA, Germany 
MgSO4.7H2O 10 mM 2.465 g Merck KGaA, Germany 
MgCl2.6H2O 10 mM 2.033 g Merck KGaA, Germany 
Glucose 20 mM 3.603 g Merck KGaA, Germany 
Autoclaved RO water - Final 1 L - 
The components were first dissolved in 900 ml of RO water. Next, the pH was 
adjusted to 7. The volume was then made up to 1 L and the solution was filtered 




l) LBA agar plates 
Component Final Amount Source 
Tryptone 1 % 10 g Oxoid, Basingstoke, England 
Yeast extract 0.5 % 5 g Oxoid, Basingstoke, England 
NaCl 1 % 10 g BDH, Poole, England 
Agar 1.5 % 15 g Oxoid, Basingstoke, England 
RO water - 1 L - 
Ampicillin (100 μg/µl)  100 μg/ml 1 ml 
Sigma-Aldrich, St. Louis, 
U.S.A. 
The components, except antibiotics, were mixed and sterilized by autoclaving at 
121°C for 15 min, 15 lbs. pressure. The solution was cooled down to below 55 ºC 
before the addition of ampicillin and pouring into plates. 
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m) Agarose gel 
Component 1 % Gel 1.5 % Gel 
Molecular grade agarose 1 g 1.5 g 
RO water 100 ml 100 ml 
The agarose was dissolved in RO water by heating in the microwave for 
approximately 5 min. The solution was then cooled briefly under running tap water 
before the addition of 2 µl of ethidium bromide. Next, the solution was poured into a 
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Appendix 5 
a) IFNβ-300 promoter sequence 
Sequence of IFNβ promoters 
 
-281                     a attctcaggt cgtttgcttt cctttgcttt ctcccaagtc -241  
-240 ttgttttaca atttgcttta gtcattcact gaaactttaa aaaacattag aaaacctcac -181  
-180  agtttgtaaa tctttttccc tattatatat atcataagat aggagcttaa ataaagagtt -121 
  
    
-120  ttagaaacta ctaaaatgta aatgacatag gaaaactgaa agggagaagt gaaagtggga -61  
 
 
-60 aattcctctg aatagagaga ggaccatctc atataaatag gccataccca tggagaaagg -1 
+1 acattctaac tgcaacctt +19 
 
 
b) IFNβ-110 promoter sequence 
 
    
-110             ctaaaatgta aatgacatag gaaaactgaa agggagaagt gaaagtggga -61  
 
 




The IFNβ promoter region contains at least four Positive regulatory domains (PRD), 
namely PRD I, II, III and IV. Cis-elements PRD I and III binds interferon regulatory 





PRD I PRD III 





PRD I PRD III 
Transcriptional start site 
PRD IV 
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Appendix 6 
a) Sequencing reaction setup 
Reagents, reaction setup and conditions for sequencing 
Component Amount 
Terminator Ready Reaction Mix 4 µl 
Primer (10 µM) 1 µl 
Template 500 ng 
Autoclaved RO water Top up to 10 µl 
Total 10 µl 
 
b) Thermal cycling conditions for sequencing 
Step Sequencing 
Denaturation 96 ºC for 1 min 
Denaturation 96 ºC for 10 s 
25 cycles Annealing 50 ºC for 5 s 
Extension 60 ºC for 4 min 
Hold 4 ºC 
 
c) Ethanol / potassium acetate solution 
Component Amount 
Absolute Ethanol 25 ml 
3M potassium acetate 1 ml 
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Appendix 7 
a) Yeast Peptone-Dextrose-Adenine (YPDA) broth 
Reagents for Yeast Two-hybrid Assay 
Component Amount Source 
Peptone 20 g Clontech, Heidelberg, Germany 
Yeast extract 10 g Clontech, Heidelberg, Germany 
0.2 % Adenine hemisulphate 15 ml Sigma-Aldrich, St. Louis, 
U.S.A. 
RO water Top up to 1 L - 
All components, with the exception of adenine hemisulphate were mixed and 
sterilized by autoclaving at 121°C for 15 min, 15 lbs. pressure. The solution was 
cooled before adding adenine hemisulphate and stored at 4 °C until further use. 
 
b) Nutrient dropout Medium 
Component Amount Source 
Minimal SD base + one under-mentioned supplement 26.7 g Clontech, 
Heidelberg, 
Germany 
-Trp supplement (-Trp) 0.74 g 
-Leu supplement (-Leu) 0.69 g 
-His supplement (-His) 0.77 g 
-Trp-Leu supplement (DDO) 0.64 g 
-Trp-Leu-His supplement (TDO) 0.62 g 
-Trp-Leu-His-Ade supplement (QDO) 0.6 g 
Agar (for plates only) 20 g 
RO water 1 L - 
The dropout broth was prepared by adding the minimal SD base together with one of 
the respective nutrient supplement using RO water. The pH was adjusted to 5.8 
before autoclaving. Plates were prepared as described above but with addition of agar 
powder.  
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c) Quadruple dropout plates with X-α-galactoside 
Component Amount Source 
Minimal SD base + one under-mentioned supplement 26.7 g Clontech, 
Heidelberg, 
Germany 
-Trp-Leu-His-Ade supplement (QDO) 0.6 g 
X-α-Galactoside (X-α-Gal) 20 µg 
Agar (for plates only) 20 g 
RO water 1 L - 
All components, except X-α-Gal, were mixed and auto-claved. X-α-Gal was 
dissolved first in N, N’-dimethylformamide (Sigma-Aldrich, St. Louis, U.S.A.) 
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Appendix 8 
a) 4 % formaldehyde in PBS 
Reagents for immunofluorescence assay 
Component Amount Source 
Paraformaldehyde 40 g Merck KGaA, Germany 
PBS (Appendix 1h) Final 1000 ml - 
Paraformaldehyde was first dissolved in 800 ml of PBS. This was facilitated by 
heating at 60 ºC on a hotplate. A few drops of 1 M NaOH solution were added to 
help in the dissolution of the paraformaldehyde. The solution was then cooled to 
room temperature and made up to 1 L with PBS.  
 
b) 50 mM glycine 
Component Amount Source 
Glycine 3.75 g Sinopharm Chemical Reagent Co., China 
PBS (Appendix 1) Final 1000 ml - 
 
c) 0.2 % Triton-X-100 
Component Amount Source 
Triton-X-100 0.2 ml Sigma-Aldrich, St. Louis, U.S.A. 
PBS (Appendix 1) 100 ml - 
 
d) 4, 6-diamidino-2-phenylindole (DAPI) (500x) 
Component Amount Source 
DAPI 10 mg Carlsbad, CA, U.S.A. 
Sterile RO water 5 ml - 
DAPI was diluted to 1x in PBS prior to use. 
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Appendix 9 
a) Triton-X-100 lysis buffer 
Reagents for cell-lysis, sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western Blot 
Component Final Conc Amount 
1 M NaCl 150 mM 15 ml 
1 M Tris-HCL, pH 8.0 50 mM 5 ml 
Triton-X-100 1 % 1 ml 
Top up with RO water to - 100 ml 
One tablet of complete, mini protease inhibitors cocktail (Roche, Mannheim, 
Germany) was dissolved in 10 ml of Triton-X-100 lysis buffer just prior to use. 
 






40% Acrylamide/Bis 0.25 ml 2.5 ml 
0.5 M Tris-HCl (pH 6.8) 0.63 ml - 
1.5 M Tris-HCl (pH 8.8) - 2.5 ml 
10 % SDS 25 µl 0.1 ml 
RO water 1.59 ml 4.85 ml 
TEMED 2.5 µl 5 µl 
10 % APS 12.5 µl 0.1 ml 
Total volume 2.5 ml 10 ml 
The resolving gel (approximately 5 ml) was first cast in mini-gel caster sets (Bio-Rad 
Laboratories, Hercules, CA, U.S.A.). After the solidification of the resolving gel, the 
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c) Sodium dodecyl sulphate (SDS) loading dye (4x) 
Component Final Conc Amount 
1 M Tris.HCl (pH 6.8) 0.25 M 25 ml 
Bromophenol Blue 0.008 % 0.008 g 
Glycerol 40 % 46 ml 
SDS 8 % 8 g 
Top up with RO water to - 100 ml 
 
d) Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Running Buffer (Concentrate) 
Component Amount 
Tris 12.14 g 
Glycine 47.46 g 
SDS 2 g 
RO water Top up to 1 L 
All components, except SDS, were dissolved in 800 ml of RO water and the pH was 
adjusted to 8.3. Next, SDS was added and the volume was made up to 1 L. The 
cathode buffer (upper tank) was made by mixing the SDS-PAGE Running Buffer 
(Concentrate) with RO water at a 2:8.6 ratio. The anode buffer (lower tank) was 
prepared by mixing the SDS-PAGE Running Buffer (Concentrate) with RO water at 
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e) Tris-buffered saline Tween-20 (TBST) (pH 7.4) 
Component Amount 
NaCl 9.0 g 
Tris 6.1 g 
Tween-20 0.5 ml 
RO water Top up to 1 L 
All components, except Tween-20, were dissolved in 800 ml of RO water and the pH 
was adjusted to 7.4. Next, Tween-20 was added and the volume was made up to 1 L. 
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Appendix 10 
Thermal cycling conditions using ABI Prism® 7000 real-time PCR system 
Thermal cycling conditions for PCR array 
Step Sequencing 
Denaturation 95 ºC for 10 min 
Denaturation 95 ºC for 15 s 
40 cycles Annealing & 
extension 
60 ºC for 1 min 
 
 
